|
|
|
Delaware
|
37-1744899
|
(State or other jurisdiction of
incorporation or organization)
|
(I.R.S. Employer
Identification No.)
|
|
|
1450 Centrepark Boulevard, Suite 210
West Palm Beach, Florida
|
33401
(Zip Code)
|
(Address of principal executive offices)
|
|
|
Title of Each Class
|
Name of Each Exchange on Which Registered
|
Common Stock, par value $0.01 per share
|
The New York Stock Exchange
|
Large accelerated filer
x
|
Accelerated filer
o
|
Non-Accelerated filer
o
|
Smaller reporting company
o
|
|
|
|
Emerging growth company
o
|
Glossary
|
Page
|
||
|
|
|
|
|
|||
|
|
|
|
|
|||
|
|
|
|
|
|||
|
|||
|
|||
|
|||
|
|||
|
|||
|
|
|
|
|
|||
|
|
|
|
|
|||
|
|||
|
|||
|
|||
|
|||
|
|||
|
|||
|
|||
|
|
|
|
|
|||
|
|
|
|
|
|||
|
|||
|
|||
|
|||
|
|||
|
|
|
|
|
|||
|
|
|
|
|
|||
|
Terms
|
|
Definitions
|
Platform; Successor;
We; Us; Our; the Company
|
|
Platform Specialty Products Corporation, a Delaware corporation, and its subsidiaries, collectively, for all periods subsequent to the MacDermid Acquisition.
|
Acquisitions
|
|
Agriphar Acquisition, Alent Acquisition, Arysta Acquisition, CAS Acquisition, MacDermid Acquisition, OMG Acquisition and OMG Malaysia Acquisition, collectively.
|
Agriphar
|
|
Percival S.A., a formerly Belgium
société anonyme
, and its agrochemical business, Agriphar.
|
Agriphar Acquisition
|
|
Acquisition of a 100% interest in Agriphar, completed on October 1, 2014.
|
AIs
|
|
Active ingredients.
|
Alent
|
|
Alent plc, a formerly public limited company registered in England and Wales.
|
Alent Acquisition
|
|
Acquisition of a 100% interest in Alent, completed on December 1, 2015 under the U.K. Companies Act 2006, as amended.
|
Amended and Restated
Credit Agreement
|
|
Platform's Second Amended and Restated Credit Agreement, dated as of August 6, 2014, among, inter alia, Platform, MacDermid Holdings, LLC, MacDermid, the subsidiaries of Platform and MacDermid Holdings, LLC from time to time parties thereto, the lenders from time to time parties thereto and Barclays Bank PLC, as administrative agent and collateral agent, as amended and restated from time to time.
|
Arysta
|
|
Arysta LifeScience Limited, formerly an Irish private limited company.
|
Arysta Acquisition
|
|
Acquisition of a 100% interest in Arysta, completed on February 13, 2015.
|
Arysta Seller
|
|
Nalozo, L.P., an affiliate of Nalozo S.à.r.l., a Luxembourg limited liability company and the original seller in the Arysta Acquisition.
|
ASC
|
|
Accounting Standard Codification.
|
ASU
|
|
Accounting Standards Update.
|
Board
|
|
Platform’s board of directors.
|
Bribery Act
|
|
The United Kingdom Bribery Act 2010.
|
CAS
|
|
Chemtura AgroSolutions business of Chemtura.
|
CAS Acquisition
|
|
Acquisition of a 100% interest in CAS, completed on November 3, 2014.
|
Chemtura
|
|
Chemtura Corporation, a Delaware corporation.
|
Credit Facilities
|
|
The First Lien Credit Facility and the Revolving Credit Facility, collectively, available under the Amended and Restated Credit Agreement.
|
EBITDA
|
|
Earnings before interest, taxes, depreciation and amortization.
|
ESPP
|
|
Platform Specialty Products Corporation 2014 Employee Stock Purchase Plan.
|
E.U.
|
|
European Union.
|
Exchange Act
|
|
Securities Exchange Act of 1934, as amended.
|
FASB
|
|
Financial Accounting Standard Board.
|
FCPA
|
|
Foreign Corrupt Practices Act of 1977.
|
February 2015 Notes Offering
|
|
Platform's private offering of $1.10 billion aggregate principal amount of 6.50% USD Notes due 2022 and €350 million aggregate principal amount of 6.00% EUR Notes due 2023, completed on February 2, 2015.
|
First Lien Credit Facility
|
|
First lien credit facility available under the Amended and Restated Credit Agreement.
|
Founder Entities
|
|
Mariposa Acquisition, LLC and Berggruen Holdings Ltd. and its affiliates, collectively.
|
GAAP
|
|
Generally Accepted Accounting Principles in the United States.
|
June 2015 Equity Offering
|
|
Platform's public offering of 18,226,414 shares of its common stock at a public offering price of $26.50 per share, which closed on June 29, 2015, raising gross proceeds of approximately $483 million.
|
MacDermid
|
|
MacDermid, Incorporated, a Connecticut corporation.
|
MacDermid Acquisition
|
|
Platform’s acquisition on October 31, 2013 of substantially all of the equity of MacDermid Holdings, LLC, which, at the time, owned approximately 97% of MacDermid. Platform acquired the remaining 3% of MacDermid on March 4, 2014, pursuant to the terms of the Exchange Agreement, dated October 25, 2013, between Platform and the fiduciaries of the MacDermid, Incorporated Profit Sharing and Employee Savings Plan.
|
MacDermid Printing
|
|
MacDermid Printing Solutions LLC, now known as MacDermid Graphics Solutions LLC.
|
Terms
|
|
Definitions
|
November 2015 Notes Offering
|
|
Platform's private offering of $500 million aggregate principal amount of 10.375% USD Notes due 2021, completed on November 10, 2015.
|
NYSE
|
|
New York Stock Exchange.
|
OEM
|
|
Original Equipment Manufacturer.
|
OMG
|
|
OM Group, Inc. (NYSE:OMG), a Delaware corporation.
|
OMG Businesses
|
|
OMG's Electronic Chemicals and Photomasks businesses, collectively, other than their Malaysian subsidiary acquired separately.
|
OMG Acquisition
|
|
Platform's acquisition of the OMG Businesses completed on October 28, 2015.
|
OMG Malaysia
|
|
OMG Electronic Chemicals (M) Sdn Bhd, a subsidiary of OMG located in Malaysia, acquired separately by Platform in the OMG Malaysia Acquisition.
|
OMG Malaysia Acquisition
|
|
Platform's acquisition of 100% interest in OMG Malaysia completed on January 31, 2016.
|
PCAOB
|
|
Public Company Accounting Oversight Board.
|
PDH
|
|
Platform Delaware Holdings, Inc., a subsidiary of Platform.
|
PDH Common Stock
|
|
Shares of common stock of PDH.
|
Predecessor
|
|
MacDermid and its subsidiaries, collectively, for all periods prior to the MacDermid Acquisition.
|
Predecessor 2013 Period
|
|
Ten-month period from January 1, 2013 through October 31, 2013.
|
Prior Senior Notes
|
|
Platform's 6.00% EUR Notes due 2023 and 6.50% USD Notes due 2022, collectively.
|
Proposed Separation
|
|
Platform's proposed separation of its Agricultural Solutions and Performance Solutions businesses which we expect to complete in 2018.
|
Retaining Holder
|
|
Each Holder of an equity interest of MacDermid Holdings, LLC immediately prior to the closing of the MacDermid Acquisition, not owned by Platform, who executed a RHSA.
|
Revolving Credit
Facility
|
|
Revolving Credit Facility (in U.S. dollars or multicurrency) available under the Amended and Restated Credit Agreement.
|
RHSA
|
|
Retaining Holder Securityholders’ Agreement, dated as of October 31, 2013, entered into by and between Platform and each Retaining Holder pursuant to which they agreed to exchange their respective interests in MacDermid Holdings, LLC for shares of PDH Common Stock, at an exchange rate of $11.00 per share plus (i) a proportionate share of the $100 million contingent consideration and (ii) an interest in certain MacDermid pending litigation.
|
ROA
|
|
Return on assets.
|
RSUs
|
|
Restricted stock units issued by Platform from time to time under the 2013 Plan.
|
SEC
|
|
Securities and Exchange Commission.
|
Securities Act
|
|
Securities Act of 1933, as amended.
|
Senior Notes
|
|
Platform's 5.875% USD Notes due 2025, 6.00% EUR Notes due 2023 and 6.50% USD Notes due 2022, collectively.
|
September 2016 Equity Offering
|
|
Platform's public offering of 48,787,878 shares of its common stock at a public offering price of $8.25 per share, which closed on September 21, 2016, raising gross proceeds of approximately $402.5 million.
|
Series A Preferred Stock
|
|
Platform's 2,000,000 shares of Series A convertible preferred stock, which are convertible into shares of Platform’s common stock, on a one-for-one basis, at any time at the option of the Founder Entities.
|
Series B Convertible Preferred Stock
|
|
Platform's 600,000 shares of Series B convertible preferred stock issued to the Arysta Seller in connection with the Arysta Acquisition. At December 31, 2016, none of the Series B Convertible Preferred Stock remained outstanding.
|
SERP
|
|
Supplemental Executive Retirement Plan for executive officers of Platform.
|
Successor
|
|
Platform and its subsidiaries, collectively, for all periods subsequent to the MacDermid Acquisition.
|
Successor 2013 Period
|
|
Period from April 23, 2013 (inception) through December 31, 2013.
|
TCJA
|
|
Tax Cuts and Jobs Act of 2017.
|
USD Incremental Term Loan
|
|
Incremental term loan under the Incremental Amendment to the Amended and Restated Credit Agreement in an aggregate principal amount of $300 million used to finance the Agriphar Acquisition.
|
WACC
|
|
Weighted Average Cost of Capital.
|
Terms
|
|
Definitions
|
2013 Plan
|
|
Platform Specialty Products Corporation Amended and Restated 2013 Incentive Compensation Plan.
|
2017 Annual Report
|
|
This annual report on Form 10-K for the fiscal year ended December 31, 2017.
|
2017 Notes Offerings
|
|
Platform's private offering of $550 million aggregate principal amount of 5.875% USD Notes due 2025, completed on November 24, 2017, and tack-on private offering of $250 million aggregate principal amount of additional 5.875% USD Notes due 2025, completed on December 8, 2017, collectively.
|
2018 Proxy Statement
|
|
Platform’s definitive proxy statement for its 2018 annual meeting of stockholders expected to be filed no later than 120 days after December 31, 2017.
|
5.875% USD Notes Indenture
|
|
The indenture, dated as of November 24, 2017, governing the 5.875% USD Notes due 2025.
|
5.875% USD Notes due 2025
|
|
Platform's 5.875% senior notes due 2023, denominated in U.S. dollars, issued in the 2017 Notes Offering.
|
6.00% EUR Notes due 2023
|
|
Platform’s 6.00% senior notes due 2023, denominated in euros, issued in the February 2015 Notes Offering.
|
6.50% USD Notes due 2022
|
|
Platform’s 6.50% senior notes due 2022, denominated in U.S. dollars, issued in the February 2015 Notes Offering.
|
10.375% USD Notes Indenture
|
|
The indenture, dated November 10, 2015, as amended from time to time, governing the 10.375% USD Notes due 2021.
|
10.375% USD Notes due 2021
|
|
Platform's 10.375% senior notes due 2021, denominated in U.S. dollars, issued in the November 2015 Notes Offering. As of December 31, 2017, none of the 10.375% USD Notes due 2021 remained outstanding.
|
Assembly Solutions
|
|||
|
Electronic Assembly Materials
|
|
Assembly Solutions focuses on the development, manufacture, and sale of innovative interconnect materials, primarily into the electronic market by providing specialized fluxes, solder spheres, organic encapsulants, and die attach materials that enable successful interconnection of semiconductor devices. We also offer metal reclaim systems, primarily for tin, used in electronic assembly.
|
|
Water Treatment
|
|
Fernox
is our water treatment product line used for the filtration and conditioning of water in residential boiler systems.
|
Electronic Solutions
|
|||
|
Plating
Products
|
|
Plating products are used to plate holes drilled through printed circuit boards to connect opposite sides of the board and the different layers of multi-layer printed circuit boards. Our key products include the
MacuSpec
,
M-Copper
and
M-System
.
|
|
Solderable
Finishes
|
|
Solderable finishing formulations are used to deposit coatings on printed circuit boards to preserve the solderability of the finished boards.
|
|
Circuit Formation Products
|
|
Circuit formation products represent an assortment of products for defining circuit patterns and bonding conductors to insulating materials.
|
|
Semiconductor Materials & Packaging
|
|
Our
Viaform
product family of copper damascene chemistry is used in semiconductor plating applications for creating conductors as narrow as 10 nanometers. Our
Microfab
family of plating chemistry is used in wafer level packaging applications, including copper pillar, redistribution layers (RDLs), nickel, tin bump, gold bump and thru-silicon via (TSV) applications.
|
|
Functional Conversion Coatings
|
|
Our products plate various parts that are used in automotive and aerospace equipment, appliances, computer hard disks and other electronic products.
|
Industrial Solutions
|
|||
|
Electroless
Nickel
|
|
Electroless nickel is applied to a variety of metal and plastic surfaces to enhance corrosion resistance, wear resistance, solderability (from Electronic Solutions), and to repair worn or over-machined surfaces in a variety of applications.
|
|
Plating
Products
|
|
The
CuMac
range of products for applications such as plating on aluminum wheels, plastic substrates and zinc-based die castings, and the
ChromKlad
and
ANKOR
range of hard chromium plating processes are utilized in various industrial finishing applications.
|
|
Pre-treatment and Cleaning Solutions
|
|
Pre-treatment and cleaning solutions are applied to prepare the surfaces of a wide variety of industrial products for additional treatment. We have a complete line of aqueous and semi-aqueous pre-treatment and cleaning products.
|
|
Functional Conversion Coatings
|
|
Functional conversion coatings are applied to metals to enhance corrosion resistance and paint adhesion in a wide spectrum of industrial applications where heavy duty usage and exposure to unfavorable environments are anticipated.
|
|
Hard-coated Films
|
|
Hard-coated films are used for the membrane switch in the touch screen applications.
|
Graphic Solutions
|
|||
|
Solid Sheet
Printing Elements
|
|
Solid sheet printing elements are digital and analog printing sheets, used in the flexographic printing and platemaking processes. Our extensive line of
Lux
flexographic plates are used in the commercial packaging letterpress newspaper and publication industries.
|
|
Liquid
Imaging
Products
|
|
Liquid products are liquid photopolymers used to produce printing plates for transferring images onto commercial packaging. Our key products are
MWH photopolymer
,
MWB 50 photopolymer
,
and M Stamp 40 photopolymer
. We also offer products that are used in the production of liquid photopolymer plates such as substrate, coverfilms and detergents.
|
Offshore Solutions
|
|||
|
Offshore
Fluids
|
|
Production fluids are used to operate valves for the deep water oil extraction and transportation process, and drilling fluids are used to operate valves for drilling rigs on the ocean floor. Production and drilling fluids are water-based hydraulic fluids used in subsea control systems.
|
Crop Protection
|
|
We are one of the largest Crop Protection chemical companies by revenue. Our diverse Crop Protection chemicals control biotic stresses, such as diseases (fungicides), weeds (herbicides) and insects (insecticides).
|
Fungicides
|
|
Fungicides prevent the spread of fungal diseases in crops. Our fungicides products include Evito, Fortix, Kasumin and Proplant.
|
Herbicides
|
|
Herbicides are used to control unwanted plants while leaving the targeted crops to grow unharmed. We offer total, non-selective and selective, herbicides with a variety of formulations for many temperate and tropical crops such as soybeans, corn, wheat, oil seed rape/canola, vegetables and sugar cane. Our main herbicide products are Dinamic, Everest, Pantera and Select.
|
Insecticides
|
|
Our insecticides, such as Cythrin Max, Orthene and Talisma, are products used against insect pests at different stages of the pest life cycle, from egg and larvae to nymph and adult. These products can have both crop and public health applications. Acaricides or miticides control a variety of mite pests on crops. These products are primarily targeted at tree fruit and nut, vine, ornamental and selected row crop applications for effective mite control programs. Our main miticide products, such as Acramite, Floramite and Omite, are sold globally.
|
BioSolutions
|
|
We believe we are have a strong position as innovator in BioSolutions and BioStimulants. These products are derived from natural sources that fall into several categories described below. This portfolio is highly differentiated through innovative technologies and mixtures and primarily protected by trade secrets.
|
BioStimulants
|
|
Biostimulants (biological stimulants) enhance crop vigor, yield and/or quality through physiological stimuli. Our BioStimulant products include Biozyme, BM Start and Appetizer.
|
Innovative Nutrition
|
|
Innovative nutrition products optimize the nutrition in plants by enhancing nutrient availability or use efficiency. Our Innovative Nutrition products include the Poliquel line.
|
BioControl
|
|
BioControl (biological control) products operate as conventional Crop Protection products with, in many cases, reduced residues of a synthetic origin. Our BioControl products, mainly biofungicides and bioinsecticides, include Ph-D, Carpovirusine, Vacciplant, Noctovi and a wide line of natural enemies and beneficial insects for Integrated Pest Management solutions in Japan.
|
Seed Treatment
|
|
Our diverse Seed Treatment portfolio encompasses products, such as Rancona and Vitavax. Our Seed Treatments are applied before planting by coating the seed in order to protect it during germination and the plant during its initial growth phases. We anticipate growth in Seed Treatments as a result of the increasing value of seeds and the use of higher-value GM seeds.
|
•
|
“Asset-Lite, High-Touch” Business Model.
Our businesses are evidenced by high margins and low capital expenditures which translates into high cash flow margins and returns on capital. Over
40%
of our employees are in either technological innovation or sales and services areas; hence “high-touch.” Our commitment to technological innovation and our extensive intellectual property portfolio enables us to develop our cutting-edge products. In order to continue to provide innovative products and highly specialized technical service to our customers, we place a premium on maintaining an expert and qualified employee base. Our business involves the formulation of a broad range of specialty chemicals, created by blending raw materials or developing new uses for existing AIs. This model allows us to conservatively manage our investments in fixed assets to both maintain and grow our businesses. Our existing fixed asset base is modern and well-maintained and, accordingly, requires low capital expenditures for maintenance.
|
•
|
Industry Leading Positions
.
Our businesses strategically focus on acquiring and maintaining leading positions in niche sectors of high-growth markets by offering high value-added services to our customers. We believe our scale and global reach in product development, marketing, and formulation provides us with advantages over many of our competitors, allowing us to maintain strong market share positions and drive profitable growth. Our strong market positions contribute to our ability to attract new customers and successfully enter new end-markets
.
|
•
|
Customer Driven Innovation and Partnerships.
We frequently work alongside our customers and other industry participants to develop new products and identify new market opportunities. We participate in a variety of dynamic end-markets where new unmet needs are always materializing. Our large sales and technical service teams provide continuous insights that help ensure our research and development efforts are appropriately focused. Customer requirements can lead to improved or uniquely tailored formulations of existing product offerings or to the development of completely new products to satisfy previously unmet needs. Tailoring products for specific OEMs or specific localized growing regions leads to sticky sales and significant customer switching costs. In our Agricultural Solutions business, we also frequently partner with molecule discovery focused companies to source new and complementary AIs for our portfolio. We believe these companies value our vast knowledge of local markets, regulations and distribution channels as they look to establish post-patent management strategies for their existing molecules.
|
•
|
Strong Expertise in Registration and Distribution
. Product registration is complex and crucial, particularly in the agrochemical space. Our Agricultural Solutions segment has a large team of specialists dedicated to the regulatory process across various jurisdictions, and we believe we are well-experienced in obtaining and defending the required registrations for our products in each country in which they are sold and for each crop on which they are applied. Once obtained, these registrations provide a right to use a product for a specified crop in that country or region for a number of years. In addition, our Agricultural Solutions segment has a strong network of distributors, which currently reaches over
100
countries and jurisdictions. Our large distribution network enables us to focus on profitable niche applications, which we believe are less sensitive to competitive pricing pressures. This distribution network, together with our geographical footprint, also allows us to attract licensing and resale opportunities from partner companies for new products, technologies, and applications.
|
•
|
Comprehensive Product Offering
. We provide our customers with a comprehensive offering of products that meet many of their specialty chemical needs. In many cases, we offer a full suite of products with complementary capabilities that provide a complete functional solution to the customer. We believe the ability to provide a “top-to-bottom” product offering is a significant competitive advantage over many of our smaller and regional competitors. We also believe that our existing product offerings offer many opportunities for growth in adjacent end-markets.
|
•
|
Performance-Driven Culture and Board with Proven Track Record
. We believe we have outstanding people who can deliver superior performance under the tutelage and oversight of proven and experienced leadership. Our culture is performance-focused and driven by empowering team members and then holding them accountable for their outcomes. We measure people on financial results, safety, customer satisfaction and commitments, legal compliance, and environmental stewardship. We measure our performance against benchmarks and drive operational excellence through continuous improvement. Our experienced management team is complemented by an experienced Board, which includes individuals with proven track records of successfully acquiring and managing businesses. Our business segments are also led by executives that have extensive experience in their respective fields.
|
•
|
Expand our Core Businesses.
We believe that we can capitalize on our existing capabilities to further enhance our technical capabilities, sophisticated process know-how, solutions orientation, strong customer relationships and deep industry knowledge. The Acquisitions enhanced the growth of each of our segments by extending their respective products breadth and expanding their international reach. We intend to further extend many of our product offerings through the development of new applications for our existing products or through synergistic combinations, and to target geographies with attractive market fundamentals where our strengths in marketing, portfolio development, regulation and customer education can add value for our customers.
|
•
|
Focused Investment in Product Innovation.
We place a strong emphasis on innovation. New products are developed and created by drawing upon our significant intellectual property portfolio and technical expertise. Building on our core competencies in product innovation, applications development, and technical services, we intend to drive organic
|
•
|
Leverage Customer Relationships.
We intend to continue to leverage our close customer relationships to execute our growth strategy by working directly with our customers to identify opportunities for new products. We also have strong collaborative relationships with OEMs who specify which specialty materials, chemistries, and technologies they need in their products. Working directly with our customers allows us to increase OEM qualification of our products and identify opportunities to grow with our customers. Such close customer relationships also provide a solid barrier to entry for competition.
|
•
|
Pursue Strategic Inorganic Growth
. Our founder, Martin E. Franklin and our Chief Executive Officer, Rakesh Sachdev have significant experience and expertise and have been highly successful in acquiring, integrating, and growing value-added businesses. We intend to pursue further inorganic initiatives as a way to enhance our growth and strategic position. We intend to focus primarily on businesses or assets within our existing end-markets that share our “Asset-Lite, High-Touch” philosophy, with product offerings that provide geographic or product complementarity. We expect to achieve commercial and distribution efficiencies by expanding into related categories that can be marketed through our existing distribution channels or provide us with new distribution channels for our existing products. We plan to only pursue opportunities that we believe meet our acquisition criteria and when we deem it to be financially prudent.
|
•
|
Focus on Human Capital.
The success of our business depends on our ability to continue to capitalize on our technical capabilities, unique process know-how, strong customer relationships, and industry knowledge. The technical expertise and history of innovation demonstrated by our employees reflect the specialized and highly skilled nature of our research and development personnel. As such, we intend to focus on attracting, retaining, and developing the best human capital across all levels of our organization, which is key to our ability to successfully operate and grow our business.
|
Name
|
|
Title
|
Rakesh Sachdev
|
|
Chief Executive Officer
|
John P. Connolly
|
|
Chief Financial Officer
|
John E. Capps
|
|
Executive Vice President - General Counsel and Secretary
|
Benjamin Gliklich
|
|
Executive Vice President - Operations and Strategy
|
J. David Tolbert
|
|
Chief Human Resources Officer
|
Scot R. Benson
|
|
President - Performance Solutions
|
Diego Lopez Casanello
|
|
President - Agricultural Solutions
|
•
|
market conditions and volatility;
|
•
|
inability or delays in obtaining any legal or regulatory approvals;
|
•
|
inability or difficulty in refinancing our Credit Facilities and other material indebtedness, including our Prior Senior Notes;
|
•
|
challenges in establishing infrastructure or processes; and
|
•
|
the possibility of more attractive strategic options arising in the future.
|
•
|
execution of the Proposed Separation requires and will continue to require significant time and attention from management, which may distract management from the operation of our businesses and the execution of other initiatives that may have been beneficial to us;
|
•
|
our employees may also be distracted due to uncertainty about their future roles with us and Agricultural Solutions pending the completion of the Proposed Separation;
|
•
|
some of our suppliers or customers may delay or defer decisions or may end their relationships with us or our Agricultural Solutions business; and
|
•
|
we expect to incur incremental costs and expenses relating to the Proposed Separation, such as legal, accounting, tax and other professional fees.
|
•
|
increasing debt levels to fund sizable acquisitions, resulting in additional liabilities, constraints and requirements on our business and financial performance;
|
•
|
the acquired businesses failing to provide, or delays in realizing, the benefits originally anticipated by management;
|
•
|
potential disruption of our businesses, tax costs or inefficiencies, inconsistencies or deficiencies in standards, controls (including internal control over financial reporting, environmental compliance and health and safety compliance), information technology systems, procedures and policies;
|
•
|
difficulties managing tax costs or inefficiencies associated with integrating our operations following completion of acquisitions;
|
•
|
difficulties in integrating the operations and systems of the acquired businesses and in realizing operating synergies by identifying and eliminating redundant operations and assets;
|
•
|
difficulties in assimilating and retaining key employees, customers, suppliers and other partners of the acquired companies;
|
•
|
challenges related to the lack of experience in operating in the geographical or product markets of the acquired business;
|
•
|
management’s attention being diverted to the integration of the acquired businesses or acceptance of the acquired technology;
|
•
|
rising interest rates on debt needed or dilution resulting from equity issuances to provide cash to fund the purchase price of acquisitions; and
|
•
|
unanticipated contract or regulatory issues and the assumption of, and exposure to, unknown or contingent liabilities of the acquired businesses.
|
•
|
require us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, thereby reducing the availability of our cash flow to fund acquisitions, working capital, capital expenditures, dividends, research and development efforts and other general corporate purposes;
|
•
|
increase the amount of our interest expense, because our borrowings include instruments with variable rates of interest, which, if interest rates increase, would result in higher interest expense;
|
•
|
increase our vulnerability to general adverse economic and industry conditions;
|
•
|
limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate;
|
•
|
limit our ability to make strategic acquisitions, introduce new technologies or exploit business opportunities;
|
•
|
place us at a competitive disadvantage compared to our competitors that have less indebtedness; and
|
•
|
limit, among other things, our ability to borrow additional funds.
|
•
|
fluctuations in currency values and foreign currency exchange rates;
|
•
|
increased credit risk and different financial conditions, which may necessitate longer payment cycles of accounts receivable or result in increased bad debt write-offs (including due to bankruptcy) or additions to reserves;
|
•
|
additional withholding taxes or other taxes on foreign income, tariffs, duties, export controls, import restrictions or other restrictions on foreign trade or investment, including currency exchange controls;
|
•
|
foreign exchange controls or other currency restrictions and limitation on the movement of funds, including the prohibition of the repatriation of funds into the United States, which may result in adverse tax consequences and tax inefficiencies;
|
•
|
export licenses may be difficult to obtain, and the transportation of our products may be delayed or interrupted;
|
•
|
general economic and political conditions in the countries in which we operate, including devaluation or fluctuations in the value of currencies, gross domestic product, interest rates, market demand, labor costs and other factors beyond our control;
|
•
|
unexpected adverse changes in foreign laws or foreign regulatory requirements, including in laws or regulatory requirements pertaining to employee benefits, the environment and health and safety, such as China's latest environmental crackdown;
|
•
|
protectionist policies, which may restrict or impair the manufacturing, sales or import and export of our products;
|
•
|
new restrictions on access to markets, such as adverse trade policies or trade barriers;
|
•
|
a lack of or inadequate infrastructure;
|
•
|
political crises;
|
•
|
uncertainties as to the enforceability of contract rights and reduced protection of intellectual property rights in some countries;
|
•
|
expropriation of assets or forced relocations of operations;
|
•
|
inflation and hyperinflationary economic conditions and adverse economic effects resulting from governmental attempts to control inflation, such as imposition of wage and price controls and higher interest rates;
|
•
|
business cultures accepting of various levels of corruption;
|
•
|
the requirement to comply with a wide variety of foreign and U.S. laws and regulations that apply to international operations, including, without limitation, economic sanctions regulations, labor laws, import and export regulations, anti-corruption and anti-bribery laws;
|
•
|
challenges in maintaining an effective internal control environment with operations in multiple international locations, including language and cultural differences, varying levels of GAAP expertise and internal control over financial reporting in international locations and multiple financial information systems;
|
•
|
difficulties managing and administering an internationally dispersed business, as the management of our personnel across many countries can present legal, logistical and managerial challenges; and
|
•
|
labor disruptions, civil unrest, significant social, political or economic instability, wars or other armed conflict or acts of terrorism.
|
•
|
2,000,000
shares of Series A Preferred Stock which are convertible into shares of our common stock, on a one-for-one basis, at any time at the option of the holder;
|
•
|
4,812,742
exchange rights which require us to issue shares of our common stock in exchange for shares of common stock of our subsidiary, PDH, on a one-for-one basis, at any time at the option of the holder;
|
•
|
approximately
732,197
options which are exercisable to purchase shares of our common stock, on a one-for-one basis, at any time at the option of the holder, of which
557,197
shares were issued under the 2013 Plan; and
|
•
|
approximately
2,943,529
RSUs which were granted to employees under our 2013 Plan. Each RSU represents a contingent right to receive one (1) share of our common stock.
|
•
|
quarterly variations in our operating results;
|
•
|
changes in the market’s expectations about our operating results;
|
•
|
our operating results failing to meet the expectation of management, securities analysts or investors in a particular period;
|
•
|
the failure to remediate identified material weaknesses;
|
•
|
changes in financial estimates and recommendations by securities analysts concerning our Company or our industry in general;
|
•
|
operating and securities price performance of companies that investors deem comparable to us;
|
•
|
news reports and publication of research reports relating to our business or trends in our markets;
|
•
|
changes in laws and regulations affecting our businesses;
|
•
|
announcements of strategic developments, including the Proposed Separation, or potential future acquisitions or other material events by us or our competitors;
|
•
|
sales of substantial amounts of common stock by our directors, executive officers or significant stockholders or the perception that such sales could occur;
|
•
|
adverse market reaction to any additional debt we incur in the future;
|
•
|
the failure to identify and complete acquisitions in the future or unexpected difficulties or developments related to the integration of recently completed, pending or future acquisitions;
|
•
|
actions by institutional stockholders;
|
•
|
general economic and political conditions such as recessions and acts of war or terrorism; and
|
•
|
the risk factors set forth in this 2017 Annual Report and other matters discussed herein.
|
|
|
2017
|
|
2016
|
||||||||||||
Period
|
|
High
|
|
Low
|
|
High
|
|
Low
|
||||||||
First Quarter
|
|
$
|
13.47
|
|
|
$
|
9.83
|
|
|
$
|
12.22
|
|
|
$
|
5.55
|
|
Second Quarter
|
|
14.32
|
|
|
12.11
|
|
|
10.77
|
|
|
7.99
|
|
||||
Third Quarter
|
|
14.58
|
|
|
10.92
|
|
|
9.73
|
|
|
8.06
|
|
||||
Fourth Quarter
|
|
11.70
|
|
|
9.45
|
|
|
10.40
|
|
|
7.17
|
|
($ amounts in millions,
except per share data)
|
|
Year Ended
December 31, 2017 (1) |
|
Year Ended
December 31, 2016 (2) |
|
Year Ended
December 31, 2015 (3) |
|
Year Ended
December 31, 2014 (4) |
|
Period from
Inception (April 23, 2013) through December 31,
2013
(5)
|
|
|
Period from January 1, 2013 through October 31, 2013 (6) |
||||||||||||
|
|
(Successor)
|
|
(Successor)
|
|
(Successor)
|
|
(Successor)
|
|
(Successor)
|
|
|
(Predecessor)
|
||||||||||||
Statement of Operations Data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Net sales
|
|
$
|
3,775.9
|
|
|
$
|
3,585.9
|
|
|
$
|
2,542.3
|
|
|
$
|
843.2
|
|
|
$
|
118.2
|
|
|
|
$
|
627.7
|
|
Gross profit
|
|
1,589.0
|
|
|
1,507.7
|
|
|
991.9
|
|
|
396.6
|
|
|
35.7
|
|
|
|
322.8
|
|
||||||
Operating profit (loss)
|
|
221.3
|
|
|
253.4
|
|
|
71.6
|
|
|
9.5
|
|
|
(195.6
|
)
|
|
|
91.7
|
|
||||||
(Loss) income before income taxes, non-controlling interests and dividends on preferred shares
|
|
(289.0
|
)
|
|
(48.1
|
)
|
|
(229.3
|
)
|
|
(30.9
|
)
|
|
(201.4
|
)
|
|
|
26.5
|
|
||||||
Income tax (expense) benefit
|
|
(6.6
|
)
|
|
(28.6
|
)
|
|
(75.1
|
)
|
|
6.7
|
|
|
5.8
|
|
|
|
(13.0
|
)
|
||||||
Net (loss) income
|
|
(295.6
|
)
|
|
(76.7
|
)
|
|
(304.4
|
)
|
|
(24.2
|
)
|
|
(195.6
|
)
|
|
|
13.5
|
|
||||||
Basic loss per share
|
|
(1.04
|
)
|
|
(0.17
|
)
|
|
(1.52
|
)
|
|
(1.94
|
)
|
|
(2.10
|
)
|
|
|
n/a
|
|
||||||
Diluted loss per share
|
|
(1.04
|
)
|
|
(0.65
|
)
|
|
(1.52
|
)
|
|
(1.94
|
)
|
|
(2.10
|
)
|
|
|
n/a
|
|
||||||
Adjusted EBITDA
(7)
|
|
820.9
|
|
|
769.5
|
|
|
567.7
|
|
|
212.2
|
|
|
27.4
|
|
|
|
n/a
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
|
December 31, 2017
(1)
|
|
December 31, 2016
(2)
|
|
December 31, 2015
(3)
|
|
December 31, 2014
(4)
|
|
December 31, 2013
(5)
|
|
|
October 31, 2013
(6)
|
||||||||||||
|
|
(Successor)
|
|
(Successor)
|
|
(Successor)
|
|
(Successor)
|
|
(Successor)
|
|
|
(Predecessor)
|
||||||||||||
Balance Sheet Data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Cash and cash equivalents
|
|
$
|
477.8
|
|
|
$
|
422.6
|
|
|
$
|
432.2
|
|
|
$
|
397.3
|
|
|
$
|
123.0
|
|
|
|
$
|
87.1
|
|
Working capital
(8)
|
|
1,248.8
|
|
|
988.5
|
|
|
1,175.2
|
|
|
1,355.8
|
|
|
263.8
|
|
|
|
170.1
|
|
||||||
Total assets
|
|
10,252.4
|
|
|
10,054.1
|
|
|
10,190.2
|
|
|
4,547.3
|
|
|
2,258.5
|
|
|
|
1,172.0
|
|
||||||
Total debt
|
|
5,479.5
|
|
|
5,239.0
|
|
|
5,228.3
|
|
|
1,405.6
|
|
|
750.6
|
|
|
|
1,107.4
|
|
||||||
Total equity (deficit)
|
|
2,860.0
|
|
|
2,889.8
|
|
|
2,273.3
|
|
|
2,552.6
|
|
|
1,115.1
|
|
|
|
(200.0
|
)
|
(1)
|
The results presented include the following significant items affecting comparability for the year ended December 31, 2017:
|
•
|
Goodwill impairment charge of
$160 million
related to our Agro Business reporting unit in our Agricultural Solutions segment;
|
•
|
Foreign exchange loss on foreign denominated external and internal long-term debt of
$103 million
;
|
•
|
Debt refinancing charges of
$83.2 million
;
|
•
|
Restructuring costs of
$30.8 million
, primarily related to severance;
|
•
|
Costs related to our Proposed Separation of
$12.1 million
;
|
•
|
Pension plan settlement and curtailment costs of
$10.5 million
;
|
•
|
Net interest expense of
$342 million
, primarily related to interest charges resulting from incremental debt facilities, including term loans, bonds and revolving credit borrowings, impacted by the repricing of our term debt; and
|
•
|
Effective tax rate changed from
(59.5)%
for 2016 to
(2.3)%
for 2017 primarily due to the increased level of goodwill impairment in 2017 as compared to 2016 for which there was no corresponding tax benefit, the benefit for the provisional estimate of the TCJA, the 2016 settlement gain of the Series B Convertible Preferred Stock which was treated as a non-taxable purchase price adjustment, and favorable reductions in foreign tax rates for changes in tax law.
|
(2)
|
In addition to the impact of the 2016 and 2015 acquisitions and related valuation of intangible assets, the results presented include the following significant items affecting comparability for the year ended December 31, 2016:
|
•
|
Goodwill impairment charge of
$46.6 million
related to Performance Solutions' Offshore Solutions reporting unit;
|
•
|
Amortization of inventory step-up of
$11.7 million
charged to cost of sales;
|
•
|
Acquisition and integration related costs of
$33.4 million
, primarily comprised of professional fees;
|
•
|
Restructuring costs of
$31.1 million
, primarily related to severance;
|
•
|
Net interest expense of
$376 million
, primarily related to interest charges resulting from incremental debt facilities, including term loans, bonds and revolving credit borrowings, used to fund the acquisitions;
|
•
|
Gains relating to the amendment of the Series B Convertible Preferred Stock and the related execution of a settlement agreement totaling
$32.9 million
and
$103 million
, respectively;
|
•
|
Foreign exchange loss on foreign denominated external and internal long-term debt of
$33.9 million
;
|
•
|
Debt refinancing charges of
$19.7 million
; and
|
•
|
Income tax expense which included a
$34.3 million
benefit related to the settlement of Series B Convertible Preferred Stock, a
$24.5 million
benefit related to the impact of transaction costs, and a
$24.1 million
benefit related to a net change in tax reserves, partially offset by
$68.4 million
of expense related to a change in valuation allowances and
$26.8 million
of expense related to an increase in the provision for tax on undistributed foreign earnings.
|
(3)
|
In addition to the impact of the 2015 and 2014 acquisitions and related valuation of intangible assets, the results presented include the following significant items affecting comparability for the year ended December 31, 2015:
|
•
|
Amortization of inventory step-up of
$76.5 million
charged to cost of sales;
|
•
|
Acquisition and integration related costs of
$122 million
, primarily comprised of professional fees;
|
•
|
Restructuring costs of
$25.3 million
, primarily related to severance, professional and consulting fees;
|
•
|
Net interest expense of
$214 million
, primarily related to interest charges resulting from incremental debt facilities, including term loans, bonds and revolving credit borrowings, used to fund the acquisitions;
|
•
|
Fair value loss on foreign exchange forward contract related to the Alent Acquisition of
$73.7 million
charged to other expense;
|
•
|
Foreign exchange loss on foreign denominated external and internal long-term debt of
$46.4 million
; and
|
•
|
Income tax expense which included
$72.6 million
of expense related to a change in valuation allowances,
$40.5 million
of expense related to non-deductible transaction costs, and
$27.5 million
of expense related to a net change in tax reserves.
|
(4)
|
In addition to the impact of the 2014 and 2013 acquisitions and related valuation of intangible assets, the results presented include the following significant items affecting comparability for the year ended December 31, 2014:
|
•
|
Amortization of inventory step-up of
$35.5 million
charged to cost of sales;
|
•
|
Acquisition and integration related costs of
$47.8 million
, primarily comprised of professional fees;
|
•
|
Net interest expense of
$37.9 million
' primarily related to interest charges resulting from incremental debt facilities, including term loans, bonds and revolving credit borrowings, used to fund acquisitions; and
|
•
|
Non-cash mark-to-market charge related to the contingent consideration in connection with the MacDermid acquisition of
$29.1 million
.
|
(5)
|
The results presented include the following significant items affecting comparability in the Successor 2013 Period:
|
•
|
Non-cash charge related to the preferred share dividend rights of the Founders Entities of
$172 million
;
|
•
|
Amortization of inventory step-up of
$23.9 million
charged to cost of sales; and
|
•
|
Transaction related costs, primarily comprised of professional fees, of
$15.2 million
.
|
(6)
|
The results presented include the following significant items affecting comparability in the Predecessor 2013 Period:
|
•
|
Transaction related costs, primarily for professional fees, and fees paid to Predecessor stockholders resulting from management fees payable in conjunction with consummation of the MacDermid Acquisition of
$16.9 million
; and
|
•
|
Deemed compensation expense related to pre-acquisition share awards of approximately
$9.3 million
.
|
(7)
|
Adjusted EBITDA is a non-GAAP financial measure and as such, should not be considered in isolation from, as a substitute for, or superior to performance measures calculated in accordance with GAAP. For a definition of Adjusted EBITDA and additional information on why we present this measure, its limitations and a reconciliation to the most comparable applicable GAAP measure, see "
Non-GAAP Financial Measures"
in the Management's Discussion and Analysis of Financial Condition and Results of Operations section included in Part II, Item 7, and Note 23,
Segment Information
, to the Consolidated Financial Statements, all included in this 2017 Annual Report.
|
(8)
|
Working capital is defined as current assets less current liabilities.
|
•
|
In April 2017
, we completed the repricing of
$1.93 billion
of existing term loans through Amendment No. 7 to the Second Amended and Restated Credit Agreement which, among other things, provided for the prepayment in full of previously existing term loans denominated in U.S. dollars and in euros with the aggregate proceeds of newly created term loans denominated in U.S. dollars in an aggregate principal amount of
$1.23 billion
and term loans denominated in euros in an aggregate principal amount of
€650 million
. The amendment effectively reduced interest rates by
100
basis points across both the U.S. dollar and euro tranches. In addition, the EURIBOR floor was reduced from
1.00%
to
0.75%
on the new euro denominated term loans. At the close of this refinancing, the reduced interest rates were expected to generate annual cash savings of approximately
$20.0 million
, based on foreign exchange rates then in effect.
|
•
|
In June 2017
, MacDermid Printing and E.I. du Pont de Nemours and Company, now known as DowDuPont Inc. ("DuPont"), settled all outstanding litigation between them, as well as MacDermid Printing's lawsuit against Cortron. In connection with this settlement, DuPont made a payment of
$20.0 million
to MacDermid Printing, and we recorded a net settlement gain of
$10.8 million
.
|
•
|
In October 2017
, we completed the repricing of
$1.40 billion
of existing term loans through Amendment No. 8 to the Second Amended and Restated Credit Agreement which, among other things, provided for the prepayment in full of previously existing term loans denominated in U.S. dollars and in euros with the aggregate proceeds of newly created term loans denominated in U.S. dollars in an aggregate principal amount of
$680 million
and term loans denominated in euros in an aggregate principal amount of
€630 million
. This amendment effectively reduced interest rates by
100
basis points across both the U.S. dollar and euro tranches from a combination of reduced spread and reduced EURIBOR floor from
1.00%
to
0.75%
on the new euro denominated term loans. At the close of this refinancing, the reduced interest rates were expected to generate annual cash savings of approximately
$14.0 million
, based on foreign exchange rates then in effect.
|
•
|
In November 2017
, we completed a private offering of
$550 million
aggregate principal amount of
5.875%
USD Notes due 2025. The proceeds from this offering were used to pay the consideration of the below-mentioned cash tender offer and consent solicitation for, as well as redemption of, any and all of our then outstanding 10.375% USD Notes due 2021, plus accrued and unpaid interest on the 10.375% USD Notes due 2021, along with fees and expenses.
|
•
|
In December 2017
, we completed a tack-on private offering of
$250 million
aggregate principal amount of additional 5.875% USD Notes due 2025. The additional notes have the same terms as, and are fungible and form a single series with, the 5.875% USD Notes due 2025 issued in November 2017. The proceeds from this offering were used to repay a portion of our existing terms loans under our Amended and Restated Credit Agreement. The 5.875% USD Notes Indenture provides that in connection with the satisfaction of certain financial covenants and other conditions, all of the then direct and indirect subsidiaries constituting our Agricultural Solutions business may be designated as unrestricted subsidiaries and, as applicable, released from their guarantees of the 5.875% USD Notes due 2025.
|
•
|
In December 2017
, we completed the cash tender offer and consent solicitation for, as well as the redemption of, any and all of our then outstanding 10.375% USD Notes due 2021. The tender offer and consent solicitation, as well as the redemption, were financed with the proceeds of the November offering of 5.875% USD Notes due 2025 described above.
|
•
|
Valuation Techniques
- we use a discounted cash flow analysis, which requires assumptions about short and long-term net cash flows, growth rates, as well as discount rates. Additionally, we consider guideline company and guideline transaction information, where available, to aid in the valuation of the reporting units.
|
•
|
Growth Assumptions
- Multi-year financial forecasts are developed for each reporting unit by considering several key business drivers such as new business initiatives, client service and retention standards, market share changes, historical performance, and industry and economic trends, among other considerations. We typically forecast revenue and the resulting cash flows for periods of five to seven years and include an estimated terminal growth rate at the end of the forecasted period.
|
•
|
Discount Rate Assumptions
- Discount rates are estimated based on the WACC, which combines the required return on equity and considers the risk-free interest rate, market risk premium, small stock risk premium and a company specific risk premium, with the cost of debt, based on BBB-rated corporate bonds, adjusted using an income tax factor.
|
•
|
Estimated Fair Value and Sensitivitie
s - The estimated fair value of each reporting unit is derived from the valuation techniques described above. The estimated fair value of each reporting unit is analyzed in relation to numerous market and historical factors, including current economic and market conditions, company-specific growth opportunities, and guideline company information.
|
|
|
|
|
% Change - 2017 vs 2016
|
|
|
|
% Change - 2016 vs 2015
|
||||||||||||||||
($ amounts in millions)
|
|
2017
|
|
2016
|
|
Reported
|
|
Constant Currency
|
|
Organic
|
|
2015
|
|
Reported
|
|
Constant Currency
|
|
Organic
|
||||||
Net sales
|
|
$
|
3,775.9
|
|
|
$
|
3,585.9
|
|
|
5%
|
|
4%
|
|
4%
|
|
$
|
2,542.3
|
|
|
41%
|
|
43%
|
|
2%
|
Cost of sales
|
|
2,186.9
|
|
|
2,078.2
|
|
|
5%
|
|
4%
|
|
|
|
1,550.4
|
|
|
34%
|
|
36%
|
|
|
|||
Gross profit
|
|
1,589.0
|
|
|
1,507.7
|
|
|
5%
|
|
5%
|
|
|
|
991.9
|
|
|
52%
|
|
55%
|
|
|
|||
Selling, technical, general and administrative
|
|
1,109.3
|
|
|
1,123.3
|
|
|
(1)%
|
|
(2)%
|
|
|
|
857.5
|
|
|
31%
|
|
33%
|
|
|
|||
Research and development
|
|
98.4
|
|
|
84.4
|
|
|
17%
|
|
15%
|
|
|
|
62.8
|
|
|
34%
|
|
35%
|
|
|
|||
Goodwill impairment
|
|
160.0
|
|
|
46.6
|
|
|
(nm)
|
|
(nm)
|
|
|
|
—
|
|
|
(nm)
|
|
(nm)
|
|
|
|||
Operating profit
|
|
221.3
|
|
|
253.4
|
|
|
(13)%
|
|
(9)%
|
|
|
|
71.6
|
|
|
(nm)
|
|
(nm)
|
|
|
|||
Interest expense, net
|
|
(341.6
|
)
|
|
(375.7
|
)
|
|
(9)%
|
|
|
|
|
|
(213.9
|
)
|
|
76%
|
|
|
|
|
|||
Other (expense) income, net
|
|
(168.7
|
)
|
|
74.2
|
|
|
(nm)
|
|
|
|
|
|
(87.0
|
)
|
|
(nm)
|
|
|
|
|
|||
Loss before income taxes and non-controlling interest
|
|
(289.0
|
)
|
|
(48.1
|
)
|
|
(nm)
|
|
|
|
|
|
(229.3
|
)
|
|
(79)%
|
|
|
|
|
|||
Income tax expense
|
|
(6.6
|
)
|
|
(28.6
|
)
|
|
(77)%
|
|
|
|
|
|
(75.1
|
)
|
|
(62)%
|
|
|
|
|
|||
Net loss
|
|
$
|
(295.6
|
)
|
|
$
|
(76.7
|
)
|
|
(nm)
|
|
|
|
|
|
$
|
(304.4
|
)
|
|
(75)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Adjusted EBITDA
(1)
|
|
$
|
820.9
|
|
|
$
|
769.5
|
|
|
7%
|
|
7%
|
|
|
|
$
|
567.7
|
|
|
36%
|
|
38%
|
|
|
|
Year ended December 31, 2017
|
||||||||
|
Reported Net Sales Growth
|
|
Impact of Currency
|
|
Metals
|
|
Acquisitions/Disposition
|
|
Organic Sales Growth
|
Performance Solutions
|
6%
|
|
—%
|
|
(1)%
|
|
—%
|
|
4%
|
Agricultural Solutions
|
4%
|
|
(2)%
|
|
—%
|
|
—%
|
|
3%
|
Total
|
5%
|
|
(1)%
|
|
(1)%
|
|
—%
|
|
4%
|
|
Year ended December 31, 2016
|
||||||||
|
Reported Net Sales Growth
|
|
Impact of Currency
|
|
Metals
|
|
Acquisitions/Disposition
|
|
Organic Sales Growth
|
Performance Solutions
|
121%
|
|
2%
|
|
(2)%
|
|
(120)%
|
|
1%
|
Agricultural Solutions
|
4%
|
|
2%
|
|
—%
|
|
(3)%
|
|
3%
|
Total
|
41%
|
|
2%
|
|
—%
|
|
(40)%
|
|
2%
|
|
Year ended December 31,
|
|
Change
|
||||||||||
($ amounts in millions)
|
2017
|
|
2016
|
|
Reported
|
|
Constant Currency
|
|
Organic
|
||||
Performance Solutions
|
$
|
1,878.6
|
|
|
$
|
1,770.1
|
|
|
6%
|
|
6%
|
|
4%
|
Agricultural Solutions
|
1,897.3
|
|
|
1,815.8
|
|
|
4%
|
|
3%
|
|
3%
|
||
Total
|
$
|
3,775.9
|
|
|
$
|
3,585.9
|
|
|
5%
|
|
4%
|
|
4%
|
|
Year ended December 31,
|
|
Change
|
||||||||
($ amounts in millions)
|
2017
|
|
2016
|
|
Reported
|
|
Constant Currency
|
||||
Gross profit
|
|
|
|
|
|
|
|
||||
Performance Solutions
|
$
|
813.8
|
|
|
$
|
776.8
|
|
|
5%
|
|
5%
|
Agricultural Solutions
|
775.2
|
|
|
730.9
|
|
|
6%
|
|
5%
|
||
Total
|
$
|
1,589.0
|
|
|
$
|
1,507.7
|
|
|
5%
|
|
5%
|
|
|
|
|
|
|
|
|
||||
Gross margin
|
|
|
|
|
|
|
|
||||
Performance Solutions
|
43.3%
|
|
43.9%
|
|
(57) bps
|
|
(49) bps
|
||||
Agricultural Solutions
|
40.9%
|
|
40.3%
|
|
61 bps
|
|
95 bps
|
||||
Total
|
42.1%
|
|
42.0%
|
|
4 bps
|
|
24 bps
|
|
Year ended December 31,
|
|
Change
|
||||||||
($ amounts in millions)
|
2017
|
|
2016
|
|
Reported
|
|
Constant Currency
|
||||
STG&A
|
|
|
|
|
|
|
|
||||
Performance Solutions
|
$
|
504.1
|
|
|
$
|
504.3
|
|
|
—%
|
|
—%
|
Agricultural Solutions
|
525.3
|
|
|
518.1
|
|
|
1%
|
|
(1)%
|
||
Corporate
|
79.9
|
|
|
100.9
|
|
|
(21)%
|
|
(21)%
|
||
Total
|
$
|
1,109.3
|
|
|
$
|
1,123.3
|
|
|
(1)%
|
|
(2)%
|
|
|
|
|
|
|
|
|
||||
STG&A as % of net sales
|
|
|
|
|
|
|
|
||||
Performance Solutions
|
26.8%
|
|
28.5%
|
|
(165) bps
|
|
(169) bps
|
||||
Agricultural Solutions
|
27.7%
|
|
28.5%
|
|
(85) bps
|
|
(103) bps
|
||||
Total
|
29.4%
|
|
31.3%
|
|
(195) bps
|
|
(204) bps
|
|
Year ended December 31,
|
|
Change
|
||||||||
($ amounts in millions)
|
2017
|
|
2016
|
|
Reported
|
|
Constant Currency
|
||||
R&D
|
|
|
|
|
|
|
|
||||
Performance Solutions
|
$
|
46.4
|
|
|
$
|
45.0
|
|
|
3%
|
|
4%
|
Agricultural Solutions
|
52.0
|
|
|
39.4
|
|
|
32%
|
|
28%
|
||
Total
|
$
|
98.4
|
|
|
$
|
84.4
|
|
|
17%
|
|
15%
|
|
|
|
|
|
|
|
|
||||
R&D as % of net sales
|
|
|
|
|
|
|
|
||||
Performance Solutions
|
2.5%
|
|
2.5%
|
|
(7) bps
|
|
(5) bps
|
||||
Agricultural Solutions
|
2.7%
|
|
2.2%
|
|
57 bps
|
|
53 bps
|
||||
Total
|
2.6%
|
|
2.4%
|
|
25 bps
|
|
24 bps
|
|
Year Ended December 31,
|
||||||
($ amounts in millions)
|
2017
|
|
2016
|
||||
Goodwill impairment
|
|
|
|
||||
Performance Solutions
|
$
|
—
|
|
|
$
|
46.6
|
|
Agricultural Solutions
|
160.0
|
|
|
—
|
|
||
Total
|
$
|
160.0
|
|
|
$
|
46.6
|
|
|
Year ended December 31,
|
|
Change
|
||||||||
($ amounts in millions)
|
2017
|
|
2016
|
|
Reported
|
|
Constant Currency
|
||||
Operating profit
|
|
|
|
|
|
|
|
||||
Performance Solutions
|
$
|
263.2
|
|
|
$
|
180.9
|
|
|
45%
|
|
46%
|
Agricultural Solutions
|
38.0
|
|
|
173.4
|
|
|
(78)%
|
|
(74)%
|
||
Corporate
|
(79.9
|
)
|
|
(100.9
|
)
|
|
(21)%
|
|
(21)%
|
||
Total
|
$
|
221.3
|
|
|
$
|
253.4
|
|
|
(13)%
|
|
(9)%
|
|
|
|
|
|
|
|
|
||||
Operating Margin
|
|
|
|
|
|
|
|
||||
Performance Solutions
|
14.0%
|
|
10.2%
|
|
379 bps
|
|
389 bps
|
||||
Agricultural Solutions
|
2.0%
|
|
9.5%
|
|
(755) bps
|
|
(711) bps
|
||||
Total
|
5.9%
|
|
7.1%
|
|
(121) bps
|
|
(94) bps
|
|
Year Ended December 31,
|
||||||
($ amounts in millions)
|
2017
|
|
2016
|
||||
Interest expense, net
|
$
|
(341.6
|
)
|
|
$
|
(375.7
|
)
|
Foreign exchange loss
|
(107.5
|
)
|
|
(14.1
|
)
|
||
Other (expense) income, net
|
(61.2
|
)
|
|
88.3
|
|
||
Total
|
$
|
(510.3
|
)
|
|
$
|
(301.5
|
)
|
|
Year Ended December 31,
|
||||||
($ amounts in millions)
|
2017
|
|
2016
|
||||
Income tax expense
|
$
|
(6.6
|
)
|
|
$
|
(28.6
|
)
|
Effective tax rate
|
(2.3
|
)%
|
|
(59.5
|
)%
|
|
Year Ended December 31,
|
|
Change
|
||||||||
($ amounts in millions)
|
2017
|
|
2016
|
|
Reported
|
|
Constant Currency
|
||||
Adjusted EBITDA:
|
|
|
|
|
|
|
|
|
|
||
Performance Solutions
|
$
|
432.7
|
|
|
$
|
401.3
|
|
|
8%
|
|
8%
|
Agricultural Solutions
|
388.2
|
|
|
368.2
|
|
|
5%
|
|
6%
|
||
Total
|
$
|
820.9
|
|
|
$
|
769.5
|
|
|
7%
|
|
7%
|
|
Year ended December 31,
|
|
Change
|
||||||||||
($ amounts in millions)
|
2016
|
|
2015
|
|
Reported
|
|
Constant Currency
|
|
Organic
|
||||
Performance Solutions
|
$
|
1,770.1
|
|
|
$
|
800.8
|
|
|
121%
|
|
123%
|
|
1%
|
Agricultural Solutions
|
1,815.8
|
|
|
1,741.5
|
|
|
4%
|
|
6%
|
|
3%
|
||
Total
|
$
|
3,585.9
|
|
|
$
|
2,542.3
|
|
|
41%
|
|
43%
|
|
2%
|
|
Year ended December 31,
|
|
Change
|
||||||||||
($ amounts in millions)
|
2016
|
|
2015
|
|
Reported
|
|
Constant Currency
|
|
Organic
|
||||
Gross profit
|
|
|
|
|
|
|
|
|
|
||||
Performance Solutions
|
$
|
776.8
|
|
|
$
|
387.9
|
|
|
100%
|
|
103%
|
|
1%
|
Agricultural Solutions
|
730.9
|
|
|
604.0
|
|
|
21%
|
|
23%
|
|
19%
|
||
Total
|
$
|
1,507.7
|
|
|
$
|
991.9
|
|
|
52%
|
|
55%
|
|
12%
|
|
|
|
|
|
|
|
|
|
|
||||
Gross margin
|
|
|
|
|
|
|
|
|
|
||||
Performance Solutions
|
43.9%
|
|
48.4%
|
|
(455) bps
|
|
(441) bps
|
|
(91) bps
|
||||
Agricultural Solutions
|
40.3%
|
|
34.7%
|
|
557 bps
|
|
554 bps
|
|
554 bps
|
||||
Total
|
42.0%
|
|
39.0%
|
|
303 bps
|
|
309 bps
|
|
381 bps
|
|
Year ended December 31,
|
|
Change
|
||||||||||
($ amounts in millions)
|
2016
|
|
2015
|
|
Reported
|
|
Constant Currency
|
|
Organic
|
||||
STG&A
|
|
|
|
|
|
|
|
|
|
||||
Performance Solutions
|
$
|
504.3
|
|
|
$
|
242.6
|
|
|
108%
|
|
110%
|
|
13%
|
Agricultural Solutions
|
518.1
|
|
|
488.5
|
|
|
6%
|
|
9%
|
|
3%
|
||
Corporate
|
100.9
|
|
|
126.4
|
|
|
(20)%
|
|
(20)%
|
|
(20)%
|
||
Total
|
$
|
1,123.3
|
|
|
$
|
857.5
|
|
|
31%
|
|
33%
|
|
2%
|
|
|
|
|
|
|
|
|
|
|
||||
STG&A as % of net sales
|
|
|
|
|
|
|
|
|
|
||||
Performance Solutions
|
28.5%
|
|
30.3%
|
|
(180) bps
|
|
(177) bps
|
|
286 bps
|
||||
Agricultural Solutions
|
28.5%
|
|
28.1%
|
|
48 bps
|
|
67 bps
|
|
67 bps
|
||||
Total
|
31.3%
|
|
33.7%
|
|
(240) bps
|
|
(233) bps
|
|
(30) bps
|
|
Year ended December 31,
|
|
Change
|
||||||||||
($ amounts in millions)
|
2016
|
|
2015
|
|
Reported
|
|
Constant Currency
|
|
Organic
|
||||
R&D
|
|
|
|
|
|
|
|
|
|
||||
Performance Solutions
|
$
|
45.0
|
|
|
$
|
25.4
|
|
|
77%
|
|
78%
|
|
(12)%
|
Agricultural Solutions
|
39.4
|
|
|
37.4
|
|
|
5%
|
|
5%
|
|
(4)%
|
||
Total
|
$
|
84.4
|
|
|
$
|
62.8
|
|
|
34%
|
|
35%
|
|
(7)%
|
|
|
|
|
|
|
|
|
|
|
||||
R&D as % of net sales
|
|
|
|
|
|
|
|
|
|
||||
Performance Solutions
|
2.5%
|
|
3.2%
|
|
(63) bps
|
|
(64) bps
|
|
(47) bps
|
||||
Agricultural Solutions
|
2.2%
|
|
2.1%
|
|
2 bps
|
|
(2) bps
|
|
(2) bps
|
||||
Total
|
2.4%
|
|
2.5%
|
|
(12) bps
|
|
(15) bps
|
|
(23) bps
|
|
Year Ended December 31,
|
||||||
($ amounts in millions)
|
2016
|
|
2015
|
||||
Goodwill impairment
|
$
|
46.6
|
|
|
$
|
—
|
|
|
Year ended December 31,
|
|
Change
|
||||||||||
($ amounts in millions)
|
2016
|
|
2015
|
|
Reported
|
|
Constant Currency
|
|
Organic
|
||||
Operating profit
|
|
|
|
|
|
|
|
|
|
||||
Performance Solutions
|
$
|
180.9
|
|
|
$
|
119.9
|
|
|
51%
|
|
55%
|
|
(50)%
|
Agricultural Solutions
|
173.4
|
|
|
78.6
|
|
|
120%
|
|
121%
|
|
134%
|
||
Corporate
|
(100.9
|
)
|
|
(126.9
|
)
|
|
(20)%
|
|
(20)%
|
|
(20)%
|
||
Total
|
$
|
253.4
|
|
|
$
|
71.6
|
|
|
253%
|
|
260%
|
|
77%
|
|
|
|
|
|
|
|
|
|
|
||||
Operating Margin
|
|
|
|
|
|
|
|
|
|
||||
Performance Solutions
|
10.2%
|
|
15.0%
|
|
(475) bps
|
|
(460) bps
|
|
(967) bps
|
||||
Agricultural Solutions
|
9.5%
|
|
4.5%
|
|
504 bps
|
|
486 bps
|
|
486 bps
|
||||
Total
|
7.1%
|
|
2.8%
|
|
425 bps
|
|
427 bps
|
|
245 bps
|
|
Year Ended December 31,
|
||||||
($ amounts in millions)
|
2016
|
|
2015
|
||||
Interest expense, net
|
$
|
(375.7
|
)
|
|
$
|
(213.9
|
)
|
Foreign exchange loss
|
(14.1
|
)
|
|
(43.4
|
)
|
||
Other income (expense), net
|
88.3
|
|
|
(43.6
|
)
|
||
Total
|
$
|
(301.5
|
)
|
|
$
|
(300.9
|
)
|
|
Year Ended December 31,
|
||||||
($ amounts in millions)
|
2016
|
|
2015
|
||||
Income tax expense
|
$
|
(28.6
|
)
|
|
$
|
(75.1
|
)
|
Effective tax rate
|
(59.5
|
)%
|
|
(32.8
|
)%
|
|
Year Ended December 31,
|
|
Change
|
||||||||||
($ amounts in millions)
|
2016
|
|
2015
|
|
Reported
|
|
Constant Currency
|
|
Organic
|
||||
Adjusted EBITDA:
|
|
|
|
|
|
|
|
|
|
||||
Performance Solutions
|
$
|
401.3
|
|
|
$
|
224.3
|
|
|
79%
|
|
86%
|
|
9%
|
Agricultural Solutions
|
368.2
|
|
|
343.4
|
|
|
7%
|
|
7%
|
|
6%
|
||
Total
|
$
|
769.5
|
|
|
$
|
567.7
|
|
|
36%
|
|
38%
|
|
8%
|
|
|
Year Ended December 31,
|
||||||||||
($ amounts in millions)
|
|
2017
|
|
2016
|
|
2015
|
||||||
Cash and cash equivalents, beginning of the period
|
|
$
|
422.6
|
|
|
$
|
432.2
|
|
|
$
|
397.3
|
|
Cash provided by operating activities
|
|
182.1
|
|
|
184.8
|
|
|
320.9
|
|
|||
Cash used in investing activities
|
|
(92.6
|
)
|
|
(74.7
|
)
|
|
(4,256.5
|
)
|
|||
Cash (used in) provided by financing activities
|
|
(67.4
|
)
|
|
(102.2
|
)
|
|
4,001.2
|
|
|||
Exchange rate impact on cash and cash equivalents
|
|
33.1
|
|
|
(17.5
|
)
|
|
(30.7
|
)
|
|||
Cash and cash equivalents, end of the period
|
|
$
|
477.8
|
|
|
$
|
422.6
|
|
|
$
|
432.2
|
|
•
|
$2.28 billion
of Senior Notes;
|
•
|
$3.15 billion
of term debt arrangements outstanding under our First Lien Credit Facility; and
|
•
|
$28.5 million
of borrowings under local and revolving lines of credit.
|
|
|
|
|
Payment Due by Period
|
||||||||||||||||||||||||||
($ amounts in millions)
|
|
|
|
2018
|
|
2019
|
|
2020
|
|
2021
|
|
2022
|
|
Thereafter
|
|
Total
|
||||||||||||||
Long-term debt
|
|
(1)
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,330.8
|
|
|
$
|
1,854.4
|
|
|
$
|
1,100.0
|
|
|
$
|
1,219.9
|
|
|
$
|
5,505.1
|
|
Operating leases
|
|
(2)
|
|
33.0
|
|
|
25.0
|
|
|
19.6
|
|
|
13.9
|
|
|
12.1
|
|
|
28.9
|
|
|
132.5
|
|
|||||||
Interest payments (net of interest rate swap effects)
|
|
(3)
|
|
276.7
|
|
|
276.7
|
|
|
247.6
|
|
|
212.2
|
|
|
111.0
|
|
|
155.1
|
|
|
1,279.3
|
|
|||||||
Long-term contingent consideration
|
|
(4)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
100.0
|
|
|
—
|
|
|
—
|
|
|
100.0
|
|
|||||||
Principal payments on capital leases
|
|
|
|
0.7
|
|
|
0.6
|
|
|
0.5
|
|
|
0.5
|
|
|
0.4
|
|
|
1.6
|
|
|
4.3
|
|
|||||||
Purchase obligations
|
|
(5)
|
|
72.2
|
|
|
1.1
|
|
|
0.2
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
73.5
|
|
|||||||
Other long term obligations
|
|
(6)
|
|
8.9
|
|
|
4.2
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
13.3
|
|
|
26.4
|
|
|||||||
Total cash contractual obligations
|
|
|
|
$
|
391.5
|
|
|
$
|
307.6
|
|
|
$
|
1,598.7
|
|
|
$
|
2,181.0
|
|
|
$
|
1,223.5
|
|
|
$
|
1,418.8
|
|
|
$
|
7,121.1
|
|
(1)
|
Reflects the principal payments on long-term debt. In the event the Company is able to prepay, redeem or otherwise retire and/or refinance in full its
$1.1 billion
,
6.50%
USD Notes due 2022, as permitted under the Amended and Restated Credit Agreement, on or prior to November 2, 2021, the maturity date of approximately
$1.85 billion
of first lien debt will be extended to June 7, 2023 from November 2, 2021, as currently presented in the table above.
|
(2)
|
Reflects periodic payments made in accordance with operating lease agreements.
|
(3)
|
Amounts are based on currently applicable interest rates in the case of variable interest rate debt and associated floating and floor legs of the interest rate swaps.
|
(4)
|
Reflects the maximum payout in 2021 of 100% of long-term contingent consideration related to the MacDermid Acquisition. At
December 31, 2017
, the long-term contingent consideration related to the MacDermid Acquisition was valued at
$79.2 million
. See Note 13,
Financial Instruments
, to the Consolidated Financial Statements included in this 2017 Annual Report for additional information.
|
(5)
|
Purchase obligations represent amounts committed under legally enforceable supply agreements and non-cancelable purchase contracts. We do not include purchase obligations that can be canceled with a nominal fee.
|
(6)
|
Other long-term obligations consist of asset retirement obligations, or AROs.
|
•
|
pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;
|
•
|
provide reasonable assurance that transactions are recorded as necessary to permit preparation of our financial statements in accordance with GAAP, and that receipts and expenditures are being made only in accordance with authorizations of our management and directors; and
|
•
|
provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.
|
•
|
implementing a global consolidation and planning system;
|
•
|
implementing control processes relating to newly-acquired businesses and non-routine transactions;
|
•
|
implementing enhanced monitoring controls relating to the financial reporting and performance of our newly-acquired businesses; and
|
•
|
enhancing our financial planning and analysis function within our businesses and at the corporate level.
|
•
|
improving the overall tax provision process; and
|
•
|
enhancing our income tax controls to include specific activities to assess the accounting for significant complex transactions and other tax related judgments.
|
|
|
|
|
Incorporated by Reference
|
|
Included in this 2017 Annual Report
|
||||||
Exhibit
Nb.
|
|
Exhibit Description
|
|
Form
|
|
File Nb.
|
|
Exhibit
Nb.
|
|
Filing Date
|
|
|
2.1
|
|
Settlement Agreement and Release, dated September 9, 2016
, among Platform and MacDermid Agricultural Solutions, Inc. and Permira Advisers LLC, Nalozo S.à.r.l., and Nalozo L.P.
|
|
8-K
|
|
001-36272
|
|
2.1
|
|
9/12/2016
|
|
|
3.1 (a)
|
|
|
S-4 POS
|
|
333-192778
|
|
3.1
|
|
1/24/2014
|
|
|
|
3.1 (b)
|
|
|
8-K
|
|
001-36272
|
|
3.1
|
|
6/13/2014
|
|
|
|
3.2
|
|
|
10-K
|
|
001-36272
|
|
3.2
|
|
3/31/2014
|
|
|
|
4.1
|
|
|
S-4/A
|
|
333-192778
|
|
4.1
|
|
1/2/2014
|
|
|
|
4.2
|
|
Indenture, dated as of February 2, 2015
, among Escrow Issuer, the Trustee and the EUR Agent
|
|
8-K
|
|
001-36272
|
|
4.1
|
|
2/3/2015
|
|
|
4.3
|
|
Supplemental Indenture, dated as of February 13, 2015
, among Platform, the Initial Guarantors, the Trustee and the EUR Agent
|
|
8-K
|
|
001-36272
|
|
4.2
|
|
2/17/2015
|
|
|
4.4
|
|
Second Supplemental Indenture, dated as of May 20, 2015
, among Platform, the Subsequent Guarantors, the other Guarantors, the Trustee, and the EUR Agent
|
|
10-K
|
|
001-36272
|
|
4.4
|
|
3/11/2016
|
|
|
4.5
|
|
Third Supplemental Indenture, dated as of January 26, 2016
, among Platform, the Subsequent Guarantors, the Trustee, and the EUR Agent
|
|
10-K
|
|
001-36272
|
|
4.5
|
|
3/11/2016
|
|
|
4.6
|
|
Fourth Supplemental Indenture, dated as of April 13, 2016
, among Platform, the Subsequent Guarantors, the Trustee and the EUR Agent
|
|
10-Q
|
|
001-36272
|
|
4.1
|
|
8/9/2016
|
|
|
4.7
|
|
|
8-K
|
|
001-36272
|
|
A-1 to 4.1
|
|
2/3/2015
|
|
|
|
4.8
|
|
|
8-K
|
|
001-36272
|
|
A-2 to 4.1
|
|
2/3/2015
|
|
|
|
4.9
|
|
Indenture, dated as of November 10, 2015
, among PSPC Escrow II Corp. and the Trustee
|
|
8-K
|
|
001-36272
|
|
4.1
|
|
11/12/2015
|
|
|
4.10
|
|
Supplemental Indenture, dated as of December 1, 2015
, among Platform, the Initial Guarantors and the Trustee
|
|
8-K
|
|
001-36272
|
|
4.2
|
|
12/4/2015
|
|
|
4.11
|
|
Second Supplemental Indenture, dated as of January 26, 2016
, among Platform, the Subsequent Guarantors, and the Trustee
|
|
10-K
|
|
001-36272
|
|
4.10
|
|
3/11/2016
|
|
|
4.12
|
|
Third Supplemental Indenture, dated as of April 13, 2016
, among Platform, the Subsequent Guarantors and the Trustee
|
|
10-Q
|
|
001-36272
|
|
4.2
|
|
8/9/2016
|
|
|
|
|
|
|
Incorporated by Reference
|
|
Included in this 2017 Annual Report
|
||||||
Exhibit
Nb.
|
|
Exhibit Description
|
|
Form
|
|
File Nb.
|
|
Exhibit
Nb.
|
|
Filing Date
|
|
|
4.13
|
|
Form of 10.375% senior notes due 2021
(Exhibit A)
|
|
8-K
|
|
001-36272
|
|
A to 4.1
|
|
11/12/2015
|
|
|
4.14
|
|
Indenture, dated as of November 24, 2017
, among Platform, the guarantors named therein and the Trustee
|
|
8-K
|
|
001-36272
|
|
4.1
|
|
11/27/2017
|
|
|
4.15
|
|
Form of 5.875% senior notes due 2025
(Exhibit A)
|
|
8-K
|
|
001-36272
|
|
A to 4.01
|
|
11/27/2017
|
|
|
†10.1
|
|
Employment Agreement, dated as of December 15, 2015
, between Platform and Rakesh Sachdev (effective January 5, 2016)
|
|
8-K
|
|
001-36272
|
|
10.1
|
|
12/16/2015
|
|
|
†10.2
|
|
Time and Performance-Based Restricted Stock Unit Award Agreement
by and between Platform and Rakesh Sachdev (effective January 5, 2016)
|
|
8-K
|
|
001-36272
|
|
10.2
|
|
12/16/2015
|
|
|
†10.3
|
|
|
10-Q
|
|
001-36272
|
|
10.6
|
|
5/9/2017
|
|
|
|
10.4
|
|
MacDermid, Incorporated Employees’ Pension Plan
(as amended and restated generally effective January 1, 2009)
|
|
S-4
|
|
333-192778
|
|
10.6
|
|
12/11/2013
|
|
|
10.5
|
|
Second Amendment to MacDermid, Incorporated Employees’ Pension Plan, 2009 Restatement
(effective as of January 1, 2009)
|
|
S-4/A
|
|
333-192778
|
|
10.8
|
|
1/2/2014
|
|
|
10.6
|
|
Third Amendment to Amended and Restated MacDermid, Incorporated Employees’ Pension Plan
(effective as of January 1, 2009)
|
|
S-4/A
|
|
333-192778
|
|
10.21
|
|
1/2/2014
|
|
|
10.7
|
|
MacDermid, Incorporated Supplemental Executive Retirement Plan
, effective April 1, 1994, as amended on February 25, 2005, and as further amended on July 11, 2013
|
|
S-4/A
|
|
333-192778
|
|
10.7
|
|
1/2/2014
|
|
|
10.8
|
|
Amendment No. 1, dated as of December 13, 2013, to MacDermid, Incorporated Supplemental Executive Retirement Plan
(as Previously Amended and Restated)
|
|
S-4/A
|
|
333-192778
|
|
10.9
|
|
1/2/2014
|
|
|
†10.9
|
|
Platform Specialty Products Corporation Employee Savings and 401(k) Plan
, effective as of January 1, 2014
|
|
S-8
|
|
333-205340
|
|
4.2(a)
|
|
6/29/2015
|
|
|
†10.10
|
|
Amendment No. 2 to Platform Specialty Products Corporation Employee Savings and 401(k) Plan
, dated as of September 8, 2014
|
|
S-8
|
|
333-205340
|
|
4.2(b)
|
|
6/29/2015
|
|
|
†10.11
|
|
Amendment No. 3 to Platform Specialty Products Corporation Employee Savings and 401(k) Plan
, dated as of November 17, 2014
|
|
S-8
|
|
333-205340
|
|
4.2(c)
|
|
6/29/2015
|
|
|
†10.12
|
|
Amendment No. 4 to Platform Specialty Products Corporation Employee Savings and 401(k) Plan
, dated as of February 10, 2015
|
|
S-8
|
|
333-205340
|
|
4.2(d)
|
|
6/29/2015
|
|
|
†10.13
|
|
Amendment No.5 to Platform Specialty Products Corporation Employee Savings and 401(k) Plan
, dated October 31, 2105
|
|
10-Q
|
|
001-36272
|
|
10.1
|
|
8/9/2016
|
|
|
|
|
|
|
Incorporated by Reference
|
|
Included in this 2017 Annual Report
|
||||||
Exhibit
Nb.
|
|
Exhibit Description
|
|
Form
|
|
File Nb.
|
|
Exhibit
Nb.
|
|
Filing Date
|
|
|
†10.14
|
|
Amendment No.6 to Platform Specialty Products Corporation Employee Savings and 401(k) Plan
, dated April 21, 2016
|
|
10-Q
|
|
001-36272
|
|
10.2
|
|
8/9/2016
|
|
|
†10.15
|
|
Platform Specialty Products Corporation Amended and Restated 2013 Incentive Compensation Plan
(Appendix A) (effective as of November 1, 2013)
|
|
DEF14A
|
|
001-36272
|
|
Appendix A
|
|
4/25/2014
|
|
|
†10.16
|
|
Platform Specialty Products Corporation 2014 Employee Stock Purchase Plan
(Appendix B) (effective as of March 6, 2014)
|
|
DEF14A
|
|
001-36272
|
|
Appendix B
|
|
4/25/2014
|
|
|
†10.17
|
|
Form of Restricted Stock Unit Agreement
– Platform Specialty Products Corporation Amended and Restated 2013 Incentive Compensation Plan
|
|
S-4
|
|
333-192778
|
|
10.11
|
|
1/2/2014
|
|
|
†10.18
|
|
Form of Performance-Based Restricted Stock Unit Award Agreement
– Platform Specialty Products Corporation Amended and Restated 2013 Incentive Compensation Plan
|
|
8-K
|
|
001-36272
|
|
10.2
|
|
3/25/2016
|
|
|
†10.19
|
|
Form of Non-Qualified Stock Option Agreemen
t – Platform Specialty Products Corporation Amended and Restated 2013 Incentive Compensation Plan
|
|
8-K
|
|
001-36272
|
|
10.3
|
|
3/25/2016
|
|
|
10.20
|
|
Form of Long Term Cash Bonus Award Agreement
– Platform Specialty Products Corporation Amended and Restated 2013 Incentive Compensation Plan
|
|
10-K
|
|
001-36272
|
|
10.24
|
|
3/11/2016
|
|
|
†10.21
|
|
|
S-4/A
|
|
333-192778
|
|
10.12
|
|
1/2/2014
|
|
|
|
†10.22
|
|
|
|
|
|
|
|
|
|
|
X
|
|
10.23
|
|
Amended and Restated Credit Agreement, dated as of October 31, 2013
, among, inter alia, Platform Acquisition Holding Limited, MacDermid Holdings, LLC, Matrix Acquisition Corp., MacDermid, Incorporated (as successor to Matrix Acquisition Corp., the borrower), the subsidiaries of the borrower from time to time parties thereto, the lenders from time to time parties thereto and Credit Suisse AG, as administrative agent and as collateral agent
|
|
S-4/A
|
|
333-192778
|
|
10.13
|
|
1/2/2014
|
|
|
10.24
|
|
Second Amended and Restated Credit Agreement, dated as of August 6, 2014
, among, inter alia, the Company, MacDermid Holdings, LLC, MacDermid, Incorporated, the subsidiaries of the borrower from time to time parties thereto, the lenders from time to time parties thereto and Barclays Bank PLC, as administrative agent and collateral agent
|
|
8-K
|
|
001-36272
|
|
10.1
|
|
8/8/2014
|
|
|
|
|
|
|
Incorporated by Reference
|
|
Included in this 2017 Annual Report
|
||||||
Exhibit
Nb.
|
|
Exhibit Description
|
|
Form
|
|
File Nb.
|
|
Exhibit
Nb.
|
|
Filing Date
|
|
|
10.25
|
|
Amendment No. 2, dated as of August 6, 2014
, among, inter alia, the Company, MacDermid Holdings, LLC, MacDermid, Incorporated, the subsidiaries of the borrower from time to time parties thereto, the lenders from time to time parties thereto, and Barclays Bank PLC, as administrative agent and collateral agent
|
|
8-K
|
|
001-36272
|
|
10.2
|
|
8/8/2014
|
|
|
10.26
|
|
Incremental Amendment No. 1, dated as of October 1, 2014
, among the Company, MacDermid, Incorporated, MacDermid Holdings, LLC, certain subsidiaries of MacDermid Holdings, LLC and Platform party thereto, Barclays Bank PLC, as collateral agent and administrative agent, and the lenders party thereto
|
|
8-K
|
|
001-36272
|
|
10.1
|
|
10/1/2014
|
|
|
10.27
|
|
Amendment No.3, dated February 13, 2015
, among, inter alia, Platform, Holdings, MacDermid, the subsidiaries of the borrower from time to time parties thereto, the lenders from time to time parties thereto, and Barclays Bank PLC, as administrative agent and collateral agent
|
|
8-K
|
|
001-36272
|
|
10.1
|
|
2/17/2015
|
|
|
10.28
|
|
Amendment No. 4, dated December 3, 2015
, among, inter alia, Platform, MacDermid, the subsidiaries of the borrowers from time to time parties thereto, the lenders from time to time parties thereto, and Barclays Bank PLC, as administrative agent and collateral agent
|
|
8-K
|
|
001-36272
|
|
10.3
|
|
12/4/2015
|
|
|
10.29
|
|
Amendment No. 5, dated October 14, 2016
, among, inter alios, Platform, MacDermid, the subsidiaries of the borrowers from time to time parties thereto, the lenders from time to time parties thereto, and Barclays Bank PLC, as administrative agent and collateral agent
|
|
8-K
|
|
001-36272
|
|
10.1
|
|
10/17/2016
|
|
|
10.30
|
|
Amendment No. 6, dated December 6, 2016
, among, inter alios, Platform, MacDermid, the subsidiaries of the borrowers from time to time parties thereto, the lenders from time to time parties thereto, and Barclays Bank PLC, as administrative agent and collateral agent
|
|
8-K
|
|
001-36272
|
|
10.1
|
|
12/7/2016
|
|
|
10.31
|
|
Amendment No. 7, dated April 18, 2017
, among, inter alios, Platform, MacDermid, the subsidiaries of the borrowers from time to time parties thereto, the lenders from time to time parties thereto, and Barclays Bank PLC, as administrative agent and collateral agent
|
|
8-K
|
|
001-36272
|
|
10.1
|
|
4/18/2017
|
|
|
10.32
|
|
Amendment No. 8, dated October 3, 2017
, among, inter alios, Platform, MacDermid, the subsidiaries of the borrowers from time to time parties thereto, the lenders from time to time parties thereto, and Barclays Bank PLC, as administrative agent and collateral agent
|
|
8-K
|
|
001-36272
|
|
10.1
|
|
10/3/2017
|
|
|
|
|
|
|
Incorporated by Reference
|
|
Included in this 2017 Annual Report
|
||||||
Exhibit
Nb.
|
|
Exhibit Description
|
|
Form
|
|
File Nb.
|
|
Exhibit
Nb.
|
|
Filing Date
|
|
|
10.33
|
|
Amended and Restated Pledge and Security Agreement, amended and restated as of October 31, 2013
,
among Platform, MacDermid Holdings, LLC, MacDermid, Incorporated and the subsidiaries of the borrowers from time to time parties thereto in favor of Barclays Bank PLC, as collateral agent
|
|
10-K
|
|
001-36272
|
|
10.25
|
|
3/31/2014
|
|
|
10.34
|
|
|
S-4/A
|
|
333-192778
|
|
10.14
|
|
1/2/2014
|
|
|
|
10.35
|
|
Advisory Services Agreement, dated October 31, 2013
, by and between Platform Specialty Products Corporation and Mariposa Capital, LLC
|
|
S-4/A
|
|
333-192778
|
|
10.15
|
|
1/2/2014
|
|
|
10.36
|
|
Letter Agreement with respect to Supplemental Executive Retirement Plan payment, dated as of October 29, 2013
, between Platform Acquisition Holdings Limited and Daniel H. Leever
|
|
S-4/A
|
|
333-192778
|
|
10.16
|
|
1/2/2014
|
|
|
10.37
|
|
|
S-4/A
|
|
333-192778
|
|
10.17
|
|
1/2/2014
|
|
|
|
10.38
|
|
Registration Rights Agreement, dated as of May 20, 2014
, between Platform Specialty, the placement agents thereto and the Investors stated therein
|
|
8-K
|
|
001-36272
|
|
10.1
|
|
5/21/2014
|
|
|
10.39
|
|
|
8-K
|
|
001-36272
|
|
10.3
|
|
10/8/2014
|
|
|
|
14.1
|
|
|
10-K
|
|
001-36272
|
|
14.1
|
|
3/31/2014
|
|
|
|
21.1
|
|
|
|
|
|
|
|
|
|
|
X
|
|
23.1
|
|
|
|
|
|
|
|
|
|
|
X
|
|
24.1
|
|
|
|
|
|
|
|
|
|
|
X
|
|
31.1
|
|
|
|
|
|
|
|
|
|
|
X
|
|
31.2
|
|
|
|
|
|
|
|
|
|
|
X
|
|
32.1*
|
|
|
|
|
|
|
|
|
|
|
X
|
|
101.INS
|
|
XBRL Instance Document
|
|
|
|
|
|
|
|
|
|
X
|
101.SCH
|
|
XBRL Taxonomy Extension Schema Document
|
|
|
|
|
|
|
|
|
|
X
|
101.CAL
|
|
XBRL Extension Calculation Linkbase Document
|
|
|
|
|
|
|
|
|
|
X
|
101.DEF
|
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
|
|
|
|
|
|
|
|
X
|
101.LAB
|
|
XBRL Taxonomy Extension Label Linkbase Document
|
|
|
|
|
|
|
|
|
|
X
|
101.PRE
|
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
|
|
|
|
|
|
|
|
|
X
|
*
|
|
Furnished herewith.
|
†
|
|
This Exhibit represents a management contract or a compensatory plan.
|
|
|
|
PLATFORM SPECIALTY PRODUCTS CORPORATION
|
|||
|
|
|
|
|||
|
|
|
By:
|
|
/s/ John P. Connolly
|
|
|
|
|
|
|
Name: John P. Connolly
|
|
|
|
|
|
|
Title: Chief Financial Officer
|
|
|
|
|
Date:
|
|
February 28, 2018
|
Signature
|
|
Title
|
Date
|
/s/ Rakesh Sachdev
|
|
Director and Chief Executive Officer
|
February 28, 2018
|
Rakesh Sachdev
|
|
(Principal Executive Officer)
|
|
|
|
|
|
/s/ John P. Connolly
|
|
Chief Financial Officer
|
February 28, 2018
|
John P. Connolly
|
|
(Principal Financial and Accounting Officer)
|
|
|
|
|
|
/s/ Martin E. Franklin
|
|
Chairman of the Board
|
February 28, 2018
|
Martin E. Franklin
|
|
|
|
|
|
|
|
/s/ Ian G.H. Ashken
|
|
Director
|
February 28, 2018
|
Ian G.H. Ashken
|
|
|
|
|
|
|
|
/s/ Nicolas Berggruen
|
|
Director
|
February 28, 2018
|
Nicolas Berggruen
|
|
|
|
|
|
|
|
/s/ Michael F. Goss
|
|
Director
|
February 28, 2018
|
Michael F. Goss
|
|
|
|
|
|
|
|
/s/ Ryan Israel
|
|
Director
|
February 28, 2018
|
Ryan Israel
|
|
|
|
|
|
|
|
/s / E. Stanley O’Neal
|
|
Director
|
February 28, 2018
|
E. Stanley O’Neal
|
|
|
|
|
|
Page
|
|
|
|
|
||
|
|
|
Consolidated Financial Statements:
|
|
|
|
|
|
|
|
|
Years Ended December 31, 2017, 2016 and 2015
|
|
|
|
|
|
|
|
|
Years Ended December 31, 2017, 2016 and 2015
|
|
|
|
|
|
|
|
|
December 31, 2017 and 2016
|
|
|
|
|
|
|
|
|
Years Ended December 31, 2017, 2016 and 2015
|
|
|
|
|
|
|
|
|
Years Ended December 31, 2017, 2016 and 2015
|
|
|
|
|
|
|
||
|
|
|
Financial Statement Schedule:
|
|
|
|
|
|
|
|
|
Years Ended December 31, 2017, 2016 and 2015
|
|
|
|
Year Ended December 31,
|
||||||||||
|
|
2017
|
|
2016
|
|
2015
|
||||||
Net sales
|
|
$
|
3,775.9
|
|
|
$
|
3,585.9
|
|
|
$
|
2,542.3
|
|
Cost of sales
|
|
2,186.9
|
|
|
2,078.2
|
|
|
1,550.4
|
|
|||
Gross profit
|
|
1,589.0
|
|
|
1,507.7
|
|
|
991.9
|
|
|||
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|||
Selling, technical, general and administrative
|
|
1,109.3
|
|
|
1,123.3
|
|
|
857.5
|
|
|||
Research and development
|
|
98.4
|
|
|
84.4
|
|
|
62.8
|
|
|||
Goodwill impairment
|
|
160.0
|
|
|
46.6
|
|
|
—
|
|
|||
Total operating expenses
|
|
1,367.7
|
|
|
1,254.3
|
|
|
920.3
|
|
|||
Operating profit
|
|
221.3
|
|
|
253.4
|
|
|
71.6
|
|
|||
Other (expense) income:
|
|
|
|
|
|
|
|
|
|
|||
Interest expense, net
|
|
(341.6
|
)
|
|
(375.7
|
)
|
|
(213.9
|
)
|
|||
Foreign exchange loss
|
|
(107.5
|
)
|
|
(14.1
|
)
|
|
(43.4
|
)
|
|||
Other (expense) income, net
|
|
(61.2
|
)
|
|
88.3
|
|
|
(43.6
|
)
|
|||
Total other expense
|
|
(510.3
|
)
|
|
(301.5
|
)
|
|
(300.9
|
)
|
|||
Loss before income taxes and non-controlling interests
|
|
(289.0
|
)
|
|
(48.1
|
)
|
|
(229.3
|
)
|
|||
Income tax expense
|
|
(6.6
|
)
|
|
(28.6
|
)
|
|
(75.1
|
)
|
|||
Net loss
|
|
(295.6
|
)
|
|
(76.7
|
)
|
|
(304.4
|
)
|
|||
Net (income) loss attributable to the non-controlling interests
|
|
(0.6
|
)
|
|
3.0
|
|
|
(4.2
|
)
|
|||
Net loss attributable to stockholders
|
|
(296.2
|
)
|
|
(73.7
|
)
|
|
(308.6
|
)
|
|||
Gain on amendment of Series B Convertible Preferred Stock
|
|
—
|
|
|
32.9
|
|
|
—
|
|
|||
Net loss attributable to common stockholders
|
|
$
|
(296.2
|
)
|
|
$
|
(40.8
|
)
|
|
$
|
(308.6
|
)
|
Loss per share
|
|
|
|
|
|
|
|
|
|
|||
Basic
|
|
$
|
(1.04
|
)
|
|
$
|
(0.17
|
)
|
|
$
|
(1.52
|
)
|
Diluted
|
|
$
|
(1.04
|
)
|
|
$
|
(0.65
|
)
|
|
$
|
(1.52
|
)
|
Weighted average common shares outstanding
|
|
|
|
|
|
|
|
|
|
|||
Basic
|
|
286.1
|
|
|
243.3
|
|
|
203.2
|
|
|||
Diluted
|
|
286.1
|
|
|
272.3
|
|
|
203.2
|
|
|
|
Year Ended December 31,
|
||||||||||
|
|
2017
|
|
2016
|
|
2015
|
||||||
Net loss
|
|
$
|
(295.6
|
)
|
|
$
|
(76.7
|
)
|
|
$
|
(304.4
|
)
|
|
|
|
|
|
|
|
||||||
Other comprehensive income (loss)
|
|
|
|
|
|
|
|
|
|
|||
Foreign currency translation adjustments
|
|
241.1
|
|
|
204.6
|
|
|
(777.1
|
)
|
|||
Pension and post-retirement plans:
|
|
|
|
|
|
|
|
|
|
|||
Other comprehensive income (loss), net of tax (expense) benefit of $(2.2), ($0.9) and $3.2 for 2017, 2016 and 2015, respectively
|
|
2.5
|
|
|
7.5
|
|
|
(11.4
|
)
|
|||
Reclassifications, net of tax expense of $2.1 for 2017, $0.0 for 2016 and 2015
|
|
8.4
|
|
|
—
|
|
|
—
|
|
|||
Total pension and post-retirement plans
|
|
10.9
|
|
|
7.5
|
|
|
(11.4
|
)
|
|||
Unrealized (loss) gain on available for sale securities:
|
|
|
|
|
|
|
|
|
|
|||
Other comprehensive (loss) income, net of tax benefit (expense) of $0.4, $0.6 and ($0.6) for 2017, 2016 and 2015, respectively
|
|
(2.2
|
)
|
|
(0.8
|
)
|
|
1.1
|
|
|||
Reclassifications, net of tax expense of $0.0 for 2017, 2016 and 2015
|
|
0.5
|
|
|
—
|
|
|
—
|
|
|||
Total unrealized (loss) gain on available for sale securities
|
|
(1.7
|
)
|
|
(0.8
|
)
|
|
1.1
|
|
|||
Derivative financial instrument revaluation:
|
|
|
|
|
|
|
|
|
|
|||
Other comprehensive loss before reclassifications, net of tax (expense) benefit of $(4.3), $0.0 and $4.4 for 2017, 2016 and 2015, respectively
|
|
(4.6
|
)
|
|
(9.6
|
)
|
|
(8.1
|
)
|
|||
Reclassifications, net of tax expense of $0.0 for 2017, 2016 and 2015
|
|
10.4
|
|
|
11.9
|
|
|
—
|
|
|||
Total unrealized gain (loss) arising on qualified hedging derivatives
|
|
5.8
|
|
|
2.3
|
|
|
(8.1
|
)
|
|||
Other comprehensive income (loss)
|
|
256.1
|
|
|
213.6
|
|
|
(795.5
|
)
|
|||
|
|
|
|
|
|
|
||||||
Comprehensive (loss) income
|
|
(39.5
|
)
|
|
136.9
|
|
|
(1,099.9
|
)
|
|||
Comprehensive (income) loss attributable to the non-controlling interests
|
|
(4.3
|
)
|
|
1.0
|
|
|
35.8
|
|
|||
Comprehensive income (loss) attributable to stockholders
|
|
$
|
(43.8
|
)
|
|
$
|
137.9
|
|
|
$
|
(1,064.1
|
)
|
|
|
December 31,
|
||||||
|
|
2017
|
|
2016
|
||||
Assets
|
|
|
|
|
||||
Cash & cash equivalents
|
|
$
|
477.8
|
|
|
$
|
422.6
|
|
Accounts receivable, net
|
|
1,156.0
|
|
|
1,054.8
|
|
||
Inventories
|
|
490.4
|
|
|
416.4
|
|
||
Prepaid expenses
|
|
42.8
|
|
|
71.3
|
|
||
Other current assets
|
|
173.6
|
|
|
106.1
|
|
||
Total current assets
|
|
2,340.6
|
|
|
2,071.2
|
|
||
Property, plant & equipment, net
|
|
452.3
|
|
|
460.5
|
|
||
Goodwill
|
|
4,201.2
|
|
|
4,178.9
|
|
||
Intangible assets, net
|
|
3,137.3
|
|
|
3,233.3
|
|
||
Other assets
|
|
121.0
|
|
|
110.2
|
|
||
Total assets
|
|
$
|
10,252.4
|
|
|
$
|
10,054.1
|
|
Liabilities & stockholders' equity
|
|
|
|
|
|
|
||
Accounts payable
|
|
$
|
461.8
|
|
|
$
|
383.6
|
|
Current installments of long-term debt and revolving credit facilities
|
|
38.9
|
|
|
116.1
|
|
||
Accrued expenses and other current liabilities
|
|
591.1
|
|
|
583.0
|
|
||
Total current liabilities
|
|
1,091.8
|
|
|
1,082.7
|
|
||
Debt and capital lease obligations
|
|
5,440.6
|
|
|
5,122.9
|
|
||
Pension and post-retirement benefits
|
|
69.0
|
|
|
73.8
|
|
||
Deferred income taxes
|
|
579.6
|
|
|
663.2
|
|
||
Contingent consideration
|
|
79.2
|
|
|
75.8
|
|
||
Other liabilities
|
|
132.2
|
|
|
145.9
|
|
||
Total liabilities
|
|
7,392.4
|
|
|
7,164.3
|
|
||
Commitments and contingencies (Note 18)
|
|
|
|
|
|
|
||
Stockholders' equity
|
|
|
|
|
|
|
||
Preferred stock - Series A
|
|
—
|
|
|
—
|
|
||
Common stock, 400.0 shares authorized (2017: 287.4 shares issued; 2016: 284.2 shares issued)
|
|
2.9
|
|
|
2.8
|
|
||
Treasury stock (2017: 0.0 shares; 2016: 0.0 shares)
|
|
(0.1
|
)
|
|
—
|
|
||
Additional paid-in capital
|
|
4,032.0
|
|
|
3,981.3
|
|
||
Accumulated deficit
|
|
(869.7
|
)
|
|
(573.5
|
)
|
||
Accumulated other comprehensive loss
|
|
(422.0
|
)
|
|
(674.5
|
)
|
||
Total stockholders' equity
|
|
2,743.1
|
|
|
2,736.1
|
|
||
Non-controlling interests
|
|
116.9
|
|
|
153.7
|
|
||
Total equity
|
|
2,860.0
|
|
|
2,889.8
|
|
||
Total liabilities and stockholders' equity
|
|
$
|
10,252.4
|
|
|
$
|
10,054.1
|
|
|
|
Year Ended December 31,
|
||||||||||
|
|
2017
|
|
2016
|
|
2015
|
||||||
Cash flows from operating activities:
|
|
|
|
|
|
|
||||||
Net loss
|
|
$
|
(295.6
|
)
|
|
$
|
(76.7
|
)
|
|
$
|
(304.4
|
)
|
Reconciliations of net loss to net cash flows provided by operating activities:
|
|
|
|
|
|
|
|
|
|
|||
Depreciation and amortization
|
|
354.2
|
|
|
342.3
|
|
|
251.0
|
|
|||
Deferred income taxes
|
|
(126.6
|
)
|
|
(57.4
|
)
|
|
(45.5
|
)
|
|||
Amortization of inventory step-up
|
|
—
|
|
|
11.7
|
|
|
76.5
|
|
|||
Foreign exchange loss
|
|
114.0
|
|
|
43.8
|
|
|
97.3
|
|
|||
Goodwill impairment
|
|
160.0
|
|
|
46.6
|
|
|
—
|
|
|||
Gain on settlement agreement related to Series B Convertible Preferred Stock
|
|
—
|
|
|
(103.0
|
)
|
|
—
|
|
|||
Other, net
|
|
89.9
|
|
|
85.2
|
|
|
36.6
|
|
|||
Changes in assets and liabilities, net of acquisitions:
|
|
|
|
|
|
|
|
|
|
|||
Accounts receivable
|
|
(53.1
|
)
|
|
(18.9
|
)
|
|
66.7
|
|
|||
Inventory
|
|
(30.3
|
)
|
|
70.4
|
|
|
(7.3
|
)
|
|||
Accounts payable
|
|
49.8
|
|
|
(67.3
|
)
|
|
83.2
|
|
|||
Accrued expenses
|
|
(9.2
|
)
|
|
25.4
|
|
|
51.5
|
|
|||
Prepaid expenses and other current assets
|
|
(27.0
|
)
|
|
(0.4
|
)
|
|
(20.3
|
)
|
|||
Other assets and liabilities
|
|
(44.0
|
)
|
|
(116.9
|
)
|
|
35.6
|
|
|||
Net cash flows provided by operating activities
|
|
182.1
|
|
|
184.8
|
|
|
320.9
|
|
|||
Cash flows from investing activities:
|
|
|
|
|
|
|
|
|
|
|||
Capital expenditures
|
|
(59.4
|
)
|
|
(56.3
|
)
|
|
(47.9
|
)
|
|||
Investment in registrations of products
|
|
(40.5
|
)
|
|
(36.4
|
)
|
|
(34.4
|
)
|
|||
Proceeds from disposal of property, plant and equipment
|
|
17.5
|
|
|
20.6
|
|
|
25.8
|
|
|||
Acquisition of business, net of cash acquired
|
|
(0.5
|
)
|
|
1.3
|
|
|
(4,600.3
|
)
|
|||
Restricted cash
|
|
(5.2
|
)
|
|
(0.5
|
)
|
|
599.7
|
|
|||
Note receivable
|
|
—
|
|
|
—
|
|
|
(125.0
|
)
|
|||
Settlement of foreign exchange contracts in connection with acquisition
|
|
—
|
|
|
—
|
|
|
(73.1
|
)
|
|||
Other, net
|
|
(4.5
|
)
|
|
(3.4
|
)
|
|
(1.3
|
)
|
|||
Net cash flows used in investing activities
|
|
(92.6
|
)
|
|
(74.7
|
)
|
|
(4,256.5
|
)
|
|||
Cash flows from financing activities:
|
|
|
|
|
|
|
|
|
|
|||
Debt proceeds, net of discount and premium
|
|
4,142.7
|
|
|
3,300.9
|
|
|
3,921.8
|
|
|||
Repayments of borrowings
|
|
(4,122.1
|
)
|
|
(3,340.1
|
)
|
|
(283.7
|
)
|
|||
Change in lines of credit, net
|
|
(58.8
|
)
|
|
54.0
|
|
|
(12.4
|
)
|
|||
Proceeds from issuance of common stock, net
|
|
1.4
|
|
|
391.5
|
|
|
469.5
|
|
|||
Change in on-balance sheet factoring arrangements
|
|
(3.5
|
)
|
|
(44.1
|
)
|
|
(3.9
|
)
|
|||
Payment of financing fees
|
|
(13.8
|
)
|
|
(1.1
|
)
|
|
(87.0
|
)
|
|||
Settlement of Series B Convertible Preferred Stock
|
|
—
|
|
|
(460.0
|
)
|
|
—
|
|
|||
Other, net
|
|
(13.3
|
)
|
|
(3.3
|
)
|
|
(3.1
|
)
|
|||
Net cash flows (used in) provided by financing activities
|
|
(67.4
|
)
|
|
(102.2
|
)
|
|
4,001.2
|
|
|||
Effect of exchange rate changes on cash and cash equivalents
|
|
33.1
|
|
|
(17.5
|
)
|
|
(30.7
|
)
|
|||
Net increase (decrease) in cash and cash equivalents
|
|
55.2
|
|
|
(9.6
|
)
|
|
34.9
|
|
|||
Cash and cash equivalents at beginning of period
|
|
422.6
|
|
|
432.2
|
|
|
397.3
|
|
|||
Cash and cash equivalents at end of period
|
|
$
|
477.8
|
|
|
$
|
422.6
|
|
|
$
|
432.2
|
|
|
|
|
|
|
|
|
||||||
Supplemental disclosure information:
|
|
|
|
|
|
|
||||||
Cash paid for interest
|
|
$
|
322.8
|
|
|
$
|
360.1
|
|
|
$
|
147.6
|
|
Cash paid for income taxes
|
|
$
|
145.0
|
|
|
$
|
121.2
|
|
|
$
|
73.3
|
|
|
Preferred Stock
|
|
Common Stock
|
|
Additional Paid-in Capital
|
|
Treasury Stock
|
|
Accumulated Deficit
|
|
Accumulated other Comprehensive (Loss) Income
|
|
Total Stockholders' Equity
|
|
Non- controlling Interest
|
|
Total Equity
|
|||||||||||||||||||||||||||
|
Shares
|
|
Amount
|
Shares
|
|
Amount
|
Shares
|
|
Amount
|
|||||||||||||||||||||||||||||||||||
Balance at December 31, 2016
|
2,000,000
|
|
|
$
|
—
|
|
|
284,221,168
|
|
|
$
|
2.8
|
|
|
$
|
3,981.3
|
|
|
—
|
|
|
$
|
—
|
|
|
$
|
(573.5
|
)
|
|
$
|
(674.5
|
)
|
|
$
|
2,736.1
|
|
|
$
|
153.7
|
|
|
$
|
2,889.8
|
|
Net (loss) income
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(296.2
|
)
|
|
—
|
|
|
(296.2
|
)
|
|
0.6
|
|
|
(295.6
|
)
|
|||||||||
Other comprehensive income, net of taxes
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
252.5
|
|
|
252.5
|
|
|
3.6
|
|
|
256.1
|
|
|||||||||
Exercise/ vesting of share based compensation
|
—
|
|
|
—
|
|
|
122,769
|
|
|
—
|
|
|
0.1
|
|
|
6,618
|
|
|
(0.1
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||||
Conversion of PDH Common Stock into common stock
|
—
|
|
|
—
|
|
|
2,923,436
|
|
|
0.1
|
|
|
35.6
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
35.7
|
|
|
(35.7
|
)
|
|
—
|
|
|||||||||
Issuance of common stock under ESPP
|
—
|
|
|
—
|
|
|
138,566
|
|
|
—
|
|
|
1.3
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1.3
|
|
|
—
|
|
|
1.3
|
|
|||||||||
Equity compensation expense
|
—
|
|
|
—
|
|
|
|
|
—
|
|
|
11.7
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
11.7
|
|
|
—
|
|
|
11.7
|
|
||||||||||
Changes in non-controlling interests
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
2.0
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
2.0
|
|
|
(5.3
|
)
|
|
(3.3
|
)
|
|||||||||
Balance at December 31, 2017
|
2,000,000
|
|
|
$
|
—
|
|
|
287,405,939
|
|
|
$
|
2.9
|
|
|
$
|
4,032.0
|
|
|
6,618
|
|
|
$
|
(0.1
|
)
|
|
$
|
(869.7
|
)
|
|
$
|
(422.0
|
)
|
|
$
|
2,743.1
|
|
|
$
|
116.9
|
|
|
$
|
2,860.0
|
|
|
Preferred Stock
|
|
Common Stock
|
|
Additional Paid-in Capital
|
|
Treasury Stock
|
|
Accumulated Deficit
|
|
Accumulated other Comprehensive (Loss) Income
|
|
Total Stockholders' Equity
|
|
Non- controlling Interest
|
|
Total Equity
|
|||||||||||||||||||||||||||
|
Shares
|
|
Amount
|
Shares
|
|
Amount
|
Shares
|
|
Amount
|
|||||||||||||||||||||||||||||||||||
Balance at December 31, 2015
|
2,000,000
|
|
|
$
|
—
|
|
|
229,464,157
|
|
|
$
|
2.3
|
|
|
$
|
3,520.4
|
|
|
—
|
|
|
$
|
—
|
|
|
$
|
(532.7
|
)
|
|
$
|
(886.1
|
)
|
|
$
|
2,103.9
|
|
|
$
|
169.4
|
|
|
$
|
2,273.3
|
|
Net loss
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(73.7
|
)
|
|
—
|
|
|
(73.7
|
)
|
|
(3.0
|
)
|
|
(76.7
|
)
|
|||||||||
Other comprehensive income
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
211.6
|
|
|
211.6
|
|
|
2.0
|
|
|
213.6
|
|
|||||||||
Issuance of common stock to former non-founder director for exercise of stock options
|
—
|
|
|
—
|
|
|
7,642
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||||
Conversion of PDH Common Stock into common stock
|
—
|
|
|
—
|
|
|
325,431
|
|
|
—
|
|
|
3.8
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
3.8
|
|
|
(3.8
|
)
|
|
—
|
|
|||||||||
Issuance of common stock under ESPP
|
—
|
|
|
—
|
|
|
136,060
|
|
|
—
|
|
|
0.9
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
0.9
|
|
|
—
|
|
|
0.9
|
|
|||||||||
Equity compensation expense
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
7.4
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
7.4
|
|
|
—
|
|
|
7.4
|
|
|||||||||
Issuance of common stock at $8.25 per share in the September 2016 Equity Offering
|
—
|
|
|
—
|
|
|
48,787,878
|
|
|
0.5
|
|
|
402.0
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
402.5
|
|
|
—
|
|
|
402.5
|
|
|||||||||
Issuance costs in connection with the September 2016 Equity Offering
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(11.9
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(11.9
|
)
|
|
—
|
|
|
(11.9
|
)
|
|||||||||
Series B Convertible Preferred Stock settlement
|
—
|
|
|
—
|
|
|
5,500,000
|
|
|
—
|
|
|
54.9
|
|
|
—
|
|
|
—
|
|
|
32.9
|
|
|
—
|
|
|
87.8
|
|
|
—
|
|
|
87.8
|
|
|||||||||
Changes in non-controlling interests
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
3.8
|
|
|
—
|
|
|
|
|
—
|
|
|
—
|
|
|
3.8
|
|
|
(10.9
|
)
|
|
(7.1
|
)
|
||||||||||
Balance at December 31, 2016
|
2,000,000
|
|
|
$
|
—
|
|
|
284,221,168
|
|
|
$
|
2.8
|
|
|
$
|
3,981.3
|
|
|
—
|
|
|
$
|
—
|
|
|
$
|
(573.5
|
)
|
|
$
|
(674.5
|
)
|
|
$
|
2,736.1
|
|
|
$
|
153.7
|
|
|
$
|
2,889.8
|
|
|
Preferred Stock
|
|
Common Stock
|
|
Additional
Paid-in Capital |
|
Treasury Stock
|
|
Accumulated
Deficit |
|
Accumulated
Other Comprehensive Loss |
|
Total
Stockholders' Equity |
|
Non-
controlling Interests |
|
Total Equity
|
|||||||||||||||||||||||||||
|
Shares
|
|
Amount
|
|
Shares
|
|
Amount
|
|
Shares
|
|
Amount
|
|||||||||||||||||||||||||||||||||
Balance at December 31, 2014
|
2,000,000
|
|
|
$
|
—
|
|
|
182,066,980
|
|
|
$
|
1.9
|
|
|
$
|
2,812.4
|
|
|
—
|
|
|
$
|
—
|
|
|
$
|
(224.1
|
)
|
|
$
|
(130.6
|
)
|
|
$
|
2,459.6
|
|
|
$
|
93.0
|
|
|
$
|
2,552.6
|
|
Net (loss) income
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(308.6
|
)
|
|
—
|
|
|
(308.6
|
)
|
|
4.2
|
|
|
(304.4
|
)
|
|||||||||
Other comprehensive loss
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(755.5
|
)
|
|
(755.5
|
)
|
|
(40.0
|
)
|
|
(795.5
|
)
|
|||||||||
Issuance of common stock to Founder Entities as stock dividend to Series A Preferred Stock declared on December 31, 2014
|
—
|
|
|
—
|
|
|
10,050,290
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||||
Issuance of common stock to former non-founder director for exercise of stock options
|
—
|
|
|
—
|
|
|
75,000
|
|
|
—
|
|
|
0.9
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
0.9
|
|
|
—
|
|
|
0.9
|
|
|||||||||
Conversion of PDH Common Stock into common stock
|
—
|
|
|
—
|
|
|
578,874
|
|
|
—
|
|
|
6.6
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
6.6
|
|
|
(6.6
|
)
|
|
—
|
|
|||||||||
Issuance of common stock under ESPP
|
—
|
|
|
—
|
|
|
44,361
|
|
|
—
|
|
|
0.7
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
0.7
|
|
|
—
|
|
|
0.7
|
|
|||||||||
Equity compensation expense
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
0.9
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
0.9
|
|
|
—
|
|
|
0.9
|
|
|||||||||
Acquisition of non-controlling interest with Arysta Acquisition
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
125.4
|
|
|
125.4
|
|
|||||||||
Issuance of common stock at $26.50 per share in June 2015 Equity Offering
|
—
|
|
|
—
|
|
|
18,226,414
|
|
|
0.2
|
|
|
482.7
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
482.9
|
|
|
—
|
|
|
482.9
|
|
|||||||||
Issuance costs in connection with June 2015 Equity Offering
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(15.0
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(15.0
|
)
|
|
—
|
|
|
(15.0
|
)
|
|||||||||
Issuance of common shares to non-employee
|
—
|
|
|
—
|
|
|
2,500
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||||
Acquisition of remaining interest in Arysta Colombia
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(3.3
|
)
|
|
(3.3
|
)
|
|||||||||
Issuance of common shares at $12.56 per share in connection with Alent acquisition on December 1, 2015
|
—
|
|
|
—
|
|
|
18,419,738
|
|
|
0.2
|
|
|
231.2
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
231.4
|
|
|
—
|
|
|
231.4
|
|
|||||||||
Sale of 50.65% ownership in Arysta Toyo Green Co LTD, including maintenance subsidiary
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(1.7
|
)
|
|
(1.7
|
)
|
|||||||||
Distribution to non-controlling interests
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(1.6
|
)
|
|
(1.6
|
)
|
|||||||||
Balance at December 31, 2015
|
2,000,000
|
|
|
$
|
—
|
|
|
229,464,157
|
|
|
$
|
2.3
|
|
|
$
|
3,520.4
|
|
|
—
|
|
|
$
|
—
|
|
|
$
|
(532.7
|
)
|
|
$
|
(886.1
|
)
|
|
$
|
2,103.9
|
|
|
$
|
169.4
|
|
|
$
|
2,273.3
|
|
•
|
Valuation Techniques
- the Company uses a discounted cash flow analysis, which requires assumptions about short and long-term net cash flows, growth rates, as well as discount rates. Additionally, it considers guideline company and guideline transaction information, where available, to aid in the valuation of the reporting units.
|
•
|
Growth Assumptions
- Multi-year financial forecasts are developed for each reporting unit by considering several key business drivers such as new business initiatives, client service and retention standards, market share changes, historical performance, and industry and economic trends, among other considerations.
|
•
|
Discount Rate Assumptions
- Discount rates are estimated based on the WACC, which combines the required return on equity and considers the risk-free interest rate, market risk premium, small stock risk premium and a company specific risk premium, with the cost of debt, based on rated corporate bonds, adjusted using an income tax factor.
|
•
|
Estimated Fair Value and Sensitivitie
s - The estimated fair value of each reporting unit is derived from the valuation techniques described above. The estimated fair value of each reporting unit is analyzed in relation to numerous market and historical factors, including current economic and market conditions, company-specific growth opportunities and guideline company information.
|
•
|
Level 1 – inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities.
|
•
|
Level 2 – inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in non-active markets; and model-derived valuations whose inputs are observable or whose significant valuation drivers are observable.
|
•
|
Level 3 – inputs to valuation models are unobservable and/or reflect the Company’s market assumptions.
|
•
|
Arrangements whereby the Company sells trade receivables to third parties without recourse and receives beneficial interests for a portion of these receivables, the proceeds of which are currently included in “Operating Activities” in the Condensed Consolidated Statements of Cash Flows. Under the new guidance, approximately
$69.0 million
and
$3.9 million
of beneficial interests will be disclosed as a non-cash activity, with cash receipts of approximately
$44.3 million
and
$3.4 million
classified as cash inflows from "Investing Activities" in the Consolidated Statements of Cash Flows for 2017 and 2016, respectively.
|
•
|
Cash payments for debt prepayments and debt extinguishment costs of approximately
$8.8 million
and
$8.4 million
will be reclassified from "Operating Activities" to "Financing Activities" in the Consolidated Statements of Cash Flows for 2017 and 2016, respectively.
|
($ amounts in millions)
|
|
Year of Acquisition
|
|
Net Sales
|
|
Net Income (Loss)
|
||||
OMG Malaysia
|
|
2016
|
|
$
|
30.9
|
|
|
$
|
3.2
|
|
Alent
|
|
2015
|
|
70.8
|
|
|
(12.4
|
)
|
||
OMG
|
|
2015
|
|
20.7
|
|
|
(0.4
|
)
|
||
Arysta
|
|
2015
|
|
1,197.0
|
|
|
(86.7
|
)
|
($ amounts in millions)
|
|
OMG Malaysia
|
||
Consideration
|
|
|
||
Cash, net
|
|
$
|
(1.3
|
)
|
Note receivable settlement
|
|
125.0
|
|
|
Total consideration
|
|
$
|
123.7
|
|
|
|
|
||
Acquisition costs
|
|
$
|
0.5
|
|
|
|
|
||
Identifiable assets acquired and liabilities assumed
|
|
|
||
Accounts receivable
|
|
$
|
4.3
|
|
Inventories
|
|
6.4
|
|
|
Other current assets
|
|
0.2
|
|
|
Property, plant and equipment
|
|
4.7
|
|
|
Identifiable intangible assets
|
|
43.9
|
|
|
Current liabilities
|
|
(3.5
|
)
|
|
Non-current deferred tax liability
|
|
(11.3
|
)
|
|
Total identifiable net assets
|
|
44.7
|
|
|
Goodwill
|
|
79.0
|
|
|
Total purchase price
|
|
$
|
123.7
|
|
|
|
OMG Malaysia
|
||||
($ amounts in millions)
|
|
Fair Value
|
|
Weighted average useful life (years)
|
||
Customer lists
|
|
$
|
41.0
|
|
|
15.0
|
Developed technology
|
|
2.9
|
|
|
5.0
|
|
Total
|
|
$
|
43.9
|
|
|
14.3
|
|
|
Year Ended December 31,
|
||
($ amounts in millions)
|
|
2015
|
||
Pro forma net sales
|
|
$
|
3,582.4
|
|
Pro forma net loss attributable to stockholders
|
|
(328.1
|
)
|
|
|
December 31,
|
||||||
($ amounts in millions)
|
|
2017
|
|
2016
|
||||
Total accounts receivable, net
|
|
$
|
1,157.7
|
|
|
$
|
1,058.0
|
|
Non-current accounts receivable, net
|
|
(1.7
|
)
|
|
(3.2
|
)
|
||
Current accounts receivable, net
|
|
$
|
1,156.0
|
|
|
$
|
1,054.8
|
|
|
|
December 31,
|
||||||
($ amounts in millions)
|
|
2017
|
|
2016
|
||||
Finished goods
|
|
$
|
328.9
|
|
|
$
|
273.8
|
|
Work in process
|
|
28.8
|
|
|
37.1
|
|
||
Raw materials and supplies
|
|
149.8
|
|
|
135.9
|
|
||
Total inventory, net
|
|
507.5
|
|
|
446.8
|
|
||
Non-current inventory, net
|
|
(17.0
|
)
|
|
(30.4
|
)
|
||
Current inventory, net
|
|
$
|
490.4
|
|
|
$
|
416.4
|
|
|
|
December 31,
|
||||||
($ amounts in millions)
|
|
2017
|
|
2016
|
||||
Land and leasehold improvements
|
|
$
|
108.8
|
|
|
$
|
109.2
|
|
Buildings and improvements
|
|
149.8
|
|
|
141.8
|
|
||
Machinery, equipment, fixtures, and software
|
|
344.6
|
|
|
293.2
|
|
||
Construction in process
|
|
34.3
|
|
|
36.7
|
|
||
Total property, plant and equipment
|
|
637.5
|
|
|
580.9
|
|
||
Accumulated depreciation
|
|
(185.2
|
)
|
|
(120.4
|
)
|
||
Property, plant and equipment, net
|
|
$
|
452.3
|
|
|
$
|
460.5
|
|
($ amounts in millions)
|
|
Performance Solutions
|
|
Agricultural Solutions
|
|
Total
|
||||||
Balance, December 31, 2015
|
|
|
|
|
|
|
||||||
Goodwill
|
|
$
|
2,147.2
|
|
|
$
|
1,874.7
|
|
|
$
|
4,021.9
|
|
Accumulated impairment losses
|
|
—
|
|
|
—
|
|
|
—
|
|
|||
|
|
2,147.2
|
|
|
1,874.7
|
|
|
4,021.9
|
|
|||
Addition from acquisitions
|
|
66.9
|
|
|
—
|
|
|
66.9
|
|
|||
Purchase accounting adjustments
|
|
29.7
|
|
|
15.1
|
|
|
44.8
|
|
|||
Impairment write-off
|
|
(46.6
|
)
|
|
—
|
|
|
(46.6
|
)
|
|||
Foreign currency translation and other
|
|
(64.8
|
)
|
|
156.7
|
|
|
91.9
|
|
|||
Balance, December 31, 2016
|
|
|
|
|
|
|
||||||
Goodwill, gross
|
|
2,179.0
|
|
|
2,046.5
|
|
|
4,225.5
|
|
|||
Accumulated impairment losses
|
|
(46.6
|
)
|
|
—
|
|
|
(46.6
|
)
|
|||
|
|
2,132.4
|
|
|
2,046.5
|
|
|
4,178.9
|
|
|||
Impairment write-off
|
|
—
|
|
|
(160.0
|
)
|
|
(160.0
|
)
|
|||
Foreign currency translation and other
|
|
120.2
|
|
|
62.1
|
|
|
182.3
|
|
|||
Balance, December 31, 2017
|
|
|
|
|
|
|
||||||
Goodwill, gross
|
|
2,299.2
|
|
|
2,108.6
|
|
|
4,407.8
|
|
|||
Accumulated impairment losses
|
|
(46.6
|
)
|
|
(160.0
|
)
|
|
(206.6
|
)
|
|||
|
|
$
|
2,252.6
|
|
|
$
|
1,948.6
|
|
|
$
|
4,201.2
|
|
|
|
December 31, 2017
|
|
December 31, 2016
|
||||||||||||||||||||
($ amounts in millions)
|
|
Gross Carrying Amount
|
|
Accumulated Amortization
|
|
Net Book Value
|
|
Gross Carrying Amount
|
|
Accumulated Amortization
|
|
Net Book Value
|
||||||||||||
Customer lists
|
|
$
|
1,303.3
|
|
|
$
|
(263.5
|
)
|
|
$
|
1,039.8
|
|
|
$
|
1,245.9
|
|
|
$
|
(174.5
|
)
|
|
$
|
1,071.4
|
|
Developed technology
(1)
|
|
2,250.7
|
|
|
(557.0
|
)
|
|
1,693.7
|
|
|
2,022.1
|
|
|
(254.9
|
)
|
|
1,767.2
|
|
||||||
Trade names
|
|
30.3
|
|
|
(13.8
|
)
|
|
16.5
|
|
|
25.1
|
|
|
(8.2
|
)
|
|
16.9
|
|
||||||
Non-compete agreement
|
|
2.8
|
|
|
(1.3
|
)
|
|
1.5
|
|
|
1.9
|
|
|
(1.1
|
)
|
|
0.8
|
|
||||||
Total
|
|
$
|
3,587.1
|
|
|
$
|
(835.6
|
)
|
|
$
|
2,751.5
|
|
|
$
|
3,295.0
|
|
|
$
|
(438.7
|
)
|
|
$
|
2,856.3
|
|
($ amounts in millions)
|
|
Amortization Expense
|
||
2018
|
|
$
|
282.6
|
|
2019
|
|
282.4
|
|
|
2020
|
|
277.9
|
|
|
2021
|
|
269.5
|
|
|
2022
|
|
254.9
|
|
|
|
Year Ended December 31,
|
||||||||||
($ amounts in millions)
|
|
2017
|
|
2016
|
|
2015
|
||||||
Equity classified RSUs
|
|
$
|
10.4
|
|
|
$
|
6.5
|
|
|
$
|
0.8
|
|
Liability classified share-based payments
|
|
0.6
|
|
|
0.4
|
|
|
(0.1
|
)
|
|||
Stock options
|
|
0.8
|
|
|
0.5
|
|
|
—
|
|
|||
Long-term cash bonus plans
|
|
—
|
|
|
(0.1
|
)
|
|
0.1
|
|
|||
Total
|
|
$
|
11.8
|
|
|
$
|
7.3
|
|
|
$
|
0.8
|
|
|
|
|
|
|
|
|
||||||
Unrecognized compensation expense for awards expected to vest
|
|
$
|
22.2
|
|
|
|
|
|
||||
Weighted average remaining vesting period (months)
|
|
19.1
|
|
|
|
|
|
|
|
Total
|
|
RSUs
|
|
Stock Options
(1)
|
||||||
|
|
Equity
Classified
|
|
Liability
Classified
|
|
|||||||
Outstanding at December 31, 2016
|
|
3,003,003
|
|
|
2,117,493
|
|
|
320,312
|
|
|
565,198
|
|
Granted
|
|
1,373,921
|
|
|
1,117,719
|
|
|
—
|
|
|
256,202
|
|
Exercised/Issued
|
|
(122,769
|
)
|
|
(107,450
|
)
|
|
—
|
|
|
(15,319
|
)
|
Forfeited
|
|
(578,429
|
)
|
|
(503,911
|
)
|
|
(634
|
)
|
|
(73,884
|
)
|
Outstanding at December 31, 2017
|
|
3,675,726
|
|
|
2,623,851
|
|
|
319,678
|
|
|
732,197
|
|
Year of Issuance:
|
|
RSUs
|
|
Weighted average grant date fair value
|
|
Weighted average vesting period (months)
|
|||
2017
|
|
1,117,719
|
|
|
$
|
16.08
|
|
|
31.2
|
2016
|
|
1,754,868
|
|
|
10.85
|
|
|
33.8
|
|
2015
|
|
453,260
|
|
|
24.55
|
|
|
54.6
|
|
|
Year Ended December 31,
|
||
|
|
2017
|
|
2016
|
Weighted average expected term (years)
(1)
|
|
3.00
|
|
3.00
|
Expected volatility
(2)
|
|
52.1%
|
|
53.0%
|
Risk-free rate
(3)
|
|
1.50%
|
|
1.05%
|
(1)
|
Weighted average expected term is calculated based on the award vesting period.
|
(2)
|
Expected volatility is calculated based on a blend of the implied and historical equity volatility of an index of comparable companies over a period equal to the expected term.
|
(3)
|
Risk-free rate of return is based on an interpolation of U.S. Treasury rates to reflect an expected term of
three years
at the date of grant.
|
|
|
December 31, 2017
|
||||||
Vesting Conditions:
|
|
Outstanding
|
|
Weighted average remaining vesting period (months)
|
|
Potential additional awards
|
||
Service-based
|
|
931,906
|
|
|
16.9
|
|
—
|
|
Performance-based
|
|
947,013
|
|
|
17.7
|
|
617,020
|
|
Market-based
|
|
744,932
|
|
|
21.0
|
|
1,443,238
|
|
Total
|
|
2,623,851
|
|
|
18.4
|
|
2,060,258
|
|
Year of Issuance:
|
|
Stock Options
|
|
Weighted average strike price per share
|
|
Weighted average grant date fair value per share
|
|||||
2017
|
|
256,202
|
|
|
$
|
13.30
|
|
|
$
|
6.05
|
|
2016
|
|
390,198
|
|
|
8.05
|
|
|
4.35
|
|
|
|
Year Ended December 31,
|
||
|
|
2017
|
|
2016
|
Weighted average expected term (years)
(1)
|
|
6.0
|
|
6.0
|
Expected volatility
(2)
|
|
45.0%
|
|
53.0%
|
Risk-free rate
(3)
|
|
2.09%
|
|
1.52% to 1.56%
|
Expected dividend rate
|
|
—%
|
|
—%
|
(1)
|
Weighted average expected term is calculated based on the simplified method for plain vanilla options.
|
(2)
|
Expected volatility is calculated based on a blend of the implied and historical equity volatility of an index of comparable companies over a period equal to the expected term.
|
(3)
|
Risk-free rate of return is based on an interpolation of U.S. Treasury rates to reflect an expected term of
six years
at the date of grant.
|
|
|
Year Ended December 31,
|
||||||||||||||||||||||
|
|
2017
|
|
2016
|
|
2015
|
||||||||||||||||||
($ amounts in millions)
|
|
Domestic
|
|
Foreign
|
|
Domestic
|
|
Foreign
|
|
Domestic
|
|
Foreign
|
||||||||||||
Pension and SERP Benefits
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Service cost
|
|
$
|
—
|
|
|
$
|
2.1
|
|
|
$
|
—
|
|
|
$
|
1.8
|
|
|
$
|
—
|
|
|
$
|
1.4
|
|
Interest cost on the projected benefit obligation
|
|
8.8
|
|
|
2.3
|
|
|
10.1
|
|
|
3.1
|
|
|
6.8
|
|
|
2.8
|
|
||||||
Expected return on plan assets
|
|
(10.1
|
)
|
|
(1.9
|
)
|
|
(11.6
|
)
|
|
(2.6
|
)
|
|
(9.9
|
)
|
|
(2.7
|
)
|
||||||
Amortization of prior service cost
|
|
—
|
|
|
—
|
|
|
—
|
|
|
0.6
|
|
|
—
|
|
|
—
|
|
||||||
Amortization of actuarial net loss
|
|
—
|
|
|
0.1
|
|
|
—
|
|
|
0.2
|
|
|
—
|
|
|
—
|
|
||||||
Plan curtailment
|
|
—
|
|
|
0.3
|
|
|
—
|
|
|
(0.1
|
)
|
|
—
|
|
|
—
|
|
||||||
Plan settlement
|
|
—
|
|
|
10.2
|
|
|
1.7
|
|
|
0.2
|
|
|
—
|
|
|
—
|
|
||||||
Net periodic (benefit) cost
|
|
$
|
(1.3
|
)
|
|
$
|
13.1
|
|
|
$
|
0.2
|
|
|
$
|
3.2
|
|
|
$
|
(3.1
|
)
|
|
$
|
1.5
|
|
Post-retirement Medical Benefits
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Service cost
|
|
$
|
—
|
|
|
$
|
0.1
|
|
|
$
|
—
|
|
|
$
|
0.1
|
|
|
$
|
0.1
|
|
|
$
|
0.1
|
|
Interest cost on the projected benefit obligation
|
|
0.4
|
|
|
0.4
|
|
|
0.4
|
|
|
0.2
|
|
|
0.3
|
|
|
0.1
|
|
||||||
Amortization of net loss
|
|
—
|
|
|
0.1
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
Net periodic cost
|
|
$
|
0.4
|
|
|
$
|
0.6
|
|
|
$
|
0.4
|
|
|
$
|
0.3
|
|
|
$
|
0.4
|
|
|
$
|
0.2
|
|
|
|
Year Ended December 31,
|
||||||||||||||||
|
|
2017
|
|
2016
|
|
2015
|
||||||||||||
|
|
Domestic
|
|
Foreign
|
|
Domestic
|
|
Foreign
|
|
Domestic
|
|
Foreign
|
||||||
Pension and SERP Benefits
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Discount rate
|
|
4.2
|
%
|
|
2.3
|
%
|
|
4.6
|
%
|
|
2.8
|
%
|
|
4.2
|
%
|
|
2.5
|
%
|
Rate of compensation increase
|
|
3.5
|
%
|
|
3.3
|
%
|
|
3.5
|
%
|
|
3.3
|
%
|
|
3.5
|
%
|
|
2.9
|
%
|
Long-term rate of return on assets
|
|
5.9
|
%
|
|
2.3
|
%
|
|
6.5
|
%
|
|
2.9
|
%
|
|
7.4
|
%
|
|
2.5
|
%
|
Post-retirement Medical Benefits
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Discount rate
|
|
4.2
|
%
|
|
12.2
|
%
|
|
4.4
|
%
|
|
14.0
|
%
|
|
4.2
|
%
|
|
14.5
|
%
|
|
|
Pension and SERP Benefits
|
|
Post-retirement Medical Benefits
|
||||||||||||||||||||||||||||
|
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||||||||||||||||||
($ amounts in millions)
|
|
Domestic
|
|
Foreign
|
|
Domestic
|
|
Foreign
|
|
Domestic
|
|
Foreign
|
|
Domestic
|
|
Foreign
|
||||||||||||||||
Change in Benefit Obligation:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Beginning of period balance
|
|
$
|
213.5
|
|
|
$
|
103.0
|
|
|
$
|
230.5
|
|
|
$
|
112.7
|
|
|
$
|
9.6
|
|
|
$
|
3.1
|
|
|
$
|
9.4
|
|
|
$
|
1.4
|
|
Additions
|
|
—
|
|
|
0.6
|
|
|
—
|
|
|
2.7
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||||
Service cost
|
|
—
|
|
|
2.1
|
|
|
—
|
|
|
1.8
|
|
|
—
|
|
|
0.1
|
|
|
0.1
|
|
|
0.1
|
|
||||||||
Plan amendments
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(6.9
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||||
Interest cost
|
|
8.8
|
|
|
2.3
|
|
|
10.1
|
|
|
3.1
|
|
|
0.4
|
|
|
0.4
|
|
|
0.4
|
|
|
0.2
|
|
||||||||
Plan curtailment
|
|
—
|
|
|
(0.1
|
)
|
|
—
|
|
|
(0.1
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||||
Employee contributions
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
0.3
|
|
|
—
|
|
||||||||
Actuarial (gain) loss due to assumption change
|
|
—
|
|
|
(1.4
|
)
|
|
—
|
|
|
14.5
|
|
|
—
|
|
|
0.3
|
|
|
—
|
|
|
0.5
|
|
||||||||
Actuarial loss (gain) due to plan experience
|
|
13.8
|
|
|
0.3
|
|
|
5.0
|
|
|
(2.1
|
)
|
|
0.2
|
|
|
0.9
|
|
|
0.2
|
|
|
0.6
|
|
||||||||
Benefits and expenses paid
|
|
(9.9
|
)
|
|
(6.5
|
)
|
|
(9.2
|
)
|
|
(6.6
|
)
|
|
(0.5
|
)
|
|
(0.2
|
)
|
|
(0.8
|
)
|
|
(0.1
|
)
|
||||||||
Settlement
|
|
—
|
|
|
(72.2
|
)
|
|
(22.9
|
)
|
|
(2.5
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||||
Foreign currency translation
|
|
—
|
|
|
6.1
|
|
|
—
|
|
|
(13.6
|
)
|
|
—
|
|
|
(0.1
|
)
|
|
—
|
|
|
0.4
|
|
||||||||
End of period balance
|
|
$
|
226.2
|
|
|
$
|
34.2
|
|
|
$
|
213.5
|
|
|
$
|
103.0
|
|
|
$
|
9.7
|
|
|
$
|
4.5
|
|
|
$
|
9.6
|
|
|
$
|
3.1
|
|
Change in Plan Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Beginning of period balance
|
|
$
|
176.6
|
|
|
$
|
85.0
|
|
|
$
|
184.5
|
|
|
$
|
93.7
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Additions
|
|
—
|
|
|
0.5
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||||
Actual return on plan assets, net of expenses
|
|
29.8
|
|
|
0.5
|
|
|
17.9
|
|
|
11.3
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||||
Employer contributions
|
|
3.1
|
|
|
1.8
|
|
|
6.2
|
|
|
2.5
|
|
|
0.5
|
|
|
0.2
|
|
|
0.5
|
|
|
0.1
|
|
||||||||
Employee contributions
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
0.3
|
|
|
—
|
|
||||||||
Benefits paid
|
|
(9.9
|
)
|
|
(6.5
|
)
|
|
(9.1
|
)
|
|
(6.6
|
)
|
|
(0.5
|
)
|
|
(0.2
|
)
|
|
(0.8
|
)
|
|
(0.1
|
)
|
||||||||
Settlement
|
|
—
|
|
|
(72.2
|
)
|
|
(22.9
|
)
|
|
(2.5
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||||
Foreign currency translation
|
|
—
|
|
|
3.9
|
|
|
—
|
|
|
(13.4
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||||
End of period balance
|
|
$
|
199.6
|
|
|
$
|
13.0
|
|
|
$
|
176.6
|
|
|
$
|
85.0
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Funded Status
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Funded status of plan
|
|
$
|
(26.6
|
)
|
|
$
|
(21.2
|
)
|
|
$
|
(36.9
|
)
|
|
$
|
(18.0
|
)
|
|
$
|
(9.7
|
)
|
|
$
|
(4.5
|
)
|
|
$
|
(9.6
|
)
|
|
$
|
(3.1
|
)
|
|
|
Pension and SERP Benefits
|
|
Post-retirement Medical Benefits
|
||||||||||||||||||||
|
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||||||||||
|
|
Domestic
|
|
Foreign
|
|
Domestic
|
|
Foreign
|
|
Domestic
|
|
Foreign
|
|
Domestic
|
|
Foreign
|
||||||||
Discount rate
|
|
3.7
|
%
|
|
3.0
|
%
|
|
4.2
|
%
|
|
2.3
|
%
|
|
3.7
|
%
|
|
9.9
|
%
|
|
4.2
|
%
|
|
12.2
|
%
|
Rate of compensation increase
|
|
3.5
|
%
|
|
3.4
|
%
|
|
3.5
|
%
|
|
3.0
|
%
|
|
N/A
|
|
|
N/A
|
|
|
N/A
|
|
|
N/A
|
|
|
|
Pension and SERP Benefits
|
|
Post-retirement Medical Benefits
|
||||||||||||||||||||||||||||
|
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||||||||||||||||||
($ amounts in millions)
|
|
Domestic
|
|
Foreign
|
|
Domestic
|
|
Foreign
|
|
Domestic
|
|
Foreign
|
|
Domestic
|
|
Foreign
|
||||||||||||||||
Balance Sheet
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Other assets
|
|
$
|
—
|
|
|
$
|
3.6
|
|
|
$
|
—
|
|
|
$
|
4.0
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Accrued expenses and other current liabilities
|
|
1.1
|
|
|
0.7
|
|
|
0.7
|
|
|
0.6
|
|
|
0.6
|
|
|
0.2
|
|
|
0.6
|
|
|
0.2
|
|
||||||||
Pension and post-retirement benefits
|
|
25.5
|
|
|
24.1
|
|
|
36.2
|
|
|
21.4
|
|
|
9.1
|
|
|
4.3
|
|
|
9.0
|
|
|
2.9
|
|
||||||||
Accumulated Other Comprehensive Income (Loss) Balance Sheet
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Net actuarial loss
|
|
$
|
(7.0
|
)
|
|
$
|
(3.1
|
)
|
|
$
|
(12.8
|
)
|
|
$
|
(12.3
|
)
|
|
$
|
(0.8
|
)
|
|
$
|
(2.2
|
)
|
|
$
|
(0.6
|
)
|
|
$
|
(1.1
|
)
|
Prior service costs
|
|
(0.1
|
)
|
|
—
|
|
|
(0.1
|
)
|
|
(0.3
|
)
|
|
N/A
|
|
|
N/A
|
|
|
N/A
|
|
|
N/A
|
|
|
|
|
|
December 31,
|
||||||
($ amounts in millions)
|
|
Classification
|
|
2017
|
|
2016
|
||||
Asset Category
|
|
|
|
|
|
|
||||
Domestic equities
|
|
Level 1
|
|
$
|
31.8
|
|
|
$
|
31.1
|
|
Foreign equities
|
|
Level 1
|
|
18.3
|
|
|
—
|
|
||
Mutual funds holding domestic securities
|
|
Level 1
|
|
4.0
|
|
|
5.5
|
|
||
U.S. Treasuries
|
|
Level 2
|
|
14.6
|
|
|
4.9
|
|
||
Mutual funds holding U.S. Treasury Securities
|
|
Level 1
|
|
9.2
|
|
|
12.0
|
|
||
Mutual funds holding fixed income securities
|
|
Level 1
|
|
74.6
|
|
|
14.6
|
|
||
Insurance "Buy-In" Policy
(a)
|
|
Level 3
|
|
—
|
|
|
70.2
|
|
||
Foreign public bonds
|
|
Level 2
|
|
5.3
|
|
|
5.1
|
|
||
Corporate bonds
|
|
Level 2
|
|
—
|
|
|
1.2
|
|
||
Cash and cash equivalents
|
|
Level 1
|
|
10.1
|
|
|
15.1
|
|
||
Sub-Total
|
|
|
|
167.9
|
|
|
159.7
|
|
||
Assets using net asset value (or NAV) as a practical expedient
|
|
|
|
44.7
|
|
|
101.9
|
|
||
Total
|
|
|
|
$
|
212.6
|
|
|
$
|
261.6
|
|
(a)
|
This category represents assets in the U.K. Pension Plan invested in insurance contract with PIC in connection with the “Buy-In” of the U.K. Pension Plan, which was transferred to PIC, as of December 31, 2017.
|
|
|
Pension and SERP Benefits
|
|
Post-retirement Medical Benefits
|
|
Total
|
||||||||||
($ amounts in millions)
|
|
Domestic
|
|
Foreign
|
||||||||||||
2018
|
|
$
|
12.0
|
|
|
$
|
1.6
|
|
|
$
|
0.7
|
|
|
$
|
14.3
|
|
2019
|
|
12.0
|
|
|
1.8
|
|
|
0.8
|
|
|
14.6
|
|
||||
2020
|
|
12.2
|
|
|
1.7
|
|
|
0.8
|
|
|
14.7
|
|
||||
2021
|
|
12.1
|
|
|
1.8
|
|
|
0.8
|
|
|
14.7
|
|
||||
2022
|
|
12.7
|
|
|
1.9
|
|
|
0.8
|
|
|
15.4
|
|
||||
Subsequent five years
|
|
64.1
|
|
|
11.1
|
|
|
4.0
|
|
|
79.2
|
|
||||
Total
|
|
$
|
125.1
|
|
|
$
|
19.9
|
|
|
$
|
7.9
|
|
|
$
|
152.9
|
|
|
|
Year Ended December 31,
|
||||||||||
($ amounts in millions)
|
|
2017
|
|
2016
|
|
2015
|
||||||
Domestic
|
|
$
|
(331.0
|
)
|
|
$
|
(229.1
|
)
|
|
$
|
(290.8
|
)
|
Foreign
|
|
42.0
|
|
|
181.0
|
|
|
61.5
|
|
|||
Total
|
|
$
|
(289.0
|
)
|
|
$
|
(48.1
|
)
|
|
$
|
(229.3
|
)
|
|
|
Year Ended December 31,
|
||||||||||
($ amounts in millions)
|
|
2017
|
|
2016
|
|
2015
|
||||||
Current:
|
|
|
|
|
|
|
||||||
U.S.:
|
|
|
|
|
|
|
||||||
Federal
|
|
$
|
(1.2
|
)
|
|
$
|
0.1
|
|
|
$
|
0.7
|
|
State and local
|
|
1.0
|
|
|
0.4
|
|
|
(0.2
|
)
|
|||
Foreign
|
|
133.4
|
|
|
85.5
|
|
|
120.1
|
|
|||
Total current
|
|
133.2
|
|
|
86.0
|
|
|
120.6
|
|
|||
Deferred:
|
|
|
|
|
|
|
|
|
|
|||
U.S.:
|
|
|
|
|
|
|
|
|
|
|||
Federal
|
|
(48.7
|
)
|
|
1.9
|
|
|
6.4
|
|
|||
State and local
|
|
0.4
|
|
|
(0.2
|
)
|
|
(5.2
|
)
|
|||
Foreign
|
|
(78.3
|
)
|
|
(59.1
|
)
|
|
(46.7
|
)
|
|||
Total deferred
|
|
(126.6
|
)
|
|
(57.4
|
)
|
|
(45.5
|
)
|
|||
Income tax expense
|
|
$
|
6.6
|
|
|
$
|
28.6
|
|
|
$
|
75.1
|
|
|
|
Year Ended December 31,
|
||||||||||
($ amounts in millions)
|
|
2017
|
|
2016
|
|
2015
|
||||||
U.S. federal statutory tax rate
|
|
35.0
|
%
|
|
35.0
|
%
|
|
35.0
|
%
|
|||
|
|
|
|
|
|
|
||||||
Taxes computed at U.S. statutory rate
|
|
$
|
(101.2
|
)
|
|
$
|
(16.8
|
)
|
|
$
|
(80.3
|
)
|
State income taxes, net of federal benefit
|
|
0.9
|
|
|
0.1
|
|
|
(3.6
|
)
|
|||
Foreign tax on foreign operations
|
|
(3.9
|
)
|
|
(17.2
|
)
|
|
(25.3
|
)
|
|||
U.S. tax on foreign operations
|
|
46.7
|
|
|
29.0
|
|
|
31.1
|
|
|||
Net change in reserve
|
|
(8.1
|
)
|
|
(24.1
|
)
|
|
27.5
|
|
|||
Change in valuation allowances
|
|
83.2
|
|
|
68.4
|
|
|
72.6
|
|
|||
Provision for tax on undistributed foreign earnings
|
|
(1.0
|
)
|
|
26.8
|
|
|
5.0
|
|
|||
Change of tax rate
|
|
(19.4
|
)
|
|
11.8
|
|
|
(1.0
|
)
|
|||
Impact of transaction costs
|
|
—
|
|
|
(24.5
|
)
|
|
40.5
|
|
|||
Settlement of Series B Convertible Preferred Stock
|
|
—
|
|
|
(34.3
|
)
|
|
—
|
|
|||
Goodwill impairment
|
|
53.4
|
|
|
6.2
|
|
|
—
|
|
|||
Provisional estimate of TCJA
|
|
(46.3
|
)
|
|
—
|
|
|
—
|
|
|||
Other, net
|
|
2.3
|
|
|
3.2
|
|
|
8.6
|
|
|||
Income tax expense
|
|
$
|
6.6
|
|
|
$
|
28.6
|
|
|
$
|
75.1
|
|
|
|
|
|
|
|
|
||||||
Effective tax rate
|
|
(2.3
|
)%
|
|
(59.5
|
)%
|
|
(32.8
|
)%
|
|
|
December 31,
|
||||||
($ amounts in millions)
|
|
2017
|
|
2016
|
||||
Deferred tax assets:
|
|
|
|
|
||||
Net operating losses
|
|
$
|
323.0
|
|
|
$
|
355.7
|
|
Tax credits
|
|
62.0
|
|
|
49.2
|
|
||
Interest carryforward
|
|
44.4
|
|
|
34.2
|
|
||
Employee benefits
|
|
40.3
|
|
|
56.2
|
|
||
Accrued liabilities
|
|
25.9
|
|
|
50.6
|
|
||
Financing activities
|
|
24.3
|
|
|
3.5
|
|
||
Goodwill
|
|
19.5
|
|
|
31.4
|
|
||
Accounts receivable
|
|
19.1
|
|
|
19.8
|
|
||
Research and development costs
|
|
10.3
|
|
|
15.2
|
|
||
Inventory
|
|
4.6
|
|
|
8.5
|
|
||
Other
|
|
20.7
|
|
|
24.1
|
|
||
Total deferred tax assets
|
|
594.1
|
|
|
648.4
|
|
||
Valuation allowance
|
|
(391.7
|
)
|
|
(383.3
|
)
|
||
Total gross deferred tax assets
|
|
202.4
|
|
|
265.1
|
|
||
Deferred tax liabilities:
|
|
|
|
|
|
|
||
Intangibles
|
|
710.4
|
|
|
831.9
|
|
||
Plant and equipment
|
|
24.8
|
|
|
33.9
|
|
||
Undistributed foreign earnings
|
|
21.9
|
|
|
36.8
|
|
||
Other
|
|
0.4
|
|
|
6.9
|
|
||
Total gross deferred tax liabilities
|
|
757.5
|
|
|
909.5
|
|
||
Net deferred tax liability
|
|
$
|
555.1
|
|
|
$
|
644.4
|
|
|
|
Year Ended December 31,
|
||||||||||
($ amounts in millions)
|
|
2017
|
|
2016
|
|
2015
|
||||||
Unrecognized tax benefits at beginning of period
|
|
$
|
128.3
|
|
|
$
|
112.2
|
|
|
$
|
27.7
|
|
Additions based on current year tax positions
|
|
6.5
|
|
|
76.2
|
|
|
20.7
|
|
|||
Additions based upon prior year tax positions (including acquired uncertain tax positions)
|
|
4.0
|
|
|
1.7
|
|
|
72.2
|
|
|||
Reductions due to closed statutes
|
|
(6.3
|
)
|
|
(9.9
|
)
|
|
(2.9
|
)
|
|||
Reductions for prior period positions
|
|
(38.0
|
)
|
|
(51.9
|
)
|
|
—
|
|
|||
Reductions for settlements and payments
|
|
(4.2
|
)
|
|
—
|
|
|
(5.5
|
)
|
|||
Total unrecognized tax benefits at end of period
|
|
$
|
90.3
|
|
|
$
|
128.3
|
|
|
$
|
112.2
|
|
Major Jurisdictions
|
|
Open Years
|
||
Belgium
|
|
2010
|
|
through current
|
Brazil
|
|
2011
|
|
through current
|
Canada
|
|
2012
|
|
through current
|
China
|
|
2011
|
|
through current
|
France
|
|
2011
|
|
through current
|
Germany
|
|
2013
|
|
through current
|
Japan
|
|
2012
|
|
through current
|
Mexico
|
|
2012
|
|
through current
|
Netherlands
|
|
2013
|
|
through current
|
South Africa
|
|
2013
|
|
through current
|
Taiwan
|
|
2012
|
|
through current
|
United Kingdom
|
|
2008 and 2015
|
|
through current
|
United States
|
|
2015
|
|
through current
|
($ amounts in millions)
|
|
Maturity Date
|
|
Interest Rate
|
|
December 31, 2017
|
|
December 31, 2016
|
||||
USD Senior Notes
(1)
|
|
2022
|
|
6.50%
|
|
$
|
1,086.1
|
|
|
$
|
1,083.2
|
|
EUR Senior Notes
(1)
|
|
2023
|
|
6.00%
|
|
415.1
|
|
|
362.4
|
|
||
USD Senior Notes
(1)
|
|
2021
|
|
10.375%
|
|
—
|
|
|
489.0
|
|
||
USD Senior Notes
(1)
|
|
2025
|
|
5.875%
|
|
783.2
|
|
|
—
|
|
||
First Lien Credit Facility - USD Term Loans
(2)
|
|
2020
|
|
> of 4.50% or
LIBOR plus 3.50% |
|
—
|
|
|
582.5
|
|
||
First Lien Credit Facility - USD Term Loans
(2)
|
|
2020
|
|
> of 3.50% or
LIBOR plus 2.50% |
|
620.4
|
|
|
—
|
|
||
First Lien Credit Facility - USD Term Loans
(2) (3)
|
|
2021
|
|
> of 5.00% or
LIBOR plus 4.00% |
|
—
|
|
|
1,444.2
|
|
||
First Lien Credit Facility - USD Term Loans
(2) (3)
|
|
2021
|
|
> of 4.00% or
LIBOR plus 3.00% |
|
1,121.2
|
|
|
—
|
|
||
First Lien Credit Facility - Euro Term Loans
(2)
|
|
2020
|
|
> of 4.25% or EURIBOR plus 3.25%
|
|
—
|
|
|
726.5
|
|
||
First Lien Credit Facility - Euro Term Loans
(2)
|
|
2020
|
|
> of 3.25% or EURIBOR plus 2.50%
|
|
694.3
|
|
|
—
|
|
||
First Lien Credit Facility - Euro Term Loans
(2) (3)
|
|
2021
|
|
> of 4.75% or EURIBOR plus 3.75%
|
|
—
|
|
|
450.7
|
|
||
First Lien Credit Facility - Euro Term Loans
(2) (3)
|
|
2021
|
|
> of 3.50% or EURIBOR plus 2.75%
|
|
716.0
|
|
|
—
|
|
||
Borrowings under the Revolving Credit Facility
|
|
|
|
LIBOR plus 3.00%
|
|
—
|
|
|
—
|
|
||
Borrowings under lines of credit
(4)
|
|
|
|
|
|
28.5
|
|
|
86.0
|
|
||
Capital leases and other
|
|
|
|
|
|
14.7
|
|
|
14.5
|
|
||
Total debt and capital lease obligations
|
|
|
|
|
|
5,479.5
|
|
|
5,239.0
|
|
||
Less: current installments of long-term debt and revolving credit facilities
|
|
|
|
|
|
38.9
|
|
|
116.1
|
|
||
Total long-term debt and capital lease obligations
|
|
|
|
|
|
$
|
5,440.6
|
|
|
$
|
5,122.9
|
|
(1)
|
Net of unamortized premium, discounts and debt issuance costs of
$35.5 million
and
$33.4 million
at
December 31, 2017
and
2016
, respectively. Weighted average effective interest rate of
6.53%
and
7.81%
at
December 31, 2017
and
2016
, respectively.
|
($ amounts in millions)
|
|
|
|
Long-Term Debt
|
|
Capital Leases
|
|
Total
|
||||||
2018
|
|
|
|
$
|
—
|
|
|
$
|
0.7
|
|
|
$
|
0.7
|
|
2019
|
|
|
|
—
|
|
|
0.6
|
|
|
0.6
|
|
|||
2020
|
|
|
|
1,330.8
|
|
|
0.5
|
|
|
1,331.3
|
|
|||
2021
|
|
(*)
|
|
1,854.4
|
|
|
0.5
|
|
|
1,854.9
|
|
|||
2022
|
|
|
|
1,100.0
|
|
|
0.4
|
|
|
1,100.4
|
|
|||
Thereafter
|
|
|
|
1,219.9
|
|
|
1.6
|
|
|
1,221.5
|
|
|||
Total
|
|
|
|
$
|
5,505.1
|
|
|
$
|
4.3
|
|
|
$
|
5,509.4
|
|
($ amounts in millions)
|
|
Balance before refinancing
|
|
Refinancing
|
|
Balance after refinancing
|
||||||
U.S. Dollar Tranche B-4 Term Loan due 2021
|
|
$
|
1,467.6
|
|
|
$
|
(1,467.6
|
)
|
|
$
|
—
|
|
U.S. Dollar Tranche B-6 Term Loan due 2021
|
|
—
|
|
|
1,231.0
|
|
|
1,231.0
|
|
|||
U.S. Dollar Tranche B-5 Term Loan due 2020
|
|
603.9
|
|
|
(603.9
|
)
|
|
—
|
|
|||
U.S. Dollar Tranche B-7 Term Loan due 2020
|
|
—
|
|
|
680.0
|
|
|
680.0
|
|
|||
Euro Tranche C-3 Term Loan due 2021
|
|
462.3
|
|
|
(462.3
|
)
|
|
—
|
|
|||
Euro Tranche C-5 Term Loan due 2021
|
|
—
|
|
|
697.5
|
|
|
697.5
|
|
|||
Euro Tranche C-4 Term Loan due 2020
|
|
814.0
|
|
|
(814.0
|
)
|
|
—
|
|
|||
Euro Tranche C-6 Term Loan due 2020
|
|
—
|
|
|
740.0
|
|
|
740.0
|
|
|||
Totals repriced first lien debt
|
|
$
|
3,347.8
|
|
|
$
|
0.7
|
|
|
$
|
3,348.5
|
|
($ amounts in millions)
|
|
|
|
December 31,
|
||||||
Derivatives not designated as hedging instruments:
|
|
Location on Condensed Consolidated Statement of Operations:
|
|
2017
|
|
2016
|
||||
Foreign exchange and metals contracts
|
|
Other (expense) income, net
|
|
$
|
(9.5
|
)
|
|
$
|
(12.5
|
)
|
|
|
December 31, 2017
|
|
December 31, 2016
|
||||||||||||
($ amounts in millions)
|
|
Asset
|
|
Liability
|
|
Asset
|
|
Liability
|
||||||||
Gross amounts
|
|
$
|
5.5
|
|
|
$
|
6.2
|
|
|
$
|
6.3
|
|
|
$
|
8.9
|
|
Gross amount subject to offset in master netting arrangements that are not offset
|
|
(1.0
|
)
|
|
(2.0
|
)
|
|
(2.5
|
)
|
|
(2.6
|
)
|
||||
Cash collateral paid
|
|
—
|
|
|
(0.4
|
)
|
|
—
|
|
|
(1.0
|
)
|
||||
Net
|
|
$
|
4.5
|
|
|
$
|
3.8
|
|
|
$
|
3.8
|
|
|
$
|
5.3
|
|
|
|
|
|
|
|
December 31,
|
||||||
($ amounts in millions)
|
|
Balance sheet location
|
|
Classification
|
|
2017
|
|
2016
|
||||
Asset Category
|
|
|
|
|
|
|
|
|
||||
Foreign exchange and metals contracts not designated as hedging instruments
|
|
Other current assets
|
|
Level 2
|
|
5.5
|
|
|
8.5
|
|
||
Available for sale equity securities
|
|
Other assets
|
|
Level 1
|
|
3.7
|
|
|
5.1
|
|
||
Interest rate swaps designated as cash flow hedging instruments
|
|
Other assets
|
|
Level 2
|
|
3.4
|
|
|
—
|
|
||
Available for sale equity securities
|
|
Other assets
|
|
Level 2
|
|
0.6
|
|
|
0.6
|
|
||
Total
|
|
|
|
|
|
$
|
13.2
|
|
|
$
|
14.2
|
|
|
|
|
|
|
|
|
|
|
||||
Liability Category
|
|
|
|
|
|
|
|
|
||||
Interest rate swaps designated as cash flow hedging instruments
|
|
Accrued expenses and other liabilities
|
|
Level 2
|
|
$
|
2.8
|
|
|
$
|
10.2
|
|
Foreign exchange and metals contracts not designated as hedging instruments
|
|
Accrued expenses and other liabilities
|
|
Level 2
|
|
7.3
|
|
|
10.7
|
|
||
Interest rate swaps designated as cash flow hedging instruments
|
|
Other liabilities
|
|
Level 2
|
|
0.8
|
|
|
—
|
|
||
Long-term contingent consideration
|
|
Contingent consideration
|
|
Level 3
|
|
79.2
|
|
|
75.8
|
|
||
Total
|
|
|
|
|
|
$
|
90.1
|
|
|
$
|
96.7
|
|
($ amounts in millions)
|
|
Foreign Currency Translation Adjustments
|
|
Pension and Post-retirement Plans
|
|
Unrealized Gain (Loss) on Available for Sale Securities
|
|
Derivative Financial Instrument Revaluation
|
|
Non-Controlling Interests
|
|
Accumulated Other Comprehensive (Loss) Income
|
||||||||||||
Balance at December 31, 2014
|
|
$
|
(122.2
|
)
|
|
$
|
(14.9
|
)
|
|
$
|
0.1
|
|
|
$
|
—
|
|
|
$
|
6.4
|
|
|
$
|
(130.6
|
)
|
Other comprehensive (loss) income before reclassifications, net
|
|
(777.1
|
)
|
|
(10.9
|
)
|
|
1.1
|
|
|
(8.1
|
)
|
|
40.0
|
|
|
(755.0
|
)
|
||||||
Reclassifications, pretax
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
Tax benefit reclassified
|
|
—
|
|
|
(0.5
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(0.5
|
)
|
||||||
Balance at December 31, 2015
|
|
(899.3
|
)
|
|
(26.3
|
)
|
|
1.2
|
|
|
(8.1
|
)
|
|
46.4
|
|
|
(886.1
|
)
|
||||||
Other comprehensive income (loss) before reclassifications, net
|
|
204.6
|
|
|
8.3
|
|
|
(0.8
|
)
|
|
(9.6
|
)
|
|
(2.0
|
)
|
|
200.5
|
|
||||||
Reclassifications, pretax
|
|
—
|
|
|
(0.8
|
)
|
|
—
|
|
|
11.9
|
|
|
—
|
|
|
11.1
|
|
||||||
Tax (benefit) expense reclassified
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
Balance at December 31, 2016
|
|
(694.7
|
)
|
|
(18.8
|
)
|
|
0.4
|
|
|
(5.8
|
)
|
|
44.4
|
|
|
(674.5
|
)
|
||||||
Other comprehensive income (loss) before reclassifications, net
|
|
241.1
|
|
|
2.5
|
|
|
(2.2
|
)
|
|
(4.6
|
)
|
|
(3.6
|
)
|
|
233.2
|
|
||||||
Reclassifications, pretax
|
|
—
|
|
|
10.5
|
|
|
0.5
|
|
|
10.4
|
|
|
—
|
|
|
21.4
|
|
||||||
Tax (benefit) expense reclassified
|
|
—
|
|
|
(2.1
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(2.1
|
)
|
||||||
Balance at December 31, 2017
|
|
$
|
(453.6
|
)
|
|
$
|
(7.9
|
)
|
|
$
|
(1.3
|
)
|
|
$
|
—
|
|
|
$
|
40.8
|
|
|
$
|
(422.0
|
)
|
|
|
Year Ended December 31,
|
||||||||||
($ amounts in millions, except per share amounts)
|
|
2017
|
|
2016
|
|
2015
|
||||||
Net loss attributable to common stockholders
|
|
$
|
(296.2
|
)
|
|
$
|
(40.8
|
)
|
|
$
|
(308.6
|
)
|
Numerator adjustments for diluted loss per share:
|
|
|
|
|
|
|
||||||
Gain on settlement agreement related to Series B Convertible Preferred Stock
|
|
—
|
|
|
(103.0
|
)
|
|
—
|
|
|||
Gain on amendment of Series B Convertible Preferred Stock
|
|
—
|
|
|
(32.9
|
)
|
|
—
|
|
|||
Remeasurement adjustment associated with the Preferred Series B redemption liability
|
|
—
|
|
|
5.0
|
|
|
—
|
|
|||
Loss allocated to PDH non-controlling interest
|
|
—
|
|
|
(5.9
|
)
|
|
—
|
|
|||
Net loss attributable to common stockholders for diluted loss per share
|
|
$
|
(296.2
|
)
|
|
$
|
(177.6
|
)
|
|
$
|
(308.6
|
)
|
|
|
|
|
|
|
|
||||||
Basic weighted average common stock outstanding
|
|
286.1
|
|
|
243.3
|
|
|
203.2
|
|
|||
Denominator adjustments for diluted loss per share:
|
|
|
|
|
|
|
||||||
Conversion related to the amendment of the Series B Convertible Preferred Stock - assumed at beginning of reporting period
|
|
—
|
|
|
15.3
|
|
|
—
|
|
|||
Settlement of preferred stock redemption liability - assumed at beginning of reporting period
|
|
—
|
|
|
5.7
|
|
|
—
|
|
|||
Conversion of PDH non-controlling interest
|
|
—
|
|
|
8.0
|
|
|
—
|
|
|||
Share adjustments
|
|
—
|
|
|
29.0
|
|
|
—
|
|
|||
Dilutive weighted average common stock outstanding
|
|
286.1
|
|
|
272.3
|
|
|
203.2
|
|
|||
|
|
|
|
|
|
|
||||||
Loss per share attributable to common stockholders:
|
|
|
|
|
|
|
|
|
|
|||
Basic
|
|
$
|
(1.04
|
)
|
|
$
|
(0.17
|
)
|
|
$
|
(1.52
|
)
|
Diluted
|
|
$
|
(1.04
|
)
|
|
$
|
(0.65
|
)
|
|
$
|
(1.52
|
)
|
|
|
|
|
|
|
|
||||||
Dividends per share paid to common stockholders
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
|
Year Ended December 31,
|
|||||||
(amounts in thousands)
|
|
2017
|
|
2016
|
|
2015
|
|||
Shares issuable for the contingent consideration
|
|
7,421
|
|
|
8,553
|
|
|
4,640
|
|
Shares issuable upon conversion of PDH Common Stock
|
|
5,967
|
|
|
—
|
|
|
8,318
|
|
Shares issuable upon conversion of Series A Preferred Stock
|
|
2,000
|
|
|
2,000
|
|
|
2,000
|
|
Shares issuable upon vesting of RSUs
|
|
842
|
|
|
147
|
|
|
74
|
|
Shares issuable upon vesting and exercise of stock options
|
|
51
|
|
|
—
|
|
|
55
|
|
Shares issuable under the ESPP
|
|
3
|
|
|
2
|
|
|
1
|
|
Shares issuable upon conversion of Series B Convertible Preferred Stock
|
|
—
|
|
|
—
|
|
|
19,443
|
|
Shares contingently issuable to Founder Entities as stock dividend to Series A Preferred Stock
|
|
—
|
|
|
—
|
|
|
1,239
|
|
Total shares excluded
|
|
16,284
|
|
|
10,702
|
|
|
35,770
|
|
|
|
Year Ended December 31,
|
||||||||||
($ amounts in millions)
|
|
2017
|
|
2016
|
|
2015
|
||||||
Performance Solutions
|
|
$
|
23.5
|
|
|
$
|
25.0
|
|
|
$
|
6.9
|
|
Agricultural Solutions
|
|
7.3
|
|
|
6.1
|
|
|
18.4
|
|
|||
Total restructuring
|
|
$
|
30.8
|
|
|
$
|
31.1
|
|
|
$
|
25.3
|
|
|
|
Year Ended December 31,
|
||||||||||
($ amounts in millions)
|
|
2017
|
|
2016
|
|
2015
|
||||||
Cost of sales
|
|
$
|
0.9
|
|
|
$
|
0.9
|
|
|
$
|
6.3
|
|
Selling, technical, general and administrative
|
|
29.9
|
|
|
30.2
|
|
|
19.0
|
|
|||
Total restructuring
|
|
$
|
30.8
|
|
|
$
|
31.1
|
|
|
$
|
25.3
|
|
|
|
Year Ended December 31,
|
||||||||||
($ amounts in millions)
|
|
2017
|
|
2016
|
|
2015
|
||||||
Loss on debt extinguishments
|
|
$
|
(72.3
|
)
|
|
$
|
(11.3
|
)
|
|
$
|
—
|
|
Loss on derivative contracts
|
|
(9.5
|
)
|
|
(12.5
|
)
|
|
(74.0
|
)
|
|||
Non-cash change in fair value of preferred stock redemption liability
|
|
—
|
|
|
(5.0
|
)
|
|
—
|
|
|||
Gain on settlement agreement related to Series B Convertible Preferred Stock
|
|
—
|
|
|
103.0
|
|
|
—
|
|
|||
Legal settlements
|
|
10.8
|
|
|
—
|
|
|
17.7
|
|
|||
Sale of intellectual property and product rights
|
|
2.2
|
|
|
4.4
|
|
|
6.1
|
|
|||
Other income, net
|
|
7.6
|
|
|
9.7
|
|
|
6.6
|
|
|||
Total
|
|
$
|
(61.2
|
)
|
|
$
|
88.3
|
|
|
$
|
(43.6
|
)
|
|
|
December 31,
|
||||||
($ amounts in millions)
|
|
2017
|
|
2016
|
||||
Accrued customer rebates and sales incentives
|
|
$
|
127.7
|
|
|
$
|
120.7
|
|
Accrued salaries, wages and employee benefits
|
|
117.0
|
|
|
103.5
|
|
||
Accrued income taxes payable
|
|
73.1
|
|
|
82.5
|
|
||
Accrued interest
|
|
47.8
|
|
|
49.2
|
|
||
Other current liabilities
|
|
$
|
225.5
|
|
|
$
|
227.1
|
|
Total
|
|
$
|
591.1
|
|
|
$
|
583.0
|
|
|
|
Year Ended December 31,
|
||||||||||
(amounts in millions)
|
|
2017
|
|
2016
|
|
2015
|
||||||
Net Sales:
|
|
|
|
|
|
|
||||||
Performance Solutions
|
|
$
|
1,878.6
|
|
|
$
|
1,770.1
|
|
|
$
|
800.8
|
|
Agricultural Solutions
|
|
1,897.3
|
|
|
1,815.8
|
|
|
1,741.5
|
|
|||
Total
|
|
$
|
3,775.9
|
|
|
$
|
3,585.9
|
|
|
$
|
2,542.3
|
|
Depreciation and amortization:
|
|
|
|
|
|
|
|
|
|
|||
Performance Solutions
|
|
$
|
155.0
|
|
|
$
|
156.5
|
|
|
$
|
80.0
|
|
Agricultural Solutions
|
|
199.2
|
|
|
185.8
|
|
|
171.0
|
|
|||
Total
|
|
$
|
354.2
|
|
|
$
|
342.3
|
|
|
$
|
251.0
|
|
Capital expenditures and product registrations:
|
|
|
|
|
|
|
|
|
|
|||
Performance Solutions
|
|
$
|
29.3
|
|
|
$
|
29.3
|
|
|
$
|
17.6
|
|
Agricultural Solutions
|
|
70.6
|
|
|
63.4
|
|
|
64.7
|
|
|||
Total
|
|
$
|
99.9
|
|
|
$
|
92.7
|
|
|
$
|
82.3
|
|
Adjusted EBITDA:
|
|
|
|
|
|
|
|
|
|
|||
Performance Solutions
|
|
$
|
432.7
|
|
|
$
|
401.3
|
|
|
$
|
224.3
|
|
Agricultural Solutions
|
|
388.2
|
|
|
368.2
|
|
|
343.4
|
|
|||
Total
|
|
$
|
820.9
|
|
|
$
|
769.5
|
|
|
$
|
567.7
|
|
|
|
Year Ended December 31,
|
||||||||||
($ amounts in millions)
|
|
2017
|
|
2016
|
|
2015
|
||||||
Net loss attributable to common stockholders
|
|
$
|
(296.2
|
)
|
|
$
|
(40.8
|
)
|
|
$
|
(308.6
|
)
|
Add (subtract):
|
|
|
|
|
|
|
||||||
Gain on amendment of Series B Convertible Preferred Stock
|
|
—
|
|
|
(32.9
|
)
|
|
—
|
|
|||
Net income (loss) attributable to the non-controlling interests
|
|
0.6
|
|
|
(3.0
|
)
|
|
4.2
|
|
|||
Income tax expense
|
|
6.6
|
|
|
28.6
|
|
|
75.1
|
|
|||
Interest expense, net
|
|
341.6
|
|
|
375.7
|
|
|
213.9
|
|
|||
Depreciation expense
|
|
78.3
|
|
|
75.0
|
|
|
48.9
|
|
|||
Amortization expense
|
|
275.9
|
|
|
267.3
|
|
|
202.1
|
|
|||
EBITDA
|
|
406.8
|
|
|
669.9
|
|
|
235.6
|
|
|||
Adjustments to reconcile to Adjusted EBITDA:
|
|
|
|
|
|
|
|
|
|
|||
Restructuring expense
|
|
30.8
|
|
|
31.1
|
|
|
25.3
|
|
|||
Amortization of inventory step-up
|
|
—
|
|
|
11.7
|
|
|
76.5
|
|
|||
Acquisition and integration costs
|
|
4.8
|
|
|
33.4
|
|
|
122.4
|
|
|||
Non-cash change in fair value of contingent consideration
|
|
3.4
|
|
|
5.1
|
|
|
6.8
|
|
|||
Legal settlements
|
|
(10.8
|
)
|
|
(2.8
|
)
|
|
(16.0
|
)
|
|||
Foreign exchange loss on foreign denominated external and internal long-term debt
|
|
102.5
|
|
|
33.9
|
|
|
46.4
|
|
|||
Debt refinancing costs
|
|
83.2
|
|
|
19.7
|
|
|
—
|
|
|||
Fair value loss on foreign exchange forward contract
|
|
—
|
|
|
—
|
|
|
73.7
|
|
|||
Goodwill impairment
|
|
160.0
|
|
|
46.6
|
|
|
—
|
|
|||
Gain on settlement agreement related to Series B Convertible Preferred Stock
|
|
—
|
|
|
(103.0
|
)
|
|
—
|
|
|||
Non-cash change in fair value of preferred stock redemption liability
|
|
—
|
|
|
5.0
|
|
|
—
|
|
|||
Costs related to Proposed Separation
|
|
12.1
|
|
|
—
|
|
|
—
|
|
|||
Pension plan settlement and curtailment
|
|
10.5
|
|
|
1.8
|
|
|
—
|
|
|||
Other, net
|
|
17.6
|
|
|
17.1
|
|
|
(3.0
|
)
|
|||
Adjusted EBITDA
|
|
$
|
820.9
|
|
|
$
|
769.5
|
|
|
$
|
567.7
|
|
|
|
Year Ended December 31,
|
||||||||||
(amounts in millions)
|
|
2017
|
|
2016
|
|
2015
|
||||||
United States
|
|
$
|
654.7
|
|
|
$
|
725.4
|
|
|
$
|
474.6
|
|
Brazil
|
|
476.7
|
|
|
463.0
|
|
|
380.6
|
|
|||
Other countries
|
|
2,644.5
|
|
|
2,397.5
|
|
|
1,687.1
|
|
|||
Total
|
|
$
|
3,775.9
|
|
|
$
|
3,585.9
|
|
|
$
|
2,542.3
|
|
|
|
December 31,
|
||||||
(amounts in millions)
|
|
2017
|
|
2016
|
||||
United States
|
|
$
|
122.2
|
|
|
$
|
137.4
|
|
France
|
|
48.2
|
|
|
47.2
|
|
||
China
|
|
42.0
|
|
|
47.3
|
|
||
Other countries
|
|
239.9
|
|
|
228.6
|
|
||
Total
|
|
$
|
452.3
|
|
|
$
|
460.5
|
|
|
|
Year Ended December 31,
|
||||||||||
(amounts in millions)
|
|
2017
|
|
2016
|
|
2015
|
||||||
Performance Solutions
|
|
|
|
|
|
|
||||||
Assembly Solutions
|
|
$
|
629.7
|
|
|
$
|
554.5
|
|
|
$
|
41.1
|
|
Electronics Solutions
|
|
538.7
|
|
|
525.9
|
|
|
198.8
|
|
|||
Industrial Solutions
|
|
482.2
|
|
|
445.0
|
|
|
287.8
|
|
|||
Graphics Solutions
|
|
153.4
|
|
|
171.8
|
|
|
173.9
|
|
|||
Offshore Solutions
|
|
74.6
|
|
|
72.9
|
|
|
99.2
|
|
|||
Performance Solutions sales
|
|
1,878.6
|
|
|
1,770.1
|
|
|
800.8
|
|
|||
Agricultural Solutions
|
|
|
|
|
|
|
||||||
Agricultural Solutions
|
|
1,873.9
|
|
|
1,794.3
|
|
|
1,727.9
|
|
|||
Animal Health
|
|
23.4
|
|
|
21.5
|
|
|
13.6
|
|
|||
Agricultural Solutions
|
|
1,897.3
|
|
|
1,815.8
|
|
|
1,741.5
|
|
|||
Total
|
|
$
|
3,775.9
|
|
|
$
|
3,585.9
|
|
|
$
|
2,542.3
|
|
|
|
2017
|
||||||||||||||
($ amounts in millions, except per share amounts)
|
|
First
Quarter
|
|
Second
Quarter
|
|
Third
Quarter
|
|
Fourth
Quarter
|
||||||||
Selected Quarterly Financial Data (Unaudited)
|
|
|
|
|
|
|
|
|
||||||||
Net sales
|
|
$
|
861.8
|
|
|
$
|
941.1
|
|
|
$
|
904.3
|
|
|
$
|
1,068.7
|
|
Gross profit
|
|
378.4
|
|
|
399.9
|
|
|
371.1
|
|
|
439.6
|
|
||||
Net loss attributable to stockholders
|
|
(24.4
|
)
|
|
(61.1
|
)
|
|
(69.2
|
)
|
|
(141.5
|
)
|
||||
Net loss attributable to common stockholders
|
|
(24.4
|
)
|
|
(61.1
|
)
|
|
(69.2
|
)
|
|
(141.5
|
)
|
||||
|
|
|
|
|
|
|
|
|
||||||||
Loss per share
|
|
|
|
|
|
|
|
|
||||||||
Basic
|
|
$
|
(0.09
|
)
|
|
$
|
(0.21
|
)
|
|
$
|
(0.24
|
)
|
|
$
|
(0.49
|
)
|
Diluted
|
|
(0.09
|
)
|
|
(0.21
|
)
|
|
(0.24
|
)
|
|
(0.49
|
)
|
|
|
2016
|
||||||||||||||
($ amounts in millions, except per share amounts)
|
|
First
Quarter
|
|
Second
Quarter
|
|
Third
Quarter
|
|
Fourth
Quarter
|
||||||||
Selected Quarterly Financial Data (Unaudited)
|
|
|
|
|
|
|
|
|
||||||||
Net sales
|
|
$
|
823.8
|
|
|
$
|
921.6
|
|
|
$
|
890.5
|
|
|
$
|
950.0
|
|
Gross profit
|
|
356.0
|
|
|
380.6
|
|
|
375.1
|
|
|
396.0
|
|
||||
Net (loss) income attributable to stockholders
|
|
(134.8
|
)
|
|
(8.8
|
)
|
|
71.8
|
|
|
(1.9
|
)
|
||||
Net (loss) income attributable to common stockholders
|
|
(134.8
|
)
|
|
(8.8
|
)
|
|
104.7
|
|
|
(1.9
|
)
|
||||
|
|
|
|
|
|
|
|
|
||||||||
(Loss) earnings per share
|
|
|
|
|
|
|
|
|
||||||||
Basic
|
|
$
|
(0.59
|
)
|
|
$
|
(0.04
|
)
|
|
$
|
0.45
|
|
|
$
|
(0.01
|
)
|
Diluted
|
|
(0.59
|
)
|
|
(0.04
|
)
|
|
(0.15
|
)
|
|
(0.01
|
)
|
(amounts in millions)
|
|
Balance at
beginning of
period
|
|
Charges to
costs and
expense
|
|
Deductions
from
reserves and other
(1)
|
|
Balance at
end of period
|
||||||||
Reserves against accounts receivable:
|
|
|
|
|
|
|
|
|
||||||||
2017
|
|
$
|
(36.7
|
)
|
|
$
|
(10.0
|
)
|
|
$
|
(0.9
|
)
|
|
$
|
(47.6
|
)
|
2016
|
|
(14.4
|
)
|
|
(19.0
|
)
|
|
(3.3
|
)
|
|
(36.7
|
)
|
||||
2015
|
|
(9.6
|
)
|
|
(9.2
|
)
|
|
4.4
|
|
|
(14.4
|
)
|
(1)
|
Other activity consists primarily of currency translation effects.
|
1.
|
Term of Agreement
.
The term of this Agreement (the “
Term
”) shall commence on the date first set forth above and shall end on _______________, and shall continue in effect for successive periods of one (1) year thereafter unless either the Company or the Executive gives written notice of intent to terminate the Agreement one (1) year prior to the expiration of the then-current term of this Agreement. The Company is precluded from giving notice of intent to terminate within six (6) months of a Change in Control or at any time at which a Change in Control with an identified party is under serious consideration. If a Change of Control shall have occurred during the Term, the Term shall expire on the last day of the twenty-fourth (24
th
) month following the month in which such Change in Control occurred.
|
2.
|
Company’s Covenants Summarized
. In order to induce the Executive to remain in the employ of the Company and in consideration of the Executive’s covenants in Section 10 and the execution of the general release of claims referred to in Section 21 of this Agreement, the Company, under the conditions described herein, shall pay the Executive the Termination Payment, and the other payments and benefits described herein. No Termination Payment shall be payable under this Agreement unless there shall have been a Qualifying Termination. This Agreement shall not be construed as creating an express or implied contract of employment and, except as otherwise agreed in writing between the Executive and the Company, the Executive shall not have any rights to be retained in the employ of the Company.
|
3.
|
Definitions
.
As used herein, the terms identified below shall have the meanings indicated:
|
(a)
|
“
Annual Bonus Plan
”
shall mean, for the Executive, the plan or arrangement of the Company providing cash-denominated bonuses, on an annual basis, for Company and/or business unit performance during the applicable year in which the Executive participates.
|
(b)
|
“
Award
”
shall mean any cash award or stock-based award granted or to be granted to the Executive under any Annual Bonus Plan or Incentive Plan.
|
(c)
|
“
Benefit Continuation
”
shall mean, subject to the continued co-payment of premiums by the Executive, the continued participation for the Executive and his or her eligible dependents in the Company’s Benefit Plans, upon the same terms and conditions in effect from time to time for active employees of the Company, as determined in good faith by the Company.
|
(d)
|
“
Benefit Continuation Period
”
shall mean a period equal to [24 months, 18 months, 12 months].
|
(e)
|
“
Benefit Plans
”
shall mean all medical and dental benefit plans of the Company and any group life insurance, group accident insurance and group disability insurance plans of the Company, in each case, as may be in effect from time to time.
|
(f)
|
“
Board
”
shall mean the Company's Board of Directors.
|
(g)
|
“
Cause
”
for termination by the Company of the Executive’s employment shall mean the definition of such term as defined in any effective employment agreement between the Company and the Executive as of the Date of Termination; otherwise, Cause shall mean any of the following:
|
(i)
|
the willful and continuous failure by the Executive to substantially perform the Executive's duties with the Company (other than any such failure resulting from the Executive's incapacity due to physical or mental illness) thirty (30) days after a written demand for substantial performance is delivered to the Executive by the Board which specifically identifies the manner in which the Board believes that the Executive has not substantially performed the Executive's duties;
|
(ii)
|
willful misconduct or gross negligence by the Executive provided (A) the Board has determined that the resulting harm to the Company from the Executive's willful misconduct or gross negligence cannot be adequately remedied, or (B) the Executive fails to correct any resulting harm to the Company within thirty (30) days after a written demand for correction is delivered to the Executive by the Board which specifically identifies both the manner in which the Board believes that Executive has engaged in willful misconduct or gross negligence and an appropriate method of correcting any resulting harm to the Company;
|
(iii)
|
the Executive's conviction of or the entering of a plea of guilty or
nolo contendere
to the commission of a felony or any crime involving moral turpitude, dishonesty, fraud, embezzlement, theft or financial impropriety; or
|
(iv)
|
a material and willful violation by the Executive of the Company’s rules, policies or procedures, or of the law, which results in material economic harm to the Company.
|
(h)
|
“
Change in Control
”
shall mean, after the Effective Date, the occurrence of any of the following:
|
(i)
|
any Person becomes the “beneficial owner,” as such term is defined in Rule 13d-3 under the Exchange Act, directly or indirectly, of more than 30% of either (A) the then outstanding shares of common stock of the Company (the “
Outstanding Common Stock
”) or (B) the combined voting power of the then outstanding securities of the Company entitled to vote generally in the election of directors (the “
Outstanding Voting Securities
”)(the foregoing beneficial ownership hereinafter being referred to as a “
Controlling Interest
”);
provided, however
, that the following acquisitions and beneficial ownership shall not constitute Changes in Control pursuant to this Agreement: (v) any acquisition directly from the Company; (w) any acquisition by the Company or a “subsidiary corporation” as defined in Section 424(f) of the Code, or any successor provision (each, a “
Subsidiary
”); (x) any acquisition by any Person that as of the Effective Date beneficially owns a Controlling Interest; (y) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or one or more of its Subsidiaries; or (z) any acquisition that is a Business Combination, as described in subsection (ii) below; or
|
(ii)
|
the consummation of a reorganization, merger, share exchange or consolidation (a “
Business Combination
”), unless in each case following such Business Combination:
|
(A)
|
all or substantially all of the individuals and entities who were the beneficial owners,
|
(B)
|
no individual, entity or group (excluding any employee benefit plan (or related trust) of the Company or such entity resulting from such Business Combination) beneficially owns, directly or indirectly, more than 30% of, respectively, the then outstanding shares of common stock of the entity resulting from such Business Combination or the combined voting power of the then outstanding voting securities of such entity entitled to vote generally in the election of directors or other governing body of the entity resulting from such Business Combination, except to the extent that such individual, entity or group owned more than 30% of the Outstanding Common Stock or Outstanding Voting Securities prior to the Business Combination; and
|
(C)
|
at least a majority of the members of the board of directors or other governing body of the entity resulting from such Business Combination were individuals who constituted the Board as of the Effective Date and at the time of the execution of the initial agreement, or of the action of the Board, approving such Business Combination; or
|
(iii)
|
the Company shall sell or dispose of all or substantially all of the property and assets of the Company (in one transaction or a series of transactions).
|
(i)
|
“
COBRA
”
shall mean the continuation coverage requirements for “group health plans” under Title X of the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended, including codifications and rules thereunder and successor provisions and rules thereto.
|
(j)
|
“
Code
”
shall mean the Internal Revenue Code of 1986, as amended, and the regulations and other guidance promulgated by the Treasury Department and the Internal Revenue Service thereunder.
|
(k)
|
“
Date of Termination
”
shall mean, unless otherwise agrees by the Executive and the Company, (i) if the Executive’s employment is terminated by the Executive for Good Reason and the Company has failed to cure the condition giving rise to Good Reason within the prescribed 30-day period, a date that is within sixty (60) days of the last day of such cure period, or (ii) if the Executive’s employment is terminated for any other reason, the date on which a Notice of Termination is given or the date set forth in such notice, as applicable, which, in the event of a termination by the Executive without Good Reason, shall be less than thirty (30) days after such Notice of Termination.
|
(l)
|
“
Effective Date
”
means the date set forth in the first paragraph of this Agreement.
|
(m)
|
“
Exchange Act
” means the Securities Exchange Act of 1934, as amended.
|
(n)
|
“
Good Reason
”
for termination by the Executive of the Executive’s employment means the definition of such term as defined in any effective employment agreement between the Company and the Executive as of the Date of Termination; otherwise, Good Reason shall mean one or more of the following conditions without the written consent of the Executive, unless such condition is corrected by the Company prior to the Date of Termination specified in the Notice of Termination given in respect thereof:
|
(i)
|
a material diminution in the Executive’s authority, duties or responsibilities as in effect at any time during the six (6) months immediately prior to a Change in Control (other than, if applicable, any such change directly and solely attributable to the fact that the Company is no longer publicly owned);
|
(ii)
|
a material decrease in the Executive’s annual base salary or the failure to increase the Executive’s annual base salary substantially in accordance with increases given to other similarly situated employees of the Executive’s employer;
|
(iii)
|
a relocation of the Executive’s primary work location more than 30 miles from the Executive’s primary work location at the time of such requested relocation;
|
(iv)
|
failure to continue any Annual Bonus Plan, Incentive Plan or other arrangement (including, but not limited to, the 2013 Plan) in which the Executive is participating at the time of a Change in Control (or to substitute and continue other plans or arrangements providing the Executive with substantially the same benefits), or the taking of any action by the Company which would adversely affect the Executive’s participation in or materially reduce his or her benefits under any such Annual Bonus Plan, Incentive Plan or other arrangement;
|
(v)
|
any action or inaction that constitute a material breach by the Company of any agreement under which the Executive provides services; or
|
(vi)
|
the failure of the Company to obtain the binding agreement of any successor to the Company expressly to assume and agree to fully perform the Company’s obligations under this Agreement, as contemplated in Section 18 hereof.
|
(o)
|
“
Incentive Payment
”
shall have the meaning as set forth in Section 4.
|
(p)
|
“
Incentive Plan
”
shall mean each plan, policy, program or arrangement, including, but not limited to, the 2013 Plan, adopted or maintained by the Company pursuant to which equity-based awards or short- or long-term cash awards may be granted to the Executive, as may be amended and/or restated from time to time, other than the Annual Bonus Plan.
|
(q)
|
“
Notice of Termination
”
shall have the meaning set forth in Section 22.
|
(r)
|
“
Person
”
means an individual, corporation, partnership, limited liability company, association, trust, other entity, group or organization including a government authority.
|
(a)
|
“
PPACA
”
shall mean the Patient Protection and Affordable Care Act of 2010 and the related regulations and guidance promulgated thereunder.
|
(b)
|
“
Qualifying Termination
”
shall have the meaning as set forth in Section 6.
|
(c)
|
“
Termination Factor
”
shall mean a factor equal to [1, 2, 2.99].
|
(d)
|
“
Termination Payment
"
shall have the meaning as set forth in Section 7.
|
(e)
|
“
Total Payments
”
shall have the meaning as set forth in Section 9.
|
(f)
|
“
2013 Plan
”
shall mean the Platform Specialty Products Amended and Restated 2013 Incentive Compensation Plan, as amended and/or restated from time to time, and any successor plan thereto.
|
4.
|
Incentive Payment
.
In the event of a Change in Control during the Executive’s employment with the Company, the Executive shall be entitled to receive an “
Incentive Payment
.” Subject to the terms hereof, such Incentive Payment will be made in a lump-sum cash payment sixty (60) days following the date of the Change in Control or as soon as administratively practicable thereafter but in no event later than 2 1/2 months after the close of the year in which the Change in Control occurs. The Incentive Payment shall equal the Executive’s short- or long-term target cash bonus Awards otherwise payable under the terms of any Incentive Plan based on full
|
5.
|
Stock Rights
.
Notwithstanding anything to the contrary contained in any Incentive Plan or any Award agreement between the Company and the Executive (but subject to the provisions of Section 27(d) hereof), upon the occurrence of a Change in Control during the Executive’s employment with the Company, any non-qualified stock options, incentive stock options, stock appreciation rights, restricted stock, performance shares, performance units, restricted stock units and other equity or equity-based Awards granted by the Company to the Executive and outstanding on the date of the Change in Control, shall become immediately vested and exercisable in full.
|
6.
|
Qualifying Termination
.
Benefits become payable under Sections 7 and 8 below only if the Executive experiences a “
Qualifying Termination
.” A Qualifying Termination shall occur on the later of the following events, provided both such events occur: (1) the Company terminates the Executive’s employment without Cause or the Executive terminates his or her employment for Good Reason, provided that such termination of employment (be it without Cause or for Good Reason) occurs either during the six (6) months prior or within two (2) years following the date of a Change in Control and (2) a Change in Control occurs. For purpose of a Qualifying Termination involving Good Reason, the Executive must provide the Company with a Notice of Termination within ninety (90) days of the initial existence of a condition constituting Good Reason and afford the Company thirty (30) days in which to remedy the condition. If the Company remedies the condition during the prescribed 30-day period and the Executive terminates employment, the Executive will not be deemed to have terminated his or her employment for Good Reason for purposes of this Section 6. If the Company fails to cure the condition within the prescribed 30-day period, then the Executive must exercise the right to terminate his or her employment for Good Reason within sixty (60) days thereafter, in order for the termination to be for Good Reason for purposes of this Section 6.
|
7.
|
Termination Payment
.
Except as described below, the Executive shall receive a “
Termination Payment
” immediately upon the occurrence of a Qualifying Termination or as soon as administratively possible thereafter. The Termination Payment shall be subject to deductions for customary withholdings, including, without limitation, federal and state withholding taxes and social security taxes. Subject to all other provisions of this Agreement, including Sections 10, 21 and 24 hereof, the Termination Payment shall equal the sum of the following amounts:
|
(a)
|
All previously earned and accrued but unpaid base salary up to the Date of Termination of the Executive's employment;
|
(b)
|
An amount equal to the Termination Factor multiplied by the Executive's annual base salary as of the Date of Termination of the Executive's employment, or, if higher, the Executive’s annual base salary immediately prior the date of the occurrence of the condition giving rise to Good Reason; and
|
(c)
|
An amount equal to the Termination Factor multiplied by the Executive’s annual target incentive Award under any Annual Bonus Plan for the year in which the Date of Termination occurs, or, if higher, the Executive’s annual target incentive Award under any Annual Bonus Plan in effect immediately prior to the date of the occurrence of the condition giving rise to Good Reason, in each case assuming for this purpose attainment of 100% of any applicable target.
|
8.
|
Continuation of Benefits
.
Subject to Section 21,
for a period commencing as soon as practicable after a Qualifying Termination until the expiration of the Executive’s Benefit Continuation Period, the Executive shall receive the following benefits (including the right to reimbursements):
|
(a)
|
the Executive shall be eligible for Benefit Continuation, which shall be provided concurrently with any health care benefit required under COBRA. Notwithstanding the foregoing, if the Company’s providing Benefit Continuation would violate the non-discrimination rules applicable to non-grandfathered plans, or would result in the imposition of penalties under the PPACA, the Company shall have the right to amend this Section 8(a) in a manner it determines, in its sole discretion, to comply with the PPACA;
|
(b)
|
the Company shall pay all reasonable legal fees and related expenses incurred by the Executive: (i) as a result of the Executive’s Qualifying Termination; (ii) in seeking to obtain or enforce any right or
|
(c)
|
the Company shall make available to the Executive, at the Company’s expense, outplacement counseling. The Executive may select the organization that will provide the outplacement counseling;
provided, however
, that the Company’s obligation to provide such benefits shall be limited to reasonable expenses. This counseling must be used, if at all, no later than the end of the first calendar year after the year of the Executive’s Date of Termination.
|
9.
|
Cap on Certain Payments by the Company; Payment Procedures
.
|
(a)
|
Notwithstanding any provision in this Agreement, in the event that any payment or benefit of any type by the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise (all such payments and benefits, including, without limitation, the Termination Payment, being hereinafter referred to as the “
Total Payments
”), would exceed the greatest amount that could be paid to the Executive without the Executive incurring an excise tax imposed by Section 4999 of the Code (or any similar tax that may be imposed), then the Total Payments to the Executive under this Agreement (or any other Annual Bonus Plan, Incentive Plan, Award agreement or other arrangement) shall be reduced (or appropriately adjusted) to the maximum amount which may be paid without the Executive becoming subject to such excise tax, but only if the net after-tax proceeds of such reduced amount would be greater than the net after-tax proceeds (taking into account the excise tax) of the unreduced Total Payments. If a reduction in the Total Payments is required under this Section 9(a), the Total Payments shall be reduced by the Company in its reasonable discretion in the following order: (A) reduction of any cash payment; (B) reducing of vesting acceleration of equity Awards; and (C) reduction of other benefits paid or provided. In the event that acceleration of vesting of equity Awards is to be reduced, such acceleration of vesting will be cancelled in the reversed order of the dates of grant for the equity Awards. If two or more equity Awards are granted on the same date, each award will be reduced on a pro-rata basis. The Executive shall be advised of the determination as to which compensation will be reduced and the reasons therefor, and the Executive and his or her advisors will be entitled to present information that may be relevant to that determination. In no event will the Company pay any excise tax imposed by Section 4999 of the Code or otherwise on behalf of the Executive. No amounts or benefits which constitute nonqualified deferred compensation subject to Section 409A of the Code shall be forfeited or reduced pursuant to this Section 9 until all amount and benefits not subject to Section 409A of the Code have been forfeited, and reduction or forfeiture of amounts subject to Section 409A of the Code shall be made first (to the extent necessary) out of payments and benefits which are due at the latest future date.
|
(b)
|
For purposes of determining whether any of the Total Payments will be subject to the Excise Tax and the amount of such excise tax:
|
(i)
|
All Total Payments shall be treated as “parachute payments” within the meaning of Section 280G(b)(2) of the Code, and all “excess parachute payments” within the meaning of Section 280G(b)(1) of the Code shall be treated as subject to the excise tax, unless, and except to the extent that, in the written opinion of independent compensation consultants, counsel or auditors of nationally recognized standing (the “
Independent Auditors
”) selected by the Company and reasonably acceptable to the Executive, the Total Payments and benefits (in whole or in part) do not constitute parachute payments, or such excess parachute payments (in whole or in part) represent reasonable compensation for services actually rendered within the meaning of Section 280G(b)(4) of the Code in excess of the base amount within the meaning of Section 280G(b)(3) of the Code or are otherwise not subject to the excise tax.
|
(ii)
|
The value of any non-cash benefits or any deferred payment or benefit shall be determined by the Independent Advisors in accordance with the principles of Section 280G(d)(3) and (4) of the Code.
|
(c)
|
For purpose of determining the amount of the net after-tax proceeds of the reduced and unreduced Total Payments pursuant to Section 9(a), the Executive shall be deemed (i) to pay federal income and employment taxes at the applicable rates of federal income and employment taxation for the calendar year in which the compensation would be payable; and (ii) to pay any applicable state or local income taxes at the applicable rates of taxation for the calendar year in which the compensation would be payable taking into account any effect on federal income taxes from payment of state and local income taxes.
|
10.
|
Non-Disclosure of Confidential Information and Noncompete
.
|
(a)
|
The Executive expressly recognizes and acknowledges that during the Executive's employment with the Company, the Executive became entrusted with, had access to, or gained possession of confidential and proprietary information, data, documents, records, materials, and other trade secrets and/or other proprietary business information of the Company that is not readily available to competitors, outside third parties and/or the public, including without limitation, information about (i) current or prospective customers and/or suppliers and customer and supplier lists; (ii) employees, research, goodwill, production, prices, costs, margin, and operating unit financial performance, salaries and expertise, customer preferences, contact information, key contacts, credit and purchasing history, and purchasing requirements and preferences; (iii) business methods, processes, practices or procedures; (iv) computer software and technology development; and (v) marketing, pricing strategies, business plans, and business strategy including acquisition, merger and/or divestiture strategies, (collectively or with respect to any of the foregoing, the "
Confidential Information
"). The Executive agrees, by acceptance of a Termination Payment under this Agreement, to protect all Confidential Information of the Company.
|
(b)
|
The Executive recognizes that the Company is engaged in the business of research, development, manufacture and sale of chemicals and chemical products in laboratory proportions (the "
Company's Business
") throughout the world (the “
Restricted Area
”), which business requires for its successful operation the fullest security of its Confidential Information of which the Executive acquired or will acquire knowledge during the course of his or her employment.
|
(c)
|
The Executive shall not, directly or indirectly (whether as owner, partner, consultant, employee or otherwise), at any time during his or her employment with the Company and for a period equal to [24 months, 18 months, 12 months] following any Date of Termination which gives rise to a Termination Payment under Section 7 hereof, regardless of how or why Executive’s employment terminates, directly or indirectly, engage in, provide any services or advice to, contribute the Executive’s knowledge to or invest, in whole or in part, in the Company’s Business in the Restricted Area,
provided, however
, that the foregoing shall not prohibit the Executive from owning two percent (2%) or less of the outstanding equity securities of a publicly traded entity. Following any Date of Termination, the Executive shall continue to be obligated under the Confidential Information provisions of this Agreement not to use or to disclose Confidential Information so long as it shall remain proprietary or protectable as confidential or trade secret information. Following termination of his or her employment for any reason, the Executive agrees to advise the Company of the Executive’s new employer, work location and job responsibilities within ten (10) days after accepting new employment and agrees to keep the Company so advised of any change in the Executive’s employment for two (2) years following termination of employment with the Company.
|
(d)
|
The Executive acknowledges and agrees that the intention of this Section 10 is not to prevent the Executive from earning a livelihood, is reasonable in geographic scope and duration and is necessary to protect the Company’s Business and goodwill. The Executive and the Company acknowledge and agree that he/she/it would not have entered into this Agreement without the restrictions contained in this Section 10. The Executive agrees nothing in this Agreement would prevent the Executive from earning a livelihood.
|
(e)
|
The Executive's breach of this Section 10 shall relieve the Company of its obligations (if any) to pay that portion of any Termination Payment described in Sections 7(b) and 7(c) (the “
Noncompete Payments
”). In the event that the Executive breaches this Section 10 after he or she has received a Termination Payment, he or she shall immediately return the full amount of the Noncompete Payments to the Company, with interest at 120% of the rate provided in Section 1274(b)(2)(B) of the Code from
|
11.
|
At-Will Employment; No Mitigation
.
|
(a)
|
The Company and the Executive each acknowledges that the Executive's employment is and shall continue to be at-will, as defined under applicable law. This Agreement is not a contract of employment and does not guarantee the Executive employment for any particular period of time. If the Executive's employment terminates for any reason, the Executive shall not be entitled to any payments, benefits, damages, Awards or compensation other than as provided by this Agreement, or as may otherwise be available in accordance with the Company's established employee plans and practices or other written agreements with the Company at the time of termination.
|
(b)
|
If the Executive’s employment with the Company terminates following a Change in Control, the Executive is not required to seek other employment or to attempt in any way to reduce any amounts payable to the Executive by the Company under this Agreement. Except as set forth in Section 9, the amount of any payment or benefit provided for in this Agreement shall not be reduced by any compensation earned by the Executive as the result of employment by another employer, by retirement benefits, by offset against any amount claimed to be owed by the Executive to the Company, or otherwise.
|
12.
|
Directors and Officers Coverage
. To the extent permitted by applicable law, the Company will maintain Director and Officer insurance for the benefit of the Executive to the maximum extent and for the maximum duration provided under applicable bylaws and insurance policies in effect as of the Date of Termination.
|
13.
|
Indemnification
.
The Company will advance expenses and indemnify the Executive for all of the reasonable expenses incurred or damages paid or payable with respect to a bona fide claim against the Executive, including settlement payments, where such claim is based on actions or failures to act by the Executive in his or her capacity as an employee of the Company.
|
14.
|
General Reimbursement Procedure
.
To the extent that the Executive is entitled to any reimbursements (or in-kind benefits) under this Agreement and the procedures for such reimbursements (or in-kind benefits) are not otherwise set forth herein, such reimbursements and provision of in-kind benefits shall be made as soon as administratively practicable but in no event later than the end of year following the year in which the expense or in-kind benefit was incurred or provided..
|
15.
|
Settlement of Disputes; Arbitration
.
All claims, disputes and other matters in question between the parties arising under this Agreement, other than under Section 10 hereof (which may be enforced by the Company through injunctive or other equitable relief) shall be decided by arbitration in accordance with the rules of the American Arbitration Association (“AAA”), unless the parties mutually agree otherwise. The determination reached in such arbitration shall be final and binding on both parties without any right of appeal of further dispute. Execution of the determination by such arbitrator may be sought in any court of competent jurisdiction. The arbitrators shall not be bound by judicial formalities and may abstain from following the strict rules of evidence and shall interpret this Agreement as an honorable engagement and not merely as a legal obligation. Unless otherwise agreed by the parties, any such arbitration shall be conducted in accordance with the Rules of the AAA and the proceedings shall be private and confidential.
|
16.
|
General Creditor
.
Any and all amounts payable hereunder to the Executive shall be made from assets which shall continue, for all purposes, to be part of the general, unrestricted assets of the Company; no person shall have nor acquire any interest in any such asset by virtue of the provisions of this Agreement. The Company's obligation hereunder shall be an unfunded and unsecured promise to pay money in the future. To the extent that the Executive or any person acquires a right to receive payments from the Company under the provisions hereof, such right shall be no greater than the right of any unsecured general creditor of the Company; no such person shall have nor acquire any legal or equitable right, interest or claim in or to any property or assets of the Company.
|
17.
|
Severability and Interpretation
.
In the event of a conflict between the terms of this Agreement and any of the definitions or provisions in any Annual Bonus Plan, Incentive Plan, Award agreement or otherwise, the terms of this Agreement shall prevail. Whenever possible, each provision of this Agreement and any portion hereof shall be interpreted in such a manner as to be effective and valid under applicable law, rules and regulations. If any covenant or other provision of this Agreement (or portion thereof) shall be held to be invalid, illegal, or incapable of being enforced, by reason of any rule of law, rule, regulation, administrative order, judicial decision or public policy, all other conditions and provisions of this Agreement shall, nevertheless, remain in full force and effect, and no covenant or provision shall be deemed dependent upon any other covenant or provision (or portion) unless so expressed herein. The parties hereto desire and consent that the court or other body making such determination shall, to the extent necessary to avoid any unenforceability, so reform such covenant or other provision or portions of this Agreement to the minimum extent necessary so as to render the same enforceable in accordance with the intent herein expressed.
|
18.
|
No Assignments
.
This Agreement shall inure to the benefit of, and be binding upon, the Company, any successor and assigns of the Company, but neither this Agreement nor any rights hereunder shall be assigned by the Executive.
|
19.
|
Prior Agreements
.
Upon execution by both parties, with respect to change in control provisions, this Agreement shall supersede and replace all prior employment agreements, Award Agreements, severance agreements or otherwise between the Company and the Executive, and this Agreement shall constitute the entire agreement between the parties, except as expressly provided herein, concerning the effect of a Change in Control on the employment relationship between the Company and the Executive.
|
20.
|
Entire Agreement
.
This Agreement represents the entire and integrated Change in Control Agreement between the Executive and the Company and supersedes all prior negotiations, representations and agreements, either written or oral, with respect thereto. Should any other agreement, plan or arrangement between the Company and the Executive or other officers or employees of the Company provide for greater benefits upon a change in control, the terms of such other agreement, plan or arrangement shall apply to the Executive on a “most favored” basis.
|
21.
|
General Release of Claims
.
In consideration of the covenants under this Agreement and as a condition precedent to receiving any payments under this Agreement, the Executive agrees to the execution and non-revocation of the Company’s standard form of general release of claims in favor of the Company and its affiliates, as in effect immediately prior to a Change in Control, within sixty (60) days of the date of the Qualifying Termination or Change in Control, whichever applicable. If the sixty (60) day period spans over two (2) calendar years, any payments must be made in the later taxable year.
|
22.
|
Notice of Termination
.
After a Change in Control, any purported termination of the Executive’s employment (other than by reason of death) shall be communicated by written Notice of Termination from one party to the other party hereto in accordance with Section 23. For purposes of this Agreement, a “
Notice of Termination
” shall mean a notice which shall indicate the specific termination provision of this Agreement relied upon and shall set forth in reasonable detail any facts and circumstances claimed to provide a basis for termination of the Executive’s employment under the provision so indicated.
[
Further, a Notice of Termination for Cause from the Company to the Executive is required to include a copy of a resolution duly adopted by the affirmative vote of the entire membership of the Board at a meeting of the Board which was called and held for the purpose of considering such termination (after reasonable notice to the Executive and an opportunity for the Executive, together with the Executive’s counsel, to be heard before the Board) finding that, in the good faith opinion of the Board, the Executive was guilty of conduct set forth in clause (i), (ii), (iii) or (iv) of the definition of “Cause” herein, and specifying the particulars thereof in detail.
]
|
23.
|
Notices
. All notices and other communications hereunder shall be in writing and shall be given by hand delivery to the other party, by registered or certified mail, return receipt requested, postage prepaid, or by overnight courier, addressed as set forth in this Section 23, or to such other address (including e-mail addresses) as may hereafter be notified by such party to the other party. Notices and communications shall be effective at the time they are given in the foregoing manner.
|
__________________________________
|
__________________________________
|
__________________________________
|
24.
|
Amendments and Waivers
.
The Company may amend, terminate, or otherwise modify this Agreement at any time in such a manner as it determines in its sole discretion by written notice of intent to so amend, terminate, or modify the Agreement at least six (6) months prior to the expiration of the then-current term of this Agreement. Notwithstanding the foregoing, the Company is precluded from giving notice of intent to amend, terminate or otherwise modify within six (6) months of a Change in Control or at any time at which a Change in Control with an identified party is under serious consideration;
provided, however
that the parties may agree to amend, terminate, or otherwise modify this Agreement in writing and signed by both parties hereto at any time.
|
25.
|
Governing Law
.
The parties agree that this Agreement, and the general release of claims referred to in Section 21, shall be interpreted in accordance with and governed by the laws of the State of Delaware applicable to contracts executed and performed within that State
without regard to conflict of laws principles which would require the application of any other jurisdiction
. Subject to Section 15, any action concerning this Agreement shall be brought in the courts of the State of Delaware in New Castle County or the court of the United States, District of Delaware, and each party consents to the venue and jurisdiction of such courts. The parties agree to accept service of process in any manner permitted by any such court or by hand delivery, registered or certified mail, return receipt requested, postage pre-paid, or by overnight courier delivered to the address of such party as provided in Section 23.
|
26.
|
Headings
.
Section headings provided in this Agreement are for convenience only and shall not be deemed to substantively alter the content of such sections.
|
27.
|
Section 409A Compliance
.
This Agreement is intended to comply with the provisions of Section 409A of the Code and the regulations and guidance promulgated thereunder. Without limiting the generality of the foregoing, the Company and the Executive each agrees as follows:
|
(a)
|
Notwithstanding the foregoing, no payment of any payment or benefit under this Agreement that constitute “non-qualified deferred compensation” within the meaning of Section 409A of the Code shall be made solely upon the occurrence of a Change in Control to the extent such Change in Control does not also qualify as a “change in control event” under Section 409A of the Code and such payment or benefit shall be paid on its otherwise scheduled payment date;
|
(b)
|
Notwithstanding anything to the contrary herein, if the Executive is a “specified employee” (within the meaning of Section 409A(a)(2)(B)(i) of the Code) with respect to the Company, any amounts (or benefits) otherwise payable to or in respect of the Executive under this Agreement pursuant to the Executive's termination of employment with the Company shall be delayed, to the extent required so that taxes are not imposed on the Executive pursuant to Section 409A of the Code, and shall be paid
|
(c)
|
For purposes of this Agreement, the Executive's employment with the Company will not be treated as terminated unless and until such termination of employment constitutes a “separation from service” for purposes of Section 409A of the Code;
|
(d)
|
To the extent necessary to comply with the provisions of Section 409A of the Code and the guidance issued thereunder: (i) reimbursements to the Executive as a result of the operation of Sections 8 and 9 hereof shall be made not later than the end of the calendar year following the year in which the reimbursable expense is incurred and shall otherwise be made in a manner that complies with the requirements of Section 409A of the Code, (ii) if Executive is a “specified employee” (within the meaning of Section 409A of the Code), any reimbursements to the Executive as a result of the operation of such sections with respect to a reimbursable event within the first six (6) months following the Executive’s Date of Termination which are required to be delayed shall be made as soon as practicable following the date which is six (6) months and one (1) day following the Executive’s Date of Termination (subject to clause (i) of this sentence); and
|
(e)
|
If the provisions of Section 5 are applicable to equity or equity-based Awards subject to the provisions of Section 409A of the Code and the immediate payment of the Awards contemplated by Section 5 would result in taxation under Section 409A, payment of such Awards shall be made upon the earliest date upon which such payment may be made without resulting in taxation under Section 409A of the Code. For the avoidance of doubt, with respect to any equity or equity-based Awards which are subject to Section 409A of the Code and which comply with the permissible payment requirements of such section by providing for payments pursuant to a fixed schedule, the application of Section 5, as modified (to the extent required) by this Section 27(d), shall require that the payment of such Awards continue upon such fixed schedule following the Executive’s Date of Termination until the Award is fully vested.
|
PLATFORM SPECIALTY PRODUCTS CORPORATION
|
EXECUTIVE
|
By: ___________________________
Name:
Title:
|
By: ___________________________
Name:
Title:
|
Subsidiaries
|
State or Jurisdiction of Incorporation/Organization
|
Afgri Crop (Pty) Ltd
|
Malawi
|
Agrifocus Limitada
|
Mozambique
|
Agriphar de Colombia SAS
|
Colombia
|
Agriphar de Costa Rica SA
|
Costa Rica
|
Agriphar Poland Sp z.o.o.
|
Poland
|
Agriphar SDN BHD
|
Malaysia
|
Agripraza Ltda
|
Portugal
|
Agroquimicos y Semillas SA de CV
|
Mexico
|
AI Divestitures, Inc.
|
Delaware
|
Alent Enthone Chemistry (Shanghai) Co. Ltd.
|
China
|
Alent Finance Company (Ireland 1)
|
Ireland
|
Alent Finance Company (Ireland 2)
|
Ireland
|
Alent Finance Ltd
|
United Kingdom
|
Alent France Holdings SAS
|
France
|
Alent Germany GmbH
|
Germany
|
Alent Holdings Brazil Ltd
|
United Kingdom
|
Alent Holdings BV
|
Netherlands
|
Alent Inc.
|
Rhodes Island
|
Alent Investments Inc.
|
Delaware
|
Alent Investments Ltd
|
United Kingdom
|
Alent Italia Srl
|
Italy
|
Alent Limited
|
United Kingdom
|
Alent Management Ltd
|
United Kingdom
|
Alent New Finance (UK) Ltd
|
United Kingdom
|
Alent New Mexico Holdings Ltd
|
United Kingdom
|
Alent Property Ltd
|
United Kingdom
|
Alent Services Ltd
|
United Kingdom
|
Alent USA Holding Inc.
|
Delaware
|
Alpha Assembly Solutions Belgium NV
|
Belgium
|
Alpha Assembly Solutions Brasil Soldas Ltda
|
Brazil
|
Alpha Assembly Solutions France SAS
|
France
|
Alpha Assembly Solutions Germany GmbH
|
Germany
|
Alpha Assembly Solutions, Inc.
|
Delaware
|
Alpha Assembly Solutions Korea Ltd
|
Korea
|
Alpha Assembly Solutions Netherlands B.V.
|
Netherlands
|
Alpha Assembly Solutions (Shanghai) Trading Co. Ltd
|
China
|
Subsidiaries
|
State or Jurisdiction of Incorporation/Organization
|
Alpha Assembly Solutions (Shenzen) Co. Ltd
|
China
|
Alpha Assembly Solutions (Taiwan) Limited
|
Taiwan
|
Alpha Assembly Solutions UK Limited
|
United Kingdom
|
Alpha Metals (Ireland) Ltd
|
Ireland
|
Alpha Metals China Holdings Co. Ltd
|
China
|
Alpha Metals Ltd
|
United Kingdom
|
Alpha Metals Limited
|
Hong Kong
|
Alpha Metals Mexico S.A. de C.V.
|
Mexico
|
Alpha Metals Trading Mexico S.A. de C.V.
|
Mexico
|
Anchorprops 39 (Pty) Ltd
|
South Africa
|
Anesa SA
|
Belgium
|
Anion Quimica Industrial S.A.
|
Brazil
|
Aprochim SpA
|
Italy
|
AR Mexican Holdings Inc.
|
Delaware
|
Arvesta Bolivia SA
|
Bolivia
|
Arvesta Corporation
|
California
|
Arvesta Paraguay SA
|
Paraguay
|
Arysta Agro Private Limited
|
India
|
Arysta Agroquimicos y Fertilzantes Uruguay SA
|
Uruguay
|
Arysta Animal Health SAS
|
France
|
Arysta Health and Nutrition Sciences Corporation
|
Japan
|
Arysta LifeScience Adria, trgovina s kemicnimi proizvodi d.o.o.
|
Slovenia
|
Arysta LifeScience Agriservice Private Limited
|
India
|
Arysta LifeScience Agrochemical Products Hellas EPE
|
Greece
|
Arysta LifeScience America Inc
|
Delaware
|
Arysta LifeScience Argentina SA
|
Argentina
|
Arysta LifeScience Asia Pte Ltd
|
Singapore
|
Arysta LifeScience Australia Pty Ltd.
|
Australia
|
Arysta LifeScience Benelux SPRL
|
Belgium
|
Arysta LifeScience Bulgaria EOOD
|
Bulgaria
|
Arysta LifeScience Cameroun SA
|
Cameroon
|
Arysta LifeScience Canada BC Inc
|
Canada
|
Arysta LifeScience Canada Inc
|
Canada
|
Arysta LifeScience CentroAmerica SA
|
Guatemala
|
Arysta LifeScience Chile SA
|
Chile
|
Arysta LifeScience Colombia SA
|
Colombia
|
Arysta LifeScience Corporation
|
Japan
|
Arysta LifeScience Corporation Republica Dominicana SRL
|
Dominican Republic
|
Arysta LifeScience Costa Rica SA
|
Costa Rica
|
Arysta LifeScience Czech sro
|
Czech Republic
|
Arysta LifeScience de Guatemala SA
|
Guatemala
|
Arysta LifeScience do Brasil Industria Quimica e Agropecuaria SA
|
Brazil
|
Arysta LifeScience Ecuador SA
|
Ecuador
|
Arysta LifeScience Egypt Ltd
|
Egypt
|
Subsidiaries
|
State or Jurisdiction of Incorporation/Organization
|
Arysta LifeScience Espana SA
|
Spain
|
Arysta LifeScience Europe Sarl
|
France
|
Arysta LifeScience European Investments Limited
|
United Kingdom
|
Arysta LifeScience France SAS
|
France
|
Arysta LifeScience Germany GmbH
|
Germany
|
Arysta LifeScience Global Limited
|
United Kingdom
|
Arysta LifeScience Global Services Limited
|
Ireland
|
Arysta LifeScience Great Britain Ltd
|
United Kingdom
|
Arysta LifeScience Hellas S.A./Plant Protection, Nutrition and Other Related Products and Services
|
Greece
|
Arysta LifeScience Holdings France SAS
|
France
|
Arysta LifeScience Holdings SA (Pty) Ltd
|
South Africa
|
Arysta LifeScience Iberia SLU
|
Spain
|
Arysta LifeScience Inc.
|
Delaware
|
Arysta LifeScience India Limited
|
India
|
Arysta LifeScience Italia S.r.l
|
Italy
|
Arysta LifeScience Japan Holdings GK
|
Japan
|
Arysta LifeScience Kenya Ltd
|
Kenya
|
Arysta LifeScience Kiev LLC
|
Ukraine
|
Arysta LifeScience Korea Ltd
|
South Korea
|
Arysta LifeScience Magyarorszag Kft
|
Hungary
|
Arysta LifeScience Management Company LLC
|
Delaware
|
Arysta LifeScience (Mauritius) Ltd
|
Mauritius
|
Arysta LifeScience Mexico Holdings SA de CV
|
Mexico
|
Arysta LifeScience Mexico SA de CV
|
Mexico
|
Arysta LifeScience NA Holding LLC
|
Delaware
|
Arysta LifeScience Netherlands B.V.
|
Netherlands
|
Arysta LifeScience North America LLC
|
California
|
Arysta LifeScience Pakistan (Pvt) Ltd
|
Pakistan
|
Arysta LifeScience Paraguay SRL
|
Paraguay
|
Arysta LifeScience Peru SAC
|
Peru
|
Arysta LifeScience Philippines Inc
|
Philippines
|
Arysta LifeScience Polska Sp zoo
|
Poland
|
Arysta LifeScience Registrations Great Britain Ltd
|
United Kingdom
|
Arysta LifeScience Romania SRL
|
Romania
|
Arysta LifeScience RUS LLC
|
Russia
|
Arysta LifeScience SAS
|
France
|
Arysta LifeScience (Shanghai) Co Ltd
|
China
|
Arysta LifeScience Slovakia Sro
|
Slovakia
|
Arysta LifeScience South Africa (Pty) Ltd
|
South Africa
|
Arysta LifeScience SPC LLC
|
Delaware
|
Arysta LifeScience SRL
|
Bolivia
|
Arysta LifeScience Switzerland SARL
|
Switzerland
|
Arysta LifeScience Tanzania Ltd
|
Tanzania
|
Arysta LifeScience (Thailand) Co Ltd
|
Thailand
|
Subsidiaries
|
State or Jurisdiction of Incorporation/Organization
|
Arysta LifeScience Technology BV
|
Netherlands
|
Arysta LifeScience Tirta Indonesia
|
Indonesia
|
Arysta LifeScience Togo SAU
|
Togo
|
Arysta LifeScience Turkey Tarim Urunleri Limited Sirketi
|
Turkey
|
Arysta LifeScience UK & Ireland Ltd
|
United Kingdom
|
Arysta LifeScience UK BRL Limited
|
United Kingdom
|
Arysta LifeScience UK CAD Limited
|
United Kingdom
|
Arysta LifeScience UK Eur Limited
|
United Kingdom
|
Arysta LifeScience UK Holdings Limited
|
United Kingdom
|
Arysta LifeScience UK JPY Limited
|
United Kingdom
|
Arysta LifeScience UK Ltd
|
United Kingdom
|
Arysta LifeScience UK USD Limited
|
United Kingdom
|
Arysta LifeScience UK USD-2 Limited
|
United Kingdom
|
Arysta LifeScience Ukraine LLC
|
Ukraine
|
Arysta LifeScience Venezuela SA
|
Venezuela
|
Arysta LifeScience Vietnam Co Ltd
|
Vietnam
|
Arysta LifeScience Vostok LLC
|
Russia
|
Arysta-LifeScience Ecuador SA
|
Ecuador
|
Assupol Investments (Pty) Ltd
|
Zimbabwe
|
Autotype Holdings (USA), Inc.
|
Illinois
|
Bayport Chemical Service Inc.
|
Texas
|
Betel Reunion SA
|
France
|
Bioenzymas SA de CV
|
Mexico
|
Calli Ghana Ltd
|
Ghana
|
Callietha Investments (Pty) Ltd
|
South Africa
|
Callivoire SGFD SA
|
Cote D’Ivoire
|
Canning Gumm LLC
|
Delaware
|
Chemtura Colombia Ltda
|
Colombia
|
Chemtura (Pty) Ltd
|
South Africa
|
Chemtura Thailand Ltd
|
Thailand
|
Chimac SPRL
|
Belgium
|
Compugraphics International Ltd.
|
United Kingdom
|
Compugraphics Jena GmbH
|
Germany
|
Compugraphics USA Inc.
|
Delaware
|
Cookson Holding Company
|
Delaware
|
Cookson India Pvt Ltd
|
India
|
Cookson Pigments Inc.
|
Delaware
|
Desarrollos Inmobiliaros Alianza de Coahuila SA de CV
|
Mexico
|
Dutch Agricultural Formations CV
|
Netherlands
|
Dutch Agricultural Investment Partners LLC
|
Delaware
|
Dynacircuits LLC
|
Illinois
|
Echo International Inc.
|
Delaware
|
EI Liquidation Inc.
|
New York
|
Electroplating Engineers of Japan Ltd
|
Japan
|
Subsidiaries
|
State or Jurisdiction of Incorporation/Organization
|
Enthone (Portugal), Lda
|
Portugal
|
Enthone B.V.
|
Netherlands
|
Enthone Iberica S.A.
|
Spain
|
Enthone Limited
|
United Kingdom
|
Enthone SAS
|
France
|
Enthone Sdn Bhd
|
Malaysia
|
Enthone Sp. Z.o.o.
|
Poland
|
Enthone-OMI (Hong Kong) Co. Ltd.
|
Hong Kong
|
Enthone-OMI Holdings (U.K.) Ltd
|
United Kingdom
|
Establishment Godel SA
|
France
|
GBM USA LLC
|
Arizona
|
Goëmar Developpement SAS
|
France
|
Grupo Bioquimico Mexicano Republica Dominicana SA
|
Dominican Republic
|
Grupo Bioquimico Mexicano SA de CV
|
Mexico
|
Hua Mei (Tianjin) Electroplating Technology Company Ltd
|
China
|
Industrias Agriphar SA
|
Guatemala
|
Internacional de Manufacturas Asociadas SA
|
Spain
|
Kempton Chemicals (Pty) Ltd
|
South Africa
|
Laboratoires Goëmar SAS
|
France
|
Lane Ltd
|
Zambia
|
MacDermid (Nanjing) Chemical Ltd
|
China
|
MacDermid (Shanghai) Chemical Ltd
|
China
|
MacDermid Actium Ltd
|
United Kingdom
|
MacDermid Acumen Inc.
|
Delaware
|
MacDermid Agricultural Solutions Australia Pty Ltd
|
Australia
|
MacDermid Agricultural Solutions Holdings BV
|
Netherlands
|
MacDermid Agricultural Solutions Italy Srl
|
Italy
|
MacDermid Agricultural Solutions Korea Ltd
|
Korea
|
MacDermid Agricultural Solutions Netherlands Cooperatief UA
|
Netherlands
|
MacDermid Americas Acquisitions Inc.
|
Delaware
|
MacDermid Anion Inc.
|
Delaware
|
MacDermid Autotype Inc.
|
Delaware
|
MacDermid Autotype Ltd
|
United Kingdom
|
MacDermid Autotype Pte Ltd
|
Singapore
|
MacDermid Benelux BV
|
Netherlands
|
MacDermid Brazil Inc.
|
Delaware
|
MacDermid C.Z. Sro
|
Czech Republic
|
MacDermid Canning GmbH
|
Germany
|
MacDermid Canning Ltd
|
United Kingdom
|
MacDermid Chemicals Industries Argentina Inc.
|
Argentina
|
MacDermid Continental Investments Ltd.
|
United Kingdom
|
MacDermid Dutch Investments CV
|
Netherlands
|
MacDermid Enthone America LLC
|
Delaware
|
MacDermid Enthone (Austria) GmbH
|
Austria
|
Subsidiaries
|
State or Jurisdiction of Incorporation/Organization
|
MacDermid Enthone Bermuda BV
|
Bermuda
|
MacDermid Enthone de Mexico S.A. de C.V.
|
Mexico
|
MacDermid Enthone Inc.
|
Delaware
|
MacDermid Enthone Electronics Solutions (M) Sdn. Bhd.
|
Malaysia
|
MacDermid Enthone GmbH
|
Germany
|
MacDermid Enthone Slovakia s.r.o
|
Slovakia
|
MacDermid Enthone Sp. Z.o.o.
|
Poland
|
MacDermid Enthone Taiwan Co. Ltd.
|
Taiwan
|
MacDermid Enthone Technology (Suzhou) Co. Ltd.
|
China
|
MacDermid Enthone Trading Shanghai Co. Ltd.
|
China
|
MacDermid Enthone Singapore Pte Ltd.
|
Singapore
|
MacDermid Europe Ltd
|
United Kingdom
|
MacDermid European Capital Investments I, LLC
|
Delaware
|
MacDermid European Capital Investments II, LLC
|
Delaware
|
MacDermid European Capital Partners LLP
|
United Kingdom
|
MacDermid European Holdings BV
|
Netherlands
|
MacDermid Financial BV
|
Netherlands
|
MacDermid Funding LLC
|
Delaware
|
MacDermid Graphic Solutions Europe SAS
|
France
|
MacDermid Graphic Solutions LLC
|
Delaware
|
MacDermid Graphic Solutions Ltd
|
United Kingdom
|
MacDermid GB Holdings Ltd
|
United Kingdom
|
MacDermid Group Inc.
|
Delaware
|
MacDermid Holdings BV
|
Netherlands
|
MacDermid Holdings LLC
|
Delaware
|
MacDermid Holdings SAS
|
France
|
MacDermid Hong Kong Ltd
|
Hong Kong
|
MacDermid Houston Inc.
|
Delaware
|
MacDermid, Incorporated
|
Connecticut
|
MacDermid India Private Ltd
|
India
|
MacDermid International Investments LLC
|
Delaware
|
MacDermid International Partners
|
Delaware
|
MacDermid Investment Corp.
|
Delaware
|
MacDermid Italiana Srl
|
Italy
|
MacDermid Kft
|
Hungary
|
MacDermid MAS LLC
|
Delaware
|
MacDermid Mauritius
|
Mauritius
|
MacDermid Mexico Holdings S de RL de CV
|
Mexico
|
MacDermid Mexico SA de CV
|
Mexico
|
MacDermid Offshore Fluidos do Brazil Industrial Ltda
|
Brazil
|
MacDermid Offshore Solutions LLC
|
Delaware
|
MacDermid Operations S de RL de CV
|
Mexico
|
MacDermid Overseas Asia Ltd
|
Delaware
|
MacDermid Panyu Specialty Chemicals Co Ltd
|
China
|
Subsidiaries
|
State or Jurisdiction of Incorporation/Organization
|
MacDermid Performance Acquisition Germany GmbH I
|
Germany
|
MacDermid Performance Acquisition Germany GmbH II
|
Germany
|
MacDermid Performance Acquisitions Ltd
|
United Kingdom
|
MacDermid Performance Solutions Canada Inc.
|
Canada
|
MacDermid Performance Solutions Espanola SA
|
Spain
|
MacDermid Performance Solutions France S.A.S
|
France
|
MacDermid Performance Solutions Hong Kong Ltd.
|
Hong Kong
|
MacDermid Performance Solutions Japan K.K.
|
Japan
|
MacDermid Performance Solutions Korea Inc.
|
Korea
|
MacDermid Performance Solutions Kimyasal Sanayi ve Ticaret A.S.
|
Turkey
|
MacDermid Performance Solutions Mexico Services, S.A. de C.V.
|
Mexico
|
MacDermid Performance Solutions Singapore Pte Ltd.
|
Singapore
|
MacDermid Performance Solutions Taiwan Ltd
|
Taiwan
|
MacDermid Performance Solutions UK Ltd
|
United Kingdom
|
MacDermid Printing Solutions Acumen Inc
|
Delaware
|
MacDermid Scandinavia AB
|
Sweden
|
MacDermid Services S de RL de CV
|
Mexico
|
MacDermid Singapore, Pte Ltd
|
Singapore
|
MacDermid South America Inc.
|
Delaware
|
MacDermid South Atlantic Inc.
|
Delaware
|
MacDermid (Shenzhen) Trading Co. Ltd.
|
China
|
MacDermid Suisse Sarl.
|
Switzerland
|
MacDermid Taiwan Holdings B.V.
|
Netherlands
|
MacDermid Technology (Suzhou) Company Ltd
|
China
|
MacDermid Texas Inc.
|
Delaware
|
MacDermid Thailand
|
Thailand
|
MacDermid UK Ltd
|
United Kingdom
|
MacDermid US Holdings LLC
|
Delaware
|
Mali Protection Des Cultures (MPC) SA
|
Mali
|
Marston Bentley Ltd
|
United Kingdom
|
MIT Belgium NV
|
Belgium
|
MRD Acquisition Corp
|
Delaware
|
Myanmar Arysta LifeScience Co Ltd
|
Myanmar
|
Napp Printing Plate Distribution Inc.
|
South Dakota
|
Napp Systems Inc
|
Iowa
|
Natural Plant Protection SAS
|
France
|
Netherlands Agricultural Investment Partners LLC
|
Delaware
|
Netherlands Agricultural Technologies CV
|
Netherlands
|
Niche Offshore Solutions Ltd
|
United Kingdom
|
Niche Products Limited
|
United Kingdom
|
Nippon MacDermid Co. Ltd
|
Japan
|
Oak Barrel Investments Ltd
|
United Kingdom
|
Omega Agroindustrial SA de CV
|
Mexico
|
OMI International Corporation
|
Delaware
|
Subsidiaries
|
State or Jurisdiction of Incorporation/Organization
|
Percival SPRL
|
Belgium
|
Pinetree Investments Ltd
|
United Kingdom
|
Plates & Blankets S de RL de CV
|
Mexico
|
Platform Corporate Services LLC
|
Delaware
|
Platform Delaware Holdings, Inc
|
Delaware
|
Platform Sales Suisse GmbH
|
Switzerland
|
PPWJ Sci
|
France
|
PTI Produtos Tecnicos Para Impessao Ltd
|
Brazil
|
Revestsul Productos Quimicos Ltd
|
Brazil
|
Rockville Venture LLC
|
Delaware
|
Santamix Iberica SL
|
Spain
|
Semitronic SA
|
Spain
|
Servicios Agricolas Mundiales SA de CV
|
Mexico
|
Shenzhen Hua-Mei Electroplating Technology Company Ltd
|
China
|
Sidewalk Trading (Pty) Ltd
|
South Africa
|
SPC Divestiture Inc.
|
Delaware
|
Specialty Polymers Inc.
|
Massachusetts
|
Speedline Technologies Ltd
|
United Kingdom
|
Surface Treatments Ltd
|
United Kingdom
|
Tabitha Holdings BV
|
Netherlands
|
Tecno Extractos Vegetales SA de CV
|
Mexico
|
Tesaurus Mexico SA de CV
|
Mexico
|
Vernon-Rockville Venture LLC
|
Delaware
|
Veto-Pharma SA
|
France
|
Volcano Agrociencia Industria e Comercio de Defensivos Agricolas Ltda
|
Brazil
|
Volcano Agroscience (Pty) Ltd
|
South Africa
|
Volcano Chemicals (Pty) Ltd
|
South Africa
|
W Canning Australia Pty Ltd
|
Australia
|
W Canning USA LLC
|
Delaware
|
W. Canning Inc.
|
Delaware
|
W. Canning International B.V.
|
Netherlands
|
W. Canning Ltd
|
Texas
|
Wyjolab SA
|
France
|
Signature
|
|
Title
|
|
|
|
/s/ Martin E. Franklin
|
|
Chairman of the Board
|
Martin E. Franklin
|
|
|
|
|
|
/s/ Rakesh Sachdev
|
|
Director and Chief Executive Officer
|
Rakesh Sachdev
|
|
|
|
|
|
/s/ Ian G.H. Ashken
|
|
Director
|
Ian G.H. Ashken
|
|
|
|
|
|
/s/ Nicolas Berggruen
|
|
Director
|
Nicolas Berggruen
|
|
|
|
|
|
/s/ Michael F. Goss
|
|
Director
|
Michael F. Goss
|
|
|
|
|
|
/s/ Ryan Israel
|
|
Director
|
Ryan Israel
|
|
|
|
|
|
/s/ E. Stanley O’Neal
|
|
Director
|
E. Stanley O’Neal
|
|
|
1.
|
I have reviewed this Annual Report on Form 10-K of Platform Specialty Products Corporation;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
(a)
|
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
(b)
|
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
(c)
|
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
(d)
|
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
(a)
|
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
(b)
|
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
/s/ Rakesh Sachdev
|
Rakesh Sachdev
|
Chief Executive Officer
|
1.
|
I have reviewed this Annual Report on Form 10-K of Platform Specialty Products Corporation;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
(a)
|
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
(b)
|
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
(c)
|
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
(d)
|
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
(a)
|
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
(b)
|
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
/s/ John P. Connolly
|
John P. Connolly
|
Chief Financial Officer
|
(1)
|
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
|
(2)
|
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
/s/ Rakesh Sachdev
|
|
Rakesh Sachdev
|
|
Chief Executive Officer
|
|
February 28, 2018
|
|
(1)
|
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
|
(2)
|
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
/s/ John P. Connolly
|
|
John P. Connolly
|
|
Chief Financial Officer
|
|
February 28, 2018
|
|